

    <!DOCTYPE html>
<html class="">

        
<head>
    <title>ACCEPT - combining acalabrutinib with rituximab,... | F1000Research</title>
    <meta charset="utf-8">
    <!--<meta http-equiv="Content-Type" content="text/html; charset=utf-8"/>-->
    <!--<meta lang="$locale">-->
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta name="google-site-verification" content="9-QVycOO2_ob3Z9QzRmXv2CF08A9oyYXqWyTiVdKPlU" />
    <!-- This is commented out to fix display problems on mobile devices.
    We may use it again once we implement a responsive design that supports native device resolutions.
    <meta name="viewport" content="width=device-width"> -->

    <meta name="viewport" content="width=device-width, initial-scale=1, maximum-scale=1">



    <link rel="alternate" title="Recent articles published in F1000Research" href="/rss" type="application/rss+xml">
            <link rel="alternate" type="application/pdf" title="PDF" href="https://f1000research.com/articles/9-941/pdf"/>
        <link rel="canonical" href="https://f1000research.com/articles/9-941" />
    
            <meta name="description" content="Read the original article in full on F1000Research: ACCEPT - combining acalabrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone (R-CHOP) for Diffuse Large B-cell Lymphoma (DLBCL): study protocol for a Phase Ib/II open-label non-randomised clinical trial" />
    
            <meta name="og:title" content="F1000Research Article: ACCEPT - combining acalabrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone (R-CHOP) for Diffuse Large B-cell Lymphoma (DLBCL): study protocol for a Phase Ib/II open-label non-randomised clinical trial.">
            <meta name="og:description" content="Read the latest article version by Andrew Davies, Sharon Barrans, Cathy Burton, Katy Mercer, Joshua Caddy, Fay Chinnery, Laura Day, Diana Fernando, Kirit Ardeshna, Graham Collins, John Radford, Simon Rule, Andrew McMillan, Peter Johnson, Gareth Griffiths, at F1000Research.">
            <meta name="og:image" content="/img/sharing/og_research.png">
            <meta name="version-id" content="24618">
            <meta name="article-id" content="22318">
            <meta name="dc.title" content="ACCEPT - combining acalabrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone (R-CHOP) for Diffuse Large B-cell Lymphoma (DLBCL): study protocol for a Phase Ib/II open-label non-randomised clinical trial">
            <meta name="dc.description" content=" Background: Over 13,000 new cases of non-Hodgkin&rsquo;s lymphoma (NHL) are diagnosed in the UK, with approximately 4,900 attributable deaths each year. Diffuse Large B-cell Lymphoma (DLBCL) is the most common NHL comprising one third of adult NHL cases. R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisolone) is accepted as the international standard first-line regimen, but improvement in first line treatment is needed. Dysregulated B-cell receptor (BCR) signalling has been identified as a feature of DLBCL. Inhibition of Bruton&rsquo;s tyrosine kinase (Btk), downstream of the BCR has proven efficacious in other B-cell malignancies and in combination with R-CHOP. The second generation Btk inhibitor, acalabrutinib, may have improved target potency and specificity, and therefore better efficacy and tolerability. 
 Methods: ACCEPT is an open-label non-randomised Phase Ib/II trial testing the addition of acalabrutinib to conventional R-CHOP therapy. ACCEPT incorporates an initial 6+6 modified Phase I design of up to 24 participants followed by 15 participant single arm Phase II expansion cohort in treatment naive patients with histologically confirmed DLBCL expressing CD20. Participants are recruited from UK secondary care sites. Phase I will establish the recommended Phase II dose (RP2D, primary endpoint) of acalabrutinib in combination with R-CHOP. Phase II will gain additional information on safety and efficacy on the RP2D. The primary endpoints of Phase II are overall response rate and toxicity profile. Secondary endpoints include duration of response (progression-free survival and overall survival OS) in relation to cell of origin. Analyses are not powered for formal statistical comparisons; descriptive statistics will describe rates of toxicity, efficacy and translational endpoints. 
 Discussion: &amp;nbsp;ACCEPT will provide evidence for whether acalabrutinib in combination with R-CHOP is safe and biologically effective prior to future Phase II/III trials in patients with previously untreated CD20 positive DLBCL. 
 Trial registration: EudraCT Number: 2015-003213-18 (issued 16 July 2015); ISRCTN 13626902 (registered 07 March 2017).">
            <meta name="dc.subject" content="Diffuse large B-cell lymphoma, acalabrutinib, Btk inhibitor, R-CHOP, molecular profiling, phase I/II ">
            <meta name="dc.creator" content="Davies, Andrew">
            <meta name="dc.creator" content="Barrans, Sharon">
            <meta name="dc.creator" content="Burton, Cathy">
            <meta name="dc.creator" content="Mercer, Katy">
            <meta name="dc.creator" content="Caddy, Joshua">
            <meta name="dc.creator" content="Chinnery, Fay">
            <meta name="dc.creator" content="Day, Laura">
            <meta name="dc.creator" content="Fernando, Diana">
            <meta name="dc.creator" content="Ardeshna, Kirit">
            <meta name="dc.creator" content="Collins, Graham">
            <meta name="dc.creator" content="Radford, John">
            <meta name="dc.creator" content="Rule, Simon">
            <meta name="dc.creator" content="McMillan, Andrew">
            <meta name="dc.creator" content="Johnson, Peter">
            <meta name="dc.creator" content="Griffiths, Gareth">
            <meta name="dc.date" content="2020/08/07">
            <meta name="dc.identifier" content="doi:10.12688/f1000research.22318.1">
            <meta name="dc.source" content="F1000Research 2020 9:941">
            <meta name="dc.format" content="text/html">
            <meta name="dc.language" content="en">
            <meta name="dc.publisher" content="F1000 Research Limited">
            <meta name="dc.rights" content="https://creativecommons.org/licenses/by/3.0/igo/">
            <meta name="dc.type" content="text">
            <meta name="prism.keyword" content="Diffuse large B-cell lymphoma">
            <meta name="prism.keyword" content="acalabrutinib">
            <meta name="prism.keyword" content="Btk inhibitor">
            <meta name="prism.keyword" content="R-CHOP">
            <meta name="prism.keyword" content="molecular profiling">
            <meta name="prism.keyword" content="phase I/II ">
            <meta name="prism.publication.Name" content="F1000Research">
            <meta name="prism.publicationDate" content="2020/08/07">
            <meta name="prism.volume" content="9">
            <meta name="prism.number" content="941">
            <meta name="prism.versionIdentifier" content="1">
            <meta name="prism.doi" content="10.12688/f1000research.22318.1">
            <meta name="prism.url" content="https://f1000research.com/articles/9-941">
            <meta name="citation_title" content="ACCEPT - combining acalabrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone (R-CHOP) for Diffuse Large B-cell Lymphoma (DLBCL): study protocol for a Phase Ib/II open-label non-randomised clinical trial">
            <meta name="citation_abstract" content=" Background: Over 13,000 new cases of non-Hodgkin&rsquo;s lymphoma (NHL) are diagnosed in the UK, with approximately 4,900 attributable deaths each year. Diffuse Large B-cell Lymphoma (DLBCL) is the most common NHL comprising one third of adult NHL cases. R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisolone) is accepted as the international standard first-line regimen, but improvement in first line treatment is needed. Dysregulated B-cell receptor (BCR) signalling has been identified as a feature of DLBCL. Inhibition of Bruton&rsquo;s tyrosine kinase (Btk), downstream of the BCR has proven efficacious in other B-cell malignancies and in combination with R-CHOP. The second generation Btk inhibitor, acalabrutinib, may have improved target potency and specificity, and therefore better efficacy and tolerability. 
 Methods: ACCEPT is an open-label non-randomised Phase Ib/II trial testing the addition of acalabrutinib to conventional R-CHOP therapy. ACCEPT incorporates an initial 6+6 modified Phase I design of up to 24 participants followed by 15 participant single arm Phase II expansion cohort in treatment naive patients with histologically confirmed DLBCL expressing CD20. Participants are recruited from UK secondary care sites. Phase I will establish the recommended Phase II dose (RP2D, primary endpoint) of acalabrutinib in combination with R-CHOP. Phase II will gain additional information on safety and efficacy on the RP2D. The primary endpoints of Phase II are overall response rate and toxicity profile. Secondary endpoints include duration of response (progression-free survival and overall survival OS) in relation to cell of origin. Analyses are not powered for formal statistical comparisons; descriptive statistics will describe rates of toxicity, efficacy and translational endpoints. 
 Discussion: &amp;nbsp;ACCEPT will provide evidence for whether acalabrutinib in combination with R-CHOP is safe and biologically effective prior to future Phase II/III trials in patients with previously untreated CD20 positive DLBCL. 
 Trial registration: EudraCT Number: 2015-003213-18 (issued 16 July 2015); ISRCTN 13626902 (registered 07 March 2017).">
            <meta name="citation_description" content=" Background: Over 13,000 new cases of non-Hodgkin&rsquo;s lymphoma (NHL) are diagnosed in the UK, with approximately 4,900 attributable deaths each year. Diffuse Large B-cell Lymphoma (DLBCL) is the most common NHL comprising one third of adult NHL cases. R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisolone) is accepted as the international standard first-line regimen, but improvement in first line treatment is needed. Dysregulated B-cell receptor (BCR) signalling has been identified as a feature of DLBCL. Inhibition of Bruton&rsquo;s tyrosine kinase (Btk), downstream of the BCR has proven efficacious in other B-cell malignancies and in combination with R-CHOP. The second generation Btk inhibitor, acalabrutinib, may have improved target potency and specificity, and therefore better efficacy and tolerability. 
 Methods: ACCEPT is an open-label non-randomised Phase Ib/II trial testing the addition of acalabrutinib to conventional R-CHOP therapy. ACCEPT incorporates an initial 6+6 modified Phase I design of up to 24 participants followed by 15 participant single arm Phase II expansion cohort in treatment naive patients with histologically confirmed DLBCL expressing CD20. Participants are recruited from UK secondary care sites. Phase I will establish the recommended Phase II dose (RP2D, primary endpoint) of acalabrutinib in combination with R-CHOP. Phase II will gain additional information on safety and efficacy on the RP2D. The primary endpoints of Phase II are overall response rate and toxicity profile. Secondary endpoints include duration of response (progression-free survival and overall survival OS) in relation to cell of origin. Analyses are not powered for formal statistical comparisons; descriptive statistics will describe rates of toxicity, efficacy and translational endpoints. 
 Discussion: &amp;nbsp;ACCEPT will provide evidence for whether acalabrutinib in combination with R-CHOP is safe and biologically effective prior to future Phase II/III trials in patients with previously untreated CD20 positive DLBCL. 
 Trial registration: EudraCT Number: 2015-003213-18 (issued 16 July 2015); ISRCTN 13626902 (registered 07 March 2017).">
            <meta name="citation_keywords" content="Diffuse large B-cell lymphoma, acalabrutinib, Btk inhibitor, R-CHOP, molecular profiling, phase I/II ">
            <meta name="citation_journal_title" content="F1000Research">
            <meta name="citation_author" content="Andrew Davies">
            <meta name="citation_author_institution" content="Southampton Experimental Cancer Medicine Centre, University of Southampton and University Hospital Southampton NHS Foundation Trust, Southhampton, UK">
            <meta name="citation_author" content="Sharon Barrans">
            <meta name="citation_author_institution" content="Leeds Teaching Hospitals NHS Trust, Leeds, UK">
            <meta name="citation_author" content="Cathy Burton">
            <meta name="citation_author_institution" content="Leeds Teaching Hospitals NHS Trust, Leeds, UK">
            <meta name="citation_author" content="Katy Mercer">
            <meta name="citation_author_institution" content="Southampton Clinical Trials Unit, University of Southampton and University Hospital Southampton NHS Foundation Trust, Southampton, UK">
            <meta name="citation_author" content="Joshua Caddy">
            <meta name="citation_author_institution" content="Southampton Clinical Trials Unit, University of Southampton and University Hospital Southampton NHS Foundation Trust, Southampton, UK">
            <meta name="citation_author" content="Fay Chinnery">
            <meta name="citation_author_institution" content="Southampton Clinical Trials Unit, University of Southampton and University Hospital Southampton NHS Foundation Trust, Southampton, UK">
            <meta name="citation_author" content="Laura Day">
            <meta name="citation_author_institution" content="Southampton Clinical Trials Unit, University of Southampton and University Hospital Southampton NHS Foundation Trust, Southampton, UK">
            <meta name="citation_author" content="Diana Fernando">
            <meta name="citation_author_institution" content="Southampton Clinical Trials Unit, University of Southampton and University Hospital Southampton NHS Foundation Trust, Southampton, UK">
            <meta name="citation_author" content="Kirit Ardeshna">
            <meta name="citation_author_institution" content="University College London Hospitals NHS Foundation Trust, London, UK">
            <meta name="citation_author" content="Graham Collins">
            <meta name="citation_author_institution" content="Oxford University Hospitals NHS Trust, Oxford, UK">
            <meta name="citation_author" content="John Radford">
            <meta name="citation_author_institution" content="University of Manchester, Manchester, UK">
            <meta name="citation_author" content="Simon Rule">
            <meta name="citation_author_institution" content="Plymouth Hospitals NHS Trust and Plymouth University Peninsula School of Medicine and Dentistry, Plymouth, UK">
            <meta name="citation_author" content="Andrew McMillan">
            <meta name="citation_author_institution" content="Nottingham University Hospitals NHS Trust, Nottingham, UK">
            <meta name="citation_author" content="Peter Johnson">
            <meta name="citation_author_institution" content="Southampton Experimental Cancer Medicine Centre, University of Southampton and University Hospital Southampton NHS Foundation Trust, Southhampton, UK">
            <meta name="citation_author" content="Gareth Griffiths">
            <meta name="citation_author_institution" content="Southampton Clinical Trials Unit, University of Southampton and University Hospital Southampton NHS Foundation Trust, Southampton, UK">
            <meta name="citation_publication_date" content="2020/08/07">
            <meta name="citation_volume" content="9">
            <meta name="citation_publication_number" content="941">
            <meta name="citation_version_number" content="1">
            <meta name="citation_doi" content="10.12688/f1000research.22318.1">
            <meta name="citation_firstpage" content="941">
            <meta name="citation_pdf_url" content="https://f1000research.com/articles/9-941/v1/pdf">
    

    
    <link href="/img/favicon-research.ico" rel="shortcut icon" type="image/ico">
    <link href="/img/favicon-research.ico" rel="icon" type="image/ico">

        <link rel="stylesheet" href="/1597255280893/css/mdl/material-design-lite.css" type="text/css" media="all" />
    <link href="https://fonts.googleapis.com/icon?family=Material+Icons" rel="stylesheet">
    <link href="https://fonts.googleapis.com/css?family=Roboto:100,100i,300,300i,400,400i,500,500i,700,700i,900,900i" rel="stylesheet">
    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/MaterialDesign-Webfont/2.2.43/css/materialdesignicons.min.css" />

        
            
    <link rel="stylesheet" href="/1597255280893/css/F1000Research.css" type="text/css" media="all" />
    <link rel="stylesheet" href="/css/F1000ResearchFontIcons/F1000ResearchFontIcons.css" type="text/css" media="all" />
    <link rel="stylesheet" href="/css/F1000ResearchFontIcons/animation.css" type="text/css" media="all" />

        <!--[if IE 7]><link rel="stylesheet" href="/css/F1000ResearchFontIcons/F1000ResearchFontIcons-ie7.css" media="all" /><![endif]-->

                    <script>dataLayer = [];</script>
        <!-- Google Tag Manager -->
        <script>(function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':
        new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],
        j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src=
        'https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f);
        })(window,document,'script','dataLayer','GTM-54Z2SBK');</script>
        <!-- End Google Tag Manager -->
    
    <script src="https://ajax.googleapis.com/ajax/libs/jquery/1.8.1/jquery.min.js"></script>
    <script>window.jQuery || document.write('<script src="/js/vendor/jquery-1.8.1.min.js"><\/script>')</script>
    <script src="/1597255280893/js/vendor/modernizr-2.6.1-respond-1.1.0.min.js"></script>
    <script src="/1597255280893/js/shared_scripts/sticky.js"></script>
    <script src="/1597255280893/js/shared_scripts/helpers.js"></script>
    <script src="/1597255280893/js/shared_scripts/menu.js"></script>
    <script src="/1597255280893/js/shared_scripts/navbar.js"></script>
    <script src="/1597255280893/js/shared_scripts/platforms.js"></script>
    <script src="/1597255280893/js/shared_scripts/object-polyfills.js"></script>
            <script src="/1597255280893/js/vendor/lodash.min.js"></script>
        <script>CKEDITOR_BASEPATH='https://f1000research.com/js/ckeditor/'</script>
    <script src="https://f1000researchdata.s3-eu-west-1.amazonaws.com/js/plugins.js"></script>
    <script src="/1597255280893/js/shared_scripts/helpers.js"></script>
    <script src="/1597255280893/js/app/research.js"></script>
    <script>window.reactTheme = 'research';</script>
    <script src="/1597255280893/js/public/bundle.js"></script>

    <script src="/1597255280893/js/app/research.ui.js"></script>
    <script src="/1597255280893/js/app/login.js"></script>
    <script src="/1597255280893/js/app/main.js"></script>
    <script src="/1597255280893/js/app/js-date-format.min.js"></script>
    <script src="/1597255280893/js/app/search.js"></script>
    <script src="/1597255280893/js/app/cookies_warning.js"></script>
    <script src="/1597255280893/js/mdl/mdl.min.js"></script>

    <script src="https://cdnjs.cloudflare.com/ajax/libs/mathjax/2.7.1/MathJax.js?config=TeX-AMS-MML_HTMLorMML"></script>
                <script src="https://f1000researchdata.s3-eu-west-1.amazonaws.com/js/ckeditor.js"></script>
            <script src="/js/ckeditor/adapters/jquery.js"></script>
                <script src="/js/article/article_scrolling_module.js"></script>
            <script src="/js/article/article_stats.js"></script>
            <script src="/js/article/article.js"></script>
            <script src="/js/shared_scripts/referee_timeline_pagination.js"></script>
            <script src="/js/app/text_editor_controller.js"></script>
            <script src="//s7.addthis.com/js/250/addthis_widget.js#pubid=ra-503e5e99593dc42c"></script>
            <script src="/js/article/article_metrics.js"></script>
        
                                                                            <script>
            if (window.location.hash == '#_=_'){
                window.location = window.location.href.split('#')[0]
            }
        </script>

                    
        
    <!-- pixelId: 1641728616063202 :: assetPixelId: 6034867600215 :: funderPixelId:  -->

            <!-- Facebook pixel code (merged with EP GTM code) -->
        <script>
            !function(f,b,e,v,n,t,s){if(f.fbq)return;n=f.fbq=function()

            {n.callMethod? n.callMethod.apply(n,arguments):n.queue.push(arguments)}
            ;if(!f._fbq)f._fbq=n;
            n.push=n;n.loaded=!0;n.version='2.0';n.queue=[];t=b.createElement(e);t.async=!0;
            t.src=v;s=b.getElementsByTagName(e)[0];s.parentNode.insertBefore(t,s)}(window,
            document,'script','https://connect.facebook.net/en_US/fbevents.js');

            fbq('init', '1641728616063202');

            
            fbq('track', "PixelInitialized", {});
        </script>

        <noscript><img height="1" width="1" style="display:none"
            src="https://www.facebook.com/tr?id=1641728616063202&noscript=1&amp;ev=PixelInitialized"
        /></noscript>
        <!-- End Facebook Pixel Code -->
    
                <script>
            (function(h,o,t,j,a,r){
                h.hj=h.hj||function(){(h.hj.q=h.hj.q||[]).push(arguments)};
                h._hjSettings={hjid:917825,hjsv:6};
                a=o.getElementsByTagName('head')[0];
                r=o.createElement('script');r.async=1;
                r.src=t+h._hjSettings.hjid+j+h._hjSettings.hjsv;
                a.appendChild(r);
            })(window,document,'https://static.hotjar.com/c/hotjar-','.js?sv=');
        </script>
    
</head>
<body  class="o-page-container no-js p-article o-layout-reset   ">

    
                            <!-- Google Tag Manager (noscript) -->
        <noscript><iframe src="https://www.googletagmanager.com/ns.html?id=GTM-54Z2SBK"
        height="0" width="0" style="display:none;visibility:hidden"></iframe></noscript>
        <!-- End Google Tag Manager (noscript) -->
    
        
    <div class="o-page">

        <div id="notify-container"></div>
        <div id="pageWarning"></div>
        <div id="pageMessage"></div>
        <div id="pageFooterMessage"></div>

                                <div id="f1r-ga-data" data-name="f1r-ga-data" class="f1r-ga-data"
                data-user-registered="false"
                data-user-module=""
                data-current-path=""
                data-location=""
                data-website="F1000Research"
                data-websiteDisplayName="F1000Research">
            </div>
        
                
        
        <div class="header-wrapper   js-navbar-space ">
                            


    










        
                            
    
            



<nav class="c-navbar js-navbar js-mini-nav js-sticky c-navbar--js-sticky c-navbar--userSite c-navbar__platform-bgcolor  c-navbar--bg-f1000research ">

    <div class="c-navbar__content">

                                <div class="c-navbar__extras">
            <div class="o-wrapper">
                <div class="o-actions o-actions--middle c-navbar__extras-row">
                    <div class="o-actions__primary">
                        
                                            </div>
                                    </div>
            </div>
        </div>

        <div class="o-wrapper t-inverted js-sticky-start">

            <div class="c-navbar__branding-row">
                <div class="c-navbar__row">


                                        
                    <div class="c-navbar__primary u-mr--2">

                                                                                                                                                                                                    <a href="/" class="c-navbar__branding u-ib u-middle"   data-test-id="nav_branding"  >
                                <img class="u-ib u-middle" src="/img/research/F1000Research_white_solid.svg" alt="F1000Research">
                            </a>
                                            </div>

                    <div class="c-navbar__secondary c-navbar__row">


                                                
                                                    <form action="/search" class="-navbar__secondary u-mr--2 c-search-form js-search-form u-hide u-show@navbar">
                                <label for="searchInput" class="c-search-form__label _mdl-layout">
                                    <input name="q" type="search" class="c-search-form__input" id="searchInput" placeholder="Search">
                                    <button type="submit" class="c-search-form__submit mdl-button mdl-js-button mdl-button--icon"><i class="material-icons">search</i></button>
                                </label>
                            </form>
                        
                                                
                                                    <div class="c-navbar__primary u-hide u-show@navbar">
                                <div class="_mdl-layout c-navbar__cta">
                                    <a class="mdl-button mdl-js-button mdl-button--raised mdl-button--no-shadow mdl-button--multi-line mdl-js-ripple-effect mdl-button--inverted c-navbar__submit" href="/for-authors/publish-your-research"   data-test-id="nav_submit_research"  ><i class="material-icons">file_upload</i>Submit your research</a>
                                </div>
                            </div>
                        

                                                
                        <span class="u-hide@navbar _mdl-layout u-nowrap">

                                                            <button type="button" class="mdl-button mdl-js-button mdl-js-ripple-effect mdl-button--icon c-navbar__toggle c-navbar__toggle--menu js-navbar-toggle" data-focus="#navbar_mob_search_input" data-toggle="navbarMenu" data-target="navbarMenu" aria-controls="navbarMenu" aria-expanded="false" aria-label="Toggle navigation"   data-test-id="nav_menu_search_mob"  ><i class="material-icons">search</i></button>
                            
                                                            <button class="mdl-button mdl-js-button mdl-js-ripple-effect mdl-button--icon mdl-button--multi-line c-navbar__toggle c-navbar__toggle--menu js-navbar-toggle" type="button" data-toggle="navbarMenu" data-target="navbarMenu" aria-controls="navbarMenu" aria-expanded="false" aria-label="Toggle navigation"   data-test-id="nav_menu_toggle_mob"  >
                                    <i class="material-icons c-navbar__toggle-open">menu</i>
                                    <i class="material-icons c-navbar__toggle-close">close</i>
                                </button>
                                                    </span>
                    </div>

                </div>
            </div>

                        
                            <div class="c-navbar__menu-row js-navbar-block is-collapsed" id="navbarMenu">

                                                                                                                                                
                                                                    
                                                                    
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
                                            

                                                                
                                                                                                                                                                                                                                
                                            
                    <div class="c-navbar__menu-row-content">

                                                                            <div class="u-hide@navbar c-navbar__menu-bar-spacing">
                                <form action="/search" class="c-search-form js-search-form">
                                    <label for="navbar_mob_search_input" class="c-search-form__label _mdl-layout">
                                        <input id="navbar_mob_search_input" name="q" type="search" class="c-search-form__input" placeholder="Search">
                                        <button type="submit" class="c-search-form__submit mdl-button mdl-js-button mdl-button--icon"><i class="material-icons">search</i></button>
                                    </label>
                                </form>
                            </div>
                        
                        <div class="o-actions o-actions--middle">

                            <div class="o-actions__primary">

                                                                
    <ul class="c-menubar c-navbar__menu-bar js-main-menu"   id="main-menu"   role="menubar" aria-label="Main Navigation"  data-menu-group="navbar" >

        
            
                                                                
                                
                                
                                    <li role="none"
                        data-index="0"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="/browse/articles" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                                                    tabindex="0"
                              data-test-id="nav_browse"                              >Browse</a>

                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="1"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="/gateways" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                                                    tabindex="-1"
                              data-test-id="nav_gatewaysViewAndBrowse"                              >Gateways & Collections</a>

                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="2"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                               c-menubar__item--selected c-navbar__menu-bar-item--parent ">

                        <a href="#" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                         aria-haspopup="true" aria-expanded="false"                             tabindex="-1"
                              data-test-id="nav_for-authors"                              >How to Publish</a>

                                                    
    <ul class="c-menu js-menu
                is-collapsed                c-menubar__menu c-navbar__menu"
                  role="menu"
        aria-label="How to Publish">

        
            
                                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_submit-manuscript"                      href="/for-authors/publish-your-research"
                    role="menuitem"
                    tabindex="0">Submit your Research</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-submissions"                      href="/for-authors/my-submissions"
                    role="menuitem"
                    tabindex="-1">My Submissions</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_article-guidelines"                      href="/for-authors/article-guidelines"
                    role="menuitem"
                    tabindex="-1">Article Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_article-guidelines-new-versions"                      href="/for-authors/article-guidelines-new-versions"
                    role="menuitem"
                    tabindex="-1">Article Guidelines (New Versions)</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_data-guidelines"                      href="/for-authors/data-guidelines"
                    role="menuitem"
                    tabindex="-1">Data Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_asset-guidelines"                      href="/for-authors/posters-and-slides-guidelines"
                    role="menuitem"
                    tabindex="-1">Posters and Slides Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_document-guidelines"                      href="/for-authors/document-guidelines"
                    role="menuitem"
                    tabindex="-1">Document Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_article-processing-charges"                      href="/for-authors/article-processing-charges"
                    role="menuitem"
                    tabindex="-1">Article Processing Charges</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_finding-referees"                      href="/for-authors/tips-for-finding-referees"
                    role="menuitem"
                    tabindex="-1">Finding Article Reviewers</a>

                </li>

                        </ul>
                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="3"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                               c-menubar__item--selected c-navbar__menu-bar-item--parent ">

                        <a href="#" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                         aria-haspopup="true" aria-expanded="false"                             tabindex="-1"
                              data-test-id="nav_about-contact"                              >About</a>

                                                    
    <ul class="c-menu js-menu
                is-collapsed                c-menubar__menu c-navbar__menu"
                  role="menu"
        aria-label="About">

        
            
                                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_about-page"                      href="/about"
                    role="menuitem"
                    tabindex="0">How it Works</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_referee-guidelines"                      href="/for-referees/guidelines"
                    role="menuitem"
                    tabindex="-1">For Reviewers</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_advisoryPanel"                      href="/advisors"
                    role="menuitem"
                    tabindex="-1">Our Advisors</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_policy-page"                      href="/about/policies"
                    role="menuitem"
                    tabindex="-1">Policies</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_glossary-page"                      href="/glossary"
                    role="menuitem"
                    tabindex="-1">Glossary</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_faqs-page"                      href="/faqs"
                    role="menuitem"
                    tabindex="-1">FAQs</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              u-hide u-show@navbar"
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      u-hide u-show@navbar"
                                          data-test-id="nav_for-developers"                      href="/developers"
                    role="menuitem"
                    tabindex="-1">For Developers</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_newsroom-page"                      href="/newsroom"
                    role="menuitem"
                    tabindex="-1">Newsroom</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_contact-page"                      href="/contact"
                    role="menuitem"
                    tabindex="-1">Contact</a>

                </li>

                        </ul>
                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="4"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="https://blog.f1000.com/blogs/f1000research/" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                             target="_blank"                                                         tabindex="-1"
                              data-test-id="nav_blog"                              >Blog</a>

                                            </li>
                
            
        
    </ul>



                            </div>

                            <div class="o-actions__secondary">

                                                                
    <ul class="c-menubar c-navbar__menu-bar js-main-menu"   id="secondary-items"   role="menubar" aria-label="My Account"  data-menu-group="navbar" >

        
            
                                                                
                                
                                
                                    <li role="none"
                        data-index="0"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                               c-menubar__item--selected c-navbar__menu-bar-item--parent ">

                        <a href="#" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                         aria-haspopup="true" aria-expanded="false"                             tabindex="0"
                              data-test-id="nav_my-research"                              >My Research</a>

                                                    
    <ul class="c-menu js-menu
                is-collapsed                c-menubar__menu c-navbar__menu"
                  role="menu"
        aria-label="My Research">

        
            
                                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-submissions"                      href="/login?originalPath=/my/submissions"
                    role="menuitem"
                    tabindex="0">Submissions</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-email-alerts"                      href="/login?originalPath=/my/email-alerts"
                    role="menuitem"
                    tabindex="-1">Content and Tracking Alerts</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-user-details"                      href="/login?originalPath=/my/user-details"
                    role="menuitem"
                    tabindex="-1">My Details</a>

                </li>

                        </ul>
                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="1"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="/login?originalPath=/articles/9-941.html" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                                                    tabindex="-1"
                              data-test-id="nav_sign-in"                              >Sign In</a>

                                            </li>
                
            
        
    </ul>



                            </div>

                                                                                        <div class="_mdl-layout c-navbar__cta u-hide@navbar c-navbar__menu-bar-spacing">
                                    <a class="mdl-button mdl-js-button mdl-button--raised mdl-button--multi-line mdl-button--no-shadow mdl-js-ripple-effect mdl-button--inverted c-navbar__submit" href="/for-authors/publish-your-research"   data-test-id="nav_submit_research_mob"  ><i class="material-icons">file_upload</i>Submit your research</a>
                                </div>
                                                    </div>

                    </div>

                </div>
            
        </div>

    </div>

</nav>
                    </div>

        <div class="content-wrapper o-page__main row ">
            <div id="highlight-area" class="content ">
                





<div id=article-metadata class=hidden> <input type=hidden name=versionId value=24618 /> <input type=hidden id=articleId name=articleId value=22318 /> <input type=hidden id=xmlUrl value="/articles/9-941/v1/xml"/> <input type=hidden id=xmlFileName value="-9-941-v1.xml"> <input type=hidden id=article_uuid value=89d4ae47-5192-48b1-a8fc-0cf781e1c908 /> <input type=hidden id=referer value=""/> <input type=hidden id=meta-article-title value="ACCEPT - combining acalabrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone (R-CHOP) for Diffuse Large B-cell Lymphoma (DLBCL): study protocol for a Phase Ib/II open-label non-randomised clinical trial"/> <input type=hidden id=workspace-export-url value="https://sciwheel.com/work/api/import/external?doi=10.12688/f1000research.22318.1"/> <input type=hidden id=versionDoi value="10.12688/f1000research.22318.1"/> <input type=hidden id=usePmcStats value=true /> </div> <main class="o-wrapper p-article__wrapper js-wrapper"> <script type="application/ld+json">
{
  "@context": "https://schema.org",
  "@type": "ScholarlyArticle",
  "mainEntityOfPage": {
    "@type": "WebPage",
    "@id": "https://f1000research.com/articles/9-941"
  },
  "headline": "ACCEPT - combining acalabrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone...",
  "datePublished": "2020-08-07T12:27:50",
  "dateModified": "2020-08-07T12:27:50",
  "author": [
    {
      "@type": "Person",
      "name": "Andrew Davies"
    },    {
      "@type": "Person",
      "name": "Sharon Barrans"
    },    {
      "@type": "Person",
      "name": "Cathy Burton"
    },    {
      "@type": "Person",
      "name": "Katy Mercer"
    },    {
      "@type": "Person",
      "name": "Joshua Caddy"
    },    {
      "@type": "Person",
      "name": "Fay Chinnery"
    },    {
      "@type": "Person",
      "name": "Laura Day"
    },    {
      "@type": "Person",
      "name": "Diana Fernando"
    },    {
      "@type": "Person",
      "name": "Kirit Ardeshna"
    },    {
      "@type": "Person",
      "name": "Graham Collins"
    },    {
      "@type": "Person",
      "name": "John Radford"
    },    {
      "@type": "Person",
      "name": "Simon Rule"
    },    {
      "@type": "Person",
      "name": "Andrew McMillan"
    },    {
      "@type": "Person",
      "name": "Peter Johnson"
    },    {
      "@type": "Person",
      "name": "Gareth Griffiths"
    }  ],
  "publisher": {
    "@type": "Organization",
    "name": "F1000Research",
    "logo": {
      "@type": "ImageObject",
      "url": "https://f1000research.com/img/AMP/F1000Research_image.png",
      "height": 480,
      "width": 60
    }
  },
  "image": {
    "@type": "ImageObject",
    "url": "https://f1000research.com/img/AMP/F1000Research_image.png",
    "height": 1200,
    "width": 150
  },
  "description": "Background: Over 13,000 new cases of non-Hodgkin&rsquo;s lymphoma (NHL) are diagnosed in the UK, with approximately 4,900 attributable deaths each year. Diffuse Large B-cell Lymphoma (DLBCL) is the most common NHL comprising one third of adult NHL cases. R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisolone) is accepted as the international standard first-line regimen, but improvement in first line treatment is needed. Dysregulated B-cell receptor (BCR) signalling has been identified as a feature of DLBCL. Inhibition of Bruton&rsquo;s tyrosine kinase (Btk), downstream of the BCR has proven efficacious in other B-cell malignancies and in combination with R-CHOP. The second generation Btk inhibitor, acalabrutinib, may have improved target potency and specificity, and therefore better efficacy and tolerability.
Methods: ACCEPT is an open-label non-randomised Phase Ib/II trial testing the addition of acalabrutinib to conventional R-CHOP therapy. ACCEPT incorporates an initial 6+6 modified Phase I design of up to 24 participants followed by 15 participant single arm Phase II expansion cohort in treatment naive patients with histologically confirmed DLBCL expressing CD20. Participants are recruited from UK secondary care sites. Phase I will establish the recommended Phase II dose (RP2D, primary endpoint) of acalabrutinib in combination with R-CHOP. Phase II will gain additional information on safety and efficacy on the RP2D. The primary endpoints of Phase II are overall response rate and toxicity profile. Secondary endpoints include duration of response (progression-free survival and overall survival OS) in relation to cell of origin. Analyses are not powered for formal statistical comparisons; descriptive statistics will describe rates of toxicity, efficacy and translational endpoints.
Discussion: ACCEPT will provide evidence for whether acalabrutinib in combination with R-CHOP is safe and biologically effective prior to future Phase II/III trials in patients with previously untreated CD20 positive DLBCL.
Trial registration: EudraCT Number: 2015-003213-18 (issued 16 July 2015); ISRCTN13626902 (registered 07 March 2017)."
}
</script> <div class="o-layout o-layout--right-gutter"> <div id=article_secondary-column class="p-article__main o-layout__item u-font-size--legal u-2/3@article not-expanded "> <div class=float-left> <script type="application/ld+json">
  {
    "@context": "http://schema.org",
    "@type": "BreadcrumbList",
    "itemListElement": [
              {
          "@type": "ListItem",
          "position": "1",
          "item": {
            "@id": "https://f1000research.com/",
            "name": "Home"
          }
        },              {
          "@type": "ListItem",
          "position": "2",
          "item": {
            "@id": "https://f1000research.com/browse/articles",
            "name": "Browse"
          }
        },              {
          "@type": "ListItem",
          "position": "3",
          "item": {
            "@id": "https://f1000research.com/articles/9-941/v1",
            "name": "ACCEPT - combining acalabrutinib with rituximab, cyclophosphamide,..."
          }
        }          ]
  }
  </script> <div class="breadcrumbs js-breadcrumbs"> <a href="/" class=f1r-standard-link>Home</a> <span class=item_separator></span> <a href="/browse/articles" class=f1r-standard-link>Browse</a> <span class=item_separator></span> ACCEPT - combining acalabrutinib with rituximab, cyclophosphamide,... </div> </div> <div class="article-badges-container u-mb--2"> <div class=crossmark-new> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js"></script> <a data-target=crossmark><img height=30 width=150 src="https://crossmark-cdn.crossref.org/widget/v2.0/logos/CROSSMARK_Color_horizontal.svg"/></a> </div> <div id=crossmark-dialog style="display: none;" title=""> <iframe id=crossmark-dialog-frame frameborder=0></iframe> </div> <div class=clearfix></div> </div> <div class=article-interaction-container> <div id=main-article-count-box class=article-count-box> <div class="article-metrics-wrapper metrics-icon-wrapper" data-version-id=24618 data-id=22318 data-downloads="" data-views="" data-scholar="10.12688/f1000research.22318.1" data-recommended="" data-doi="10.12688/f1000research.22318.1" data-f1r-ga-helper="Article Page Metrics (Desktop)"> <span class="metrics-on-browse article-metrics-icon f1r-icon icon-89_metrics"></span> <div class="count-title article-metrics-text">ALL Metrics</div> <div class=js-article-metrics-container></div> </div> <div> <div class=count-delimiter></div> <div title="Total views from F1000Research and PubMed Central"> <div class="count-container view-count js-views-count">-</div> <div class=count-title><span class="count-title-icon count-title-views-icon"></span>Views</div> </div> <div class=download-counts hidden> <div class=count-delimiter></div> <div title="Total downloads from F1000Research and PubMed Central"> <div class="count-container js-downloads-count"></div> <div class=count-title><span class="count-title-icon f1r-icon icon-76_download_file"></span>Downloads</div> </div> </div> </div> </div> <div id=main-article-interaction-box class="article-interaction-box has-control-tab"> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-102_download_pdf"></span> <a href="https://f1000research.com/articles/9-941/v1/pdf?article_uuid=89d4ae47-5192-48b1-a8fc-0cf781e1c908" title="Download PDF" class="button-link download pdf-download-helper" target=_blank>Get PDF</a> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-103_download_xml"></span> <a id=download-xml href="#" class="button-link download" title="Download XML">Get XML</a> </div> </div> <div class="article-interaction-info article-page"> <div class="cite-article-popup-wrapper article-page-interaction-box"> <div class="article-interaction-button cite-article-button" title="Cite this article" data-windowref=cite-article-popup-22318-1> <span class="f1r-icon icon-82_quote"></span> <a href="#" class="button-link cite-article-popup-link" title="Cite Article">Cite</a> </div> <div id=cite-article-popup-22318-1 class="popup-window-wrapper is-hidden"> <div class=cite-popup-background></div> <div class="popup-window top-popup cite-this-article-box research-layout"> <div class="popup-window-title small cite-title">How to cite this article</div> <span id=cite-article-text-22318-1 data-test-id=copy-citation_text> <span class="article-title-and-info in-popup">Davies A, Barrans S, Burton C <em>et al.</em> ACCEPT - combining acalabrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone (R-CHOP) for Diffuse Large B-cell Lymphoma (DLBCL): study protocol for a Phase Ib/II open-label non-randomised clinical trial [version 1; peer review: awaiting peer review]</span>. <i>F1000Research</i> 2020, <b>9</b>:941 (<a class=new-orange href="https://doi.org/10.12688/f1000research.22318.1" target=_blank>https://doi.org/10.12688/f1000research.22318.1</a>) </span> <div class="popup-window-title small margin-top-20 margin-bottom-20 note"> <strong>NOTE:</strong> it is important to ensure the information in square brackets after the title is included in all citations of this article. </div> <div class=float-right> <button class="secondary no-fill orange-text-and-border margin-right-20 close-cite-popup uppercase">Close</button> <button id=copy-citation-details class="secondary orange copy-cite-article-version uppercase js-clipboard" title="Copy the current citation details to the clipboard." data-clipboard-target="#cite-article-text-22318-1" data-test-id=copy-citation_button>Copy Citation Details</button> </div> </div> </div> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-76_download_file"></span> <a id=export-citation href="#" class="button-link download" title="Export Citation">Export</a> </div> <div class="modal-window-wrapper is-hidden"> <div id=export-citation-popup class="modal-window padding-20"> <div class=modal-window-close-button></div> <div class=modal-window-title>Export Citation</div> <div class=modal-window-row> <div> <input type=radio name=export-citation-option value=WORKSPACE /> <span class=radio-label>Sciwheel</span> </div> <div> <input type=radio name=export-citation-option value=ENDNOTE /> <span class=radio-label>EndNote</span> </div> <div> <input type=radio name=export-citation-option value=REF_MANAGER /> <span class=radio-label>Ref. Manager</span> </div> <div> <input type=radio name=export-citation-option value=BIBTEX /> <span class=radio-label>Bibtex</span> </div> <div> <input type=radio name=export-citation-option value=PROCITE /> <span class=radio-label>ProCite</span> </div> <div> <input type=radio name=export-citation-option value=SENTE /> <span class=radio-label>Sente</span> </div> </div> <div class=modal-window-footer> <button class=general-white-orange-button id=export-citation-submit>EXPORT</button> </div> <div class=default-error style="display: none;">Select a format first</div> </div> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-90_track"></span> <a class="button-link track-article" data-article-id=22318 id=track-article-signin-22318 title="Receive updates on new activity such as publication of new versions, peer reviews or author responses." href="/login?originalPath=/trackArticle/22318?target=/articles/9-941/v1">Track</a> </div> </div> <div class="article-interaction-info article-page"> <div class="article-interaction-button email-article"> <span class="f1r-icon icon-6_email"></span> <a href="#" class=button-link title="Email this article">Email</a> </div> <div class="email-article-version-container small-tooltip _chrome-fix"> <div class=close-icon><span class="f1r-icon icon-3_close_big"></span></div> <script src='https://www.recaptcha.net/recaptcha/api.js'></script> <form class="recommend-version-form research-layout"> <p>All fields are required.</p> <input name=versionId type=hidden value=24618 /> <input name=articleId type=hidden value=22318 /> <input name=senderName class="form-input-field reg-form" value="" type=text placeholder="Your name"/> <input name=senderEmail class="form-input-field reg-form margin-top" value="" type=text placeholder="Your email address"/> <textarea name=recipientEmails class="form-textarea-field ninetynine-percent-wide margin-top no-resize" placeholder="Recipient email address(es) (comma delimited)"></textarea> <input class="form-input-field reg-form margin-top" name=subject type=text value="Interesting article on F1000Research" placeholder=Subject /> <textarea name=message class="form-textarea-field reg-form margin-top no-resize">I thought this article from F1000Research (https://f1000research.com) would be of interest to you.</textarea> <div class="g-recaptcha margin-top" data-sitekey=6LcHqxoUAAAAANP3_0TzpGG6qFvl4DhbUcuRzw7W></div> <input value="" name=captcha type=hidden /> <p>A full article citation will be automatically included.</p> <p><img class="ticker-email-article-details hidden" src="/img/ticker.gif" alt=loading /></p> <button class="secondary orange margin-bottom" data-test-id=version_share_email_send>SEND EMAIL</button> <div class="orange-message margin-bottom is-hidden" data-test-id=version_share_email_message></div> </form> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-34_share"></span> <a href="#" class="button-link last addthis_button share-article" title="Share this article">Share</a> </div> </div> </div> <div id=article-interaction-control-tab class=article-interaction-control-tab> <div id=hide-article-interaction class=article-interaction-control title="Hide Toolbox">&#9644;</div> <div id=show-article-interaction class="article-interaction-control open" title="Show Toolbox">&#10010;</div> </div> </div> <div class="article-header-information article-page"> <div class="f1r-article-mobile article-heading-bar"></div> <div class="article-type article-display">Study Protocol </div> <div class="c-classifications u-mt--1"> <div title="Prospective research studies on human subjects" class="c-classification c-classification--clinical-trial"> Clinical trial </div> </div> <div class="article-title-and-info article-view highlighted-article" id=anchor-title> <h1>ACCEPT - combining acalabrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone (R-CHOP) for Diffuse Large B-cell Lymphoma (DLBCL): study protocol for a Phase Ib/II open-label non-randomised clinical trial</h1><span class=other-info> [version 1; peer review: awaiting peer review]</span> </div> <div class=article-subtitle></div> <div class=f1r-article-desk> <div class="authors _mdl-layout"><span class="">Andrew Davies<a href="https://orcid.org/0000-0002-7517-6938" target=_blank id=author-orcid-0><span class=orcid-logo-for-author-list></span></a><div class="mdl-tooltip mdl-tooltip--wider" for=author-orcid-0><span class=orcid-logo-for-author-list></span> https://orcid.org/0000-0002-7517-6938</div><sup>1</sup>,&nbsp;</span><span class="">Sharon Barrans<sup>2</sup>,&nbsp;</span><span class="">Cathy Burton<sup>2</sup>,&nbsp;</span><a href="#" class=article-page-expand-authors>[...]&nbsp;</a><span class=article-page-hidden-authors><a href="mailto:K.Mercer@soton.ac.uk" title="Send email" class="cauthor research-layout"><span class='f1r-icon icon-6_email orange'></span><span>Katy Mercer</span></a><sup>3</sup>,&nbsp;</span><span class=article-page-hidden-authors>Joshua Caddy<sup>3</sup>,&nbsp;</span><span class=article-page-hidden-authors>Fay Chinnery<a href="https://orcid.org/0000-0002-8082-9016" target=_blank id=author-orcid-5><span class=orcid-logo-for-author-list></span></a><div class="mdl-tooltip mdl-tooltip--wider" for=author-orcid-5><span class=orcid-logo-for-author-list></span> https://orcid.org/0000-0002-8082-9016</div><sup>3</sup>,&nbsp;</span><span class=article-page-hidden-authors>Laura Day<sup>3</sup>,&nbsp;</span><span class=article-page-hidden-authors>Diana Fernando<sup>3</sup>,&nbsp;</span><span class=article-page-hidden-authors>Kirit Ardeshna<sup>4</sup>,&nbsp;</span><span class=article-page-hidden-authors>Graham Collins<sup>5</sup>,&nbsp;</span><span class=article-page-hidden-authors>John Radford<sup>6</sup>,&nbsp;</span><span class=article-page-hidden-authors>Simon Rule<sup>7</sup>,&nbsp;</span><span class="">Andrew McMillan<sup>8</sup>,&nbsp;</span><span class="">Peter Johnson<sup>1</sup>,&nbsp;</span><span class="">Gareth Griffiths<sup>3</sup></span><span class="author-display-control article-page-expand-authors f1r-icon icon-20_plus_big"></span><span class="author-display-control article-page-hidden-authors f1r-icon icon-12_minus_big"></span></div> </div> <div class=f1r-article-mobile> <div class="authors _mdl-layout"><span class="">Andrew Davies<a href="http://orcid.org/0000-0002-7517-6938" target=_blank id=mauthor-orcid-0><span class=orcid-logo-for-author-list></span></a><div class="mdl-tooltip mdl-tooltip--wider" for=mauthor-orcid-0><span class=orcid-logo-for-author-list></span> https://orcid.org/0000-0002-7517-6938</div><sup>1</sup>,&nbsp;</span><span class="">Sharon Barrans<sup>2</sup>,&nbsp;</span><a href="#" class=article-page-expand-authors>[...]&nbsp;</a><span class=article-page-hidden-authors>Cathy Burton<sup>2</sup>,&nbsp;</span><span class=article-page-hidden-authors><a href="mailto:K.Mercer@soton.ac.uk" title="Send email" class="cauthor research-layout"><span class='f1r-icon icon-6_email orange'></span><span>Katy Mercer</span></a><sup>3</sup>,&nbsp;</span><span class=article-page-hidden-authors>Joshua Caddy<sup>3</sup>,&nbsp;</span><span class=article-page-hidden-authors>Fay Chinnery<a href="http://orcid.org/0000-0002-8082-9016" target=_blank id=mauthor-orcid-5><span class=orcid-logo-for-author-list></span></a><div class="mdl-tooltip mdl-tooltip--wider" for=mauthor-orcid-5><span class=orcid-logo-for-author-list></span> https://orcid.org/0000-0002-8082-9016</div><sup>3</sup>,&nbsp;</span><span class=article-page-hidden-authors>Laura Day<sup>3</sup>,&nbsp;</span><span class=article-page-hidden-authors>Diana Fernando<sup>3</sup>,&nbsp;</span><span class=article-page-hidden-authors>Kirit Ardeshna<sup>4</sup>,&nbsp;</span><span class=article-page-hidden-authors>Graham Collins<sup>5</sup>,&nbsp;</span><span class=article-page-hidden-authors>John Radford<sup>6</sup>,&nbsp;</span><span class=article-page-hidden-authors>Simon Rule<sup>7</sup>,&nbsp;</span><span class=article-page-hidden-authors>Andrew McMillan<sup>8</sup>,&nbsp;</span><span class="">Peter Johnson<sup>1</sup>,&nbsp;</span><span class="">Gareth Griffiths<sup>3</sup></span><span class="author-display-control article-page-expand-authors f1r-icon icon-20_plus_big"></span><span class="author-display-control article-page-hidden-authors f1r-icon icon-12_minus_big"></span></div> </div> <div class=f1r-article-mobile> <div class=article-pubinfo-mobile> PUBLISHED 07 Aug 2020 </div> </div> <span class=Z3988 title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info:ofi/fmt:kev:mtx:journal&amp;rft_id=info:doi/10.12688%2Ff1000research.22318.1"></span> <div class=f1r-article-desk> <div class="contracted-details first"> <a href="#" class="contracted-details-label author-affiliations"><span class=contracted></span>Author details</a> <a href="#" class=section-title>Author details</a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details affiliations is-hidden"> <sup>1</sup> Southampton Experimental Cancer Medicine Centre, University of Southampton and University Hospital Southampton NHS Foundation Trust, Southhampton, UK<br/> <sup>2</sup> Leeds Teaching Hospitals NHS Trust, Leeds, UK<br/> <sup>3</sup> Southampton Clinical Trials Unit, University of Southampton and University Hospital Southampton NHS Foundation Trust, Southampton, UK<br/> <sup>4</sup> University College London Hospitals NHS Foundation Trust, London, UK<br/> <sup>5</sup> Oxford University Hospitals NHS Trust, Oxford, UK<br/> <sup>6</sup> University of Manchester, Manchester, UK<br/> <sup>7</sup> Plymouth Hospitals NHS Trust and Plymouth University Peninsula School of Medicine and Dentistry, Plymouth, UK<br/> <sup>8</sup> Nottingham University Hospitals NHS Trust, Nottingham, UK<br/> <p> <div class=margin-bottom> Andrew Davies <br/> <span>Roles: </span> Conceptualization, Funding Acquisition, Methodology, Supervision </div> <div class=margin-bottom> Sharon Barrans <br/> <span>Roles: </span> Investigation, Project Administration, Resources </div> <div class=margin-bottom> Cathy Burton <br/> <span>Roles: </span> Investigation, Resources </div> <div class=margin-bottom> Katy Mercer <br/> <span>Roles: </span> Project Administration, Writing – Review & Editing </div> <div class=margin-bottom> Joshua Caddy <br/> <span>Roles: </span> Project Administration, Writing – Review & Editing </div> <div class=margin-bottom> Fay Chinnery <br/> <span>Roles: </span> Writing – Original Draft Preparation </div> <div class=margin-bottom> Laura Day <br/> <span>Roles: </span> Formal Analysis, Writing – Review & Editing </div> <div class=margin-bottom> Diana Fernando <br/> <span>Roles: </span> Data Curation </div> <div class=margin-bottom> Kirit Ardeshna <br/> <span>Roles: </span> Investigation, Resources </div> <div class=margin-bottom> Graham Collins <br/> <span>Roles: </span> Investigation, Resources </div> <div class=margin-bottom> John Radford <br/> <span>Roles: </span> Investigation, Resources </div> <div class=margin-bottom> Simon Rule <br/> <span>Roles: </span> Investigation, Resources </div> <div class=margin-bottom> Andrew McMillan <br/> <span>Roles: </span> Investigation, Resources </div> <div class=margin-bottom> Peter Johnson <br/> <span>Roles: </span> Conceptualization, Investigation, Methodology, Resources </div> <div class=margin-bottom> Gareth Griffiths <br/> <span>Roles: </span> Conceptualization </div> </p> </div> </div> </div> <div class=f1r-article-mobile> <div class="article-page-section-box margin-bottom-40 research-layout"> <span class=box-title> <span class="f1r-icon icon-85_peer_review"></span> OPEN PEER REVIEW </span> <div class="status-row referee-reports-container"> REVIEWER STATUS <span class=status-icons> <em>AWAITING PEER REVIEW</em> </span> </div> </div> </div> </div> <h2 class="article-headings article-page-abstract" id=anchor-abstract> <span class="f1r-article-mobile-inline abstract-heading-border"></span> Abstract </h2> <div class="article-abstract article-page-general-text-mobile research-layout"> <div class="abstract-text is-expanded"> <b>Background:</b> Over 13,000 new cases of non-Hodgkin’s lymphoma (NHL) are diagnosed in the UK, with approximately 4,900 attributable deaths each year. Diffuse Large B-cell Lymphoma (DLBCL) is the most common NHL comprising one third of adult NHL cases. R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisolone) is accepted as the international standard first-line regimen, but improvement in first line treatment is needed. Dysregulated B-cell receptor (BCR) signalling has been identified as a feature of DLBCL. Inhibition of Bruton’s tyrosine kinase (Btk), downstream of the BCR has proven efficacious in other B-cell malignancies and in combination with R-CHOP. The second generation Btk inhibitor, acalabrutinib, may have improved target potency and specificity, and therefore better efficacy and tolerability.<br/> <b>Methods: </b>ACCEPT is an open-label non-randomised Phase Ib/II trial testing the addition of acalabrutinib to conventional R-CHOP therapy. ACCEPT incorporates an initial 6+6 modified Phase I design of up to 24 participants followed by 15 participant single arm Phase II expansion cohort in treatment naive patients with histologically confirmed DLBCL expressing CD20. Participants are recruited from UK secondary care sites. Phase I will establish the recommended Phase II dose (RP2D, primary endpoint) of acalabrutinib in combination with R-CHOP. Phase II will gain additional information on safety and efficacy on the RP2D. The primary endpoints of Phase II are overall response rate and toxicity profile. Secondary endpoints include duration of response (progression-free survival and overall survival OS) in relation to cell of origin. Analyses are not powered for formal statistical comparisons; descriptive statistics will describe rates of toxicity, efficacy and translational endpoints.<br/> <b>Discussion:</b>&nbsp;ACCEPT will provide evidence for whether acalabrutinib in combination with R-CHOP is safe and biologically effective prior to future Phase II/III trials in patients with previously untreated CD20 positive DLBCL.<br/> <b>Trial registration: </b>EudraCT Number: <a href="https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-003213-18">2015-003213-18</a> (issued 16 July 2015); ISRCTN<a href="https://doi.org/10.1186/ISRCTN13626902">13626902</a> (registered 07 March 2017). </div> <div class=abstract-for-mobile> <div class="margin-top-30 padding-bottom-30 research-layout is-centered"> <button class="primary orange-text white-bg bigger-text abstract-expand-button-mobile with-border show" style="display: none;"> READ ALL <span class="f1r-icon icon-14_more_small orange vmiddle big"></span> </button> <button class="primary orange-text white-bg bigger-text abstract-expand-button-mobile with-border hide"> READ LESS <span class="f1r-icon icon-10_less_small orange vmiddle big"></span> </button> </div> </div> </div> <div class=clearfix></div> <div class="article-context no-divider"> <div class="article-abstract article-page-general-text-mobile research-layout generated-article-body"> <h2 class=main-title>Keywords</h2> <p class="u-mb--0 u-pb--2"> Diffuse large B-cell lymphoma, acalabrutinib, Btk inhibitor, R-CHOP, molecular profiling, phase I/II </p> </div> </div> <div class=article-information> <span class="info-separation padding-bottom"> <div id=corresponding-author-icon class="email-icon float-left"> <span class="f1r-icon icon-6_email orange"></span> <div id=corresponding-author-window class="margin-top-20 popup-window-wrapper is-hidden"> <div class="popup-window corresponding-authors-popup"> <div class=corresponding-author-container> <div class="popup-window-title small">Corresponding Author(s)</div> <div class=authors> Katy Mercer (<a href="mailto:K.Mercer@soton.ac.uk">K.Mercer@soton.ac.uk</a>) </div> </div> <div class="margin-top margin-bottom float-left"> <button id=close-popup-window class=general-white-orange-button>Close</button> </div> </div> </div> </div> <span class="icon-text float-left" data-test-id=box-corresponding-author> <b>Corresponding author:</b> Katy Mercer </span> <div class=clearfix></div> </span> <span class="info-separation padding-bottom competing-interests-display"> <span class=competing-interests-title>Competing interests:</span> No competing interests were disclosed. </span> <div class="info-separation padding-bottom grant-information-display"> <span class=grant-information-title>Grant information:</span> The study is supported through supply of acalabrutinib and a grant from Acerta Pharma B.V. (IST-LY-801) and has endorsement from Cancer Research UK (CRUKDE/16/006).<br>The funder was not involved in the study design; writing of the protocol paper; or the decision to submit the manuscript for publication. Acerta Pharma B.V. required 30 days (in advance of submission) to review any publication involving the methods or results of the study. If the Company had objected to the publication because (a) there is Company Confidential Information included in the publication or (b) the IMP is not accurately described, the Company Confidential Information would have been removed from the publication or the inaccurate information regarding the IMP corrected, as applicable. <br/> <i>The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.</i> </div> <span class="f1r-article-desk info-separation padding-bottom"> <span class="copywrite-icon float-left"> <span class="f1r-icon icon-100_open_access"></span> </span> <span class="icon-text float-left" data-test-id=box-copyright-text> <b>Copyright:</b>&nbsp; © 2020 Davies A <em>et al</em>. This is an open access article distributed under the terms of the <a href="http://creativecommons.org/licenses/by/4.0/" target=_blank data-test-id=box-licence-link>Creative Commons Attribution License</a>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. </span> <div class=clearfix></div> </span> <span class="info-separation padding-bottom" data-test-id=box-how-to-cite> <b>How to cite:</b> <span class="article-title-and-info in-article-box"> Davies A, Barrans S, Burton C <em>et al.</em> ACCEPT - combining acalabrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone (R-CHOP) for Diffuse Large B-cell Lymphoma (DLBCL): study protocol for a Phase Ib/II open-label non-randomised clinical trial [version 1; peer review: awaiting peer review]</span>. <i>F1000Research</i> 2020, <b>9</b>:941 (<a href="https://doi.org/10.12688/f1000research.22318.1" target=_blank>https://doi.org/10.12688/f1000research.22318.1</a>) </span> <span class=info-separation data-test-id=box-first-published><b>First published:</b> 07 Aug 2020, <b>9</b>:941 (<a href="https://doi.org/10.12688/f1000research.22318.1" target=_blank>https://doi.org/10.12688/f1000research.22318.1</a>)</span> <span class=info-separation data-test-id=box-latest-published><b>Latest published:</b> 07 Aug 2020, <b>9</b>:941 (<a href="https://doi.org/10.12688/f1000research.22318.1" target=_blank>https://doi.org/10.12688/f1000research.22318.1</a>)</span> </div> <div class=clearfix></div> <div id=article-context class=article-context> <div id=article1-body class=generated-article-body><h2 class=main-title id=d2074e407>Abbreviations</h2><p class="" id=d2074e410>ABC, Activated B-cell; ADCC, Antibody dependent cellular cytotoxicity; AE, Adverse Event; AUC, Area under curve; BCR, B-cell Receptor; Btk, Bruton Tyrosine Kinase; CHOP, Cyclophosphamide, doxorubicin, vincristine, prednisolone; CLL, Chronic lymphocytic Leukaemia; Cmax, Maximum Concentration; COO, Cell of origin; CRF, Case Report Form; CT, Computer Tomography; CTCAE, Common Terminology Criteria for Adverse Events; DMEC, Data Monitoring and Ethics Committee; DLT, Dose Limiting Toxicity; DLBCL, Diffuse Large B-cell lymphoma; ECOG, Eastern Cooperative Group; FDA, Food and Drug Administration; FFPE, Formalin Fixed Paraffin Embedded; FISH, Fluorescence In Situ Hybridization; GCB, Germinal Centre B-cell; HBcAB, Hepatitis B core Antibody; HBsAB, Hepatitis B Surface antibody; HBsAg, Hepatitis B surface Antigen; HBV, Hepatitis B virus; HCV, Hepatitis C virus; HIV, Human Immunodeficiency Virus; HMDS, Haematological Malignancy Diagnostic Service; IMP, Investigational Medicinal Product; IV, Intravenous; LVEF, Left Ventricular Ejection Fraction; MAD, Maximal administered Dose; MHRA, Medicines and Healthcare products Regulatory Agency; MTD, Maximum Tolerated Dose; NCI, National Cancer Institute; NHL, Non-Hodgkin Lymphoma; Od, Once daily; ORR, Overall Response Rate; PBMC, Peripheral Blood Mononuclear cells; PK, Pharmacokinetic; PD, Progressive disease; PET CT, Positron Emission Tomography computer tomography; PIS, Patient Information Sheet; PO, By mouth; PR, Partial Response; RP2D, Recommended Phase 2 Dose; R-CHOP, Rituximab, cyclophosphamide, doxorubicin, vincristine, prednisolone; SAE, Serious Adverse Event; SCTU, Southampton Clinical Trial Unit; SUSAR, Suspected Unexpected Serious Adverse Reaction; Tmax, Time to maximum concentration</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d2074e416>Introduction</h2><div class=section><a name=d2074e419 class=n-a></a><h3 class=section-title>Background and rationale</h3><p class="" id=d2074e424>More than 13,000 new cases of non-Hodgkin’s lymphoma (NHL) were diagnosed in the UK between 2014–2016, with nearly 4,900 patients dying as a result of their disease in 2017<sup><a href="#ref-1">1</a></sup>. Diffuse large B-cell lymphoma (DLBCL) is the most common type of NHL, accounting for 30–40% of NHL cases in adults with an annual incidence of about 5,500 patients in the UK<sup><a href="#ref-1">1</a>,<a href="#ref-2">2</a></sup>.</p><p class="" id=d2074e438>Cyclophosphamide, vincristine, doxorubicin and prednisolone (CHOP) used to be the standard of care for DLBCL. But, overall survival was disappointing; CHOP only cured about 30 percent of patients with advanced stages of intermediate-grade or high-grade NHL<sup><a href="#ref-3">3</a></sup>. Addition of the anti-CD20 monoclonal antibody rituximab to CHOP resulted in higher response rates, longer event free survival and improved overall survival. R-CHOP is now accepted as the international standard, with cure rates around 75%<sup><a href="#ref-4">4</a>–<a href="#ref-8">8</a></sup>.</p><p class="" id=d2074e452>Despite this improvement, many patients either fail to respond or relapse after having achieved an initial remission. Their prognosis is poor, because earlier rituximab therapy limits the success of salvage treatment and so the majority of these patients will die from their disease<sup><a href="#ref-9">9</a></sup>. Consequently, there is an urgent need to improve the effectiveness of first line treatment.</p><p class="" id=d2074e459>Gene expression profiling of untreated DLBCL samples has identified three distinct sub-classifications of the disease: activated B-cell like [ABC-DLBCL]; germinal centre B-cell like [GCB- DLBCL] and unclassified DLBCL. Each has its own biological features and clinical outcomes when treated with CHOP or R-CHOP.</p><p class="" id=d2074e463>The cells of ABC type are driven by “chronic active” B-cell receptor (BCR) signalling<sup><a href="#ref-10">10</a></sup>. The BCR signalling pathway can be disrupted using Bruton tyrosine kinase (Btk) inhibitors. Targeting BCR signalling by inhibiting Btk with ibrutinib (a first generation Btk inhibitor) in combination with R-CHOP is known to be safe for previously untreated B-cell NHL<sup><a href="#ref-11">11</a></sup>.</p><p class="" id=d2074e474>Acalabrutinib (Acerta Pharma B.V.) is a second generation Btk inhibitor with increased target selectivity compared to ibrutinib<sup><a href="#ref-12">12</a></sup>. As of 30 December 2018, acalabrutinib has been administered to over 2600 participants in clinical studies, including patients with haematologic malignancies, solid tumour, or rheumatoid arthritis, and participants who are healthy volunteers or with mild to moderate hepatic impairment. No serious adverse events (SAEs) have been reported in the hepatic impairment study or in the healthy volunteer studies. No expected SAEs have been identified for acalabrutinib to date.</p><p class="" id=d2074e481>We hypothesised that acalabrutinib would have improved target potency and specificity and is both active and tolerable in combination with R-CHOP.</p></div></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d2074e488>Objectives</h2><p class="" id=d2074e491>The objectives of the study are described in <a href="#T1">Table 1</a>. ACCEPT aims to establish a recommended Phase II dose (RP2D) for acalabrutinib when combined with R-CHOP.</p><a name=T1 class=n-a></a><div class="table-wrap panel clearfix"><div class=caption><h3>Table 1. Primary, secondary and tertiary objectives of the ACCEPT study.</h3></div><table xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class=article-table frame=below><a name=d2074e508 class=n-a></a><thead><a name=d2074e510 class=n-a></a><tr><a name=d2074e512 class=n-a></a><th align=center colspan=1 rowspan=1><a name=d2074e514 class=n-a></a></th><th align=center colspan=1 rowspan=1><a name=d2074e516 class=n-a></a>Objective</th><th align=center colspan=1 rowspan=1><a name=d2074e519 class=n-a></a>Endpoint used to evaluate</th></tr></thead><tbody><a name=d2074e524 class=n-a></a><tr><a name=d2074e526 class=n-a></a><td align=left colspan=1 rowspan=3 valign=top><a name=d2074e528 class=n-a></a><b>Primary:</b></td><td align=left colspan=1 rowspan=1 valign=top><a name=d2074e532 class=n-a></a><span style="text-decoration: underline">Phase I – Dose Escalation</span><br class=br>To propose a recommended dose for Phase II evaluation of<br class=br>acalabrutinib in combination with R-CHOP in patients with<br class=br>DLBCL:<br class=br> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;- To examine the safety and toxicity profile of<br class=br>acalabrutinib in combination with R-CHOP and defining<br class=br>the dose limiting toxicity or maximum administered<br class=br>dose.</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2074e551 class=n-a></a><span style="text-decoration: underline">Phase I</span><br class=br>Dose limiting toxicity of acalabrutinib combined to R-CHOP.</td></tr><tr><a name=d2074e558 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d2074e560 class=n-a></a><span style="text-decoration: underline">Phase II: - Dose Expansion</span><br class=br>To document anti-tumour activity of acalabrutinib in<br class=br>combination with R-CHOP in patients with previously<br class=br>untreated CD20 positive DLBCL</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2074e570 class=n-a></a><span style="text-decoration: underline">Phase II</span><br class=br>Overall response rate of the combination acalabrutinib and<br class=br>R-CHOP.</td></tr><tr><a name=d2074e579 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d2074e581 class=n-a></a>To determine additional safety information of acalabrutinib in<br class=br>combination with R-CHOP.</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2074e586 class=n-a></a>Safety of the combination acalabrutinib and R-CHOP.</td></tr><tr><a name=d2074e590 class=n-a></a><td align=left colspan=1 rowspan=3 valign=top><a name=d2074e592 class=n-a></a><b>Secondary:</b></td><td align=left colspan=1 rowspan=1 valign=top><a name=d2074e596 class=n-a></a>To determine the pharmacokinetic (PK) profile of<br class=br>acalabrutinib when given in combination with R-CHOP in<br class=br>patients with DLBCL.</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2074e603 class=n-a></a>Pharmacokinetic of acalabrutinib, AUC, Cmax, Tmax, half-life<br class=br>T<sub>1/2</sub> and other PK parameter.</td></tr><tr><a name=d2074e612 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d2074e614 class=n-a></a>To evaluate the effect of acalabrutinib in combination with<br class=br>R-CHOP on outcomes according to COO</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2074e619 class=n-a></a>Overall response rate of the combination acalabrutinib and<br class=br>R-CHOP according to COO</td></tr><tr><a name=d2074e626 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d2074e628 class=n-a></a>To measure the duration of response to acalabrutinib in<br class=br>combination with R-CHOP over a follow-up period of 2 years</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2074e633 class=n-a></a>2-years progression-free survival; 2-years overall survival.</td></tr><tr><a name=d2074e637 class=n-a></a><td align=left colspan=1 rowspan=5 valign=top><a name=d2074e639 class=n-a></a><b>Tertiary:</b></td><td align=left colspan=1 rowspan=1 valign=top><a name=d2074e643 class=n-a></a>To determine BTK occupancy by acalabrutinib in peripheral<br class=br>blood mononuclear cells when given with R-CHOP.</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2074e648 class=n-a></a>Btk occupancy by acalabrutinib on peripheral blood using<br class=br>fluorescent affinity probe assay.</td></tr><tr><a name=d2074e654 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d2074e656 class=n-a></a>To determine the impact of addition of acalabrutinib on R-<br class=br>CHOP mediated ADCC.</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2074e661 class=n-a></a>Antibody-dependent cell-mediated cytotoxicity of R-CHOP<br class=br>when combined to acalabrutinib, post 1st R-CHOP and at<br class=br>day 8, 2nd cycle acalabrutinib + R-CHOP.</td></tr><tr><a name=d2074e669 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d2074e671 class=n-a></a>To determine evidence of B-cell receptor (BCR) activation<br class=br>in patients before and after treatment with combination of<br class=br>R-CHOP and acalabrutinib.</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2074e678 class=n-a></a>CD86 and CD69 expression as a function of BCR activation<br class=br>by flow cytometry.</td></tr><tr><a name=d2074e684 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d2074e686 class=n-a></a>To explore the use of tumour-specific circulating DNA in<br class=br>plasma/serum as a non-invasive diagnostic and prognostic<br class=br>tool, with paired lymphoma tissue, through treatment of<br class=br>DLBCL and at follow up.</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2074e695 class=n-a></a>Tumour-specific DNA in plasma will be sequenced<br class=br>throughout treatment and compared with lymphoma tissue<br class=br>and clinical course.</td></tr><tr><a name=d2074e703 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d2074e705 class=n-a></a>To explore correlation of molecular characteristics in tumour<br class=br>material to clinical outcomes.</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2074e710 class=n-a></a>Apply the following techniques to FFPE tumour material:<br class=br>mutational panel, FISH analysis, immunohistochemical<br class=br>analysis for dual protein expression of Myc and Bcl2<br class=br>and gene expression profiling using whole transcriptome<br class=br>profiling.</td></tr></tbody></table></div><p class="" id=d2074e725>Secondary objectives include the evaluation of dose limiting toxicity (DLT), assessed using CTCAE v4.03 at baseline, at each treatment cycle and at each follow-up visit; treatment compliance, assessed using patient diaries and returned Investigational Medicinal Product (IMP), as well as the electronic case report forms (eCRFs) during the treatment period; and response rate of participants enrolled in the Phase II part of the trial.</p><p class="" id=d2074e728>Translational objectives include determining the pharmacokinetic (PK) profile of acalabrutinib when given in combination with R-CHOP in patients with DLBCL. Btk occupancy by acalabrutinib of PBMC peripheral blood mononuclear cells (PBMCs) will be measured using fluorescent affinity probe assay. Pre- and post-dose blood samples will be used to measure the impact of the addition of acalabrutinib on R-CHOP mediated antibody dependent cellular cytotoxicity (ADCC), and measure BCR activation via CD86 and CD69 expression on PBMC by flow cytometry.</p><p class="" id=d2074e732>ACCEPT will prospectively validate the cell of origin (ABC versus GCB) model of DLBCL and its practicality and utility, as well as assessing the benefit/toxicity of the addition of acalabrutinib to R-CHOP. DNA extracted from tumour material will be used to perform mutation detection on BCR pathway (e.g. Btk, PI3K, CD79b). Genetic abnormalities of BCR pathway will be correlated with clinical outcomes and the expression of BCR pathway target genes.</p><div class=section><a name=d2074e735 class=n-a></a><h3 class=section-title>Trial design</h3><p class="" id=d2074e740>ACCEPT is a multicentre open-label non-randomised Phase Ib/II clinical trial conducted in two stages recruiting approximately 40 participants. Phase I will be dose escalation following the conventional rules of 6+6 modified design, escalation will proceed until a maximum tolerated dose (MTD) is defined or the maximal administered dose (MAD) is determined in order to define the RP2D. A six participant cohort design is employed to maximise patient safety<sup><a href="#ref-13">13</a></sup>, which will result in 6–24 participants recruited. Phase II will be an expansion cohort in order to gain additional information on safety and efficacy at the RP2D from a total of 15 participants recruited (<a href="#f1">Figure 1</a>).</p><a name=f1 class=n-a></a><div class="fig panel clearfix"><a target=_blank href="https://f1000researchdata.s3.amazonaws.com/manuscripts/24618/d876506d-3b0c-4632-a824-3bfeee9a1da1_figure1.gif"><img alt="d876506d-3b0c-4632-a824-3bfeee9a1da1_figure1.gif" src="https://f1000researchdata.s3.amazonaws.com/manuscripts/24618/d876506d-3b0c-4632-a824-3bfeee9a1da1_figure1.gif"></a><div class=caption><h3>Figure 1. Accept Trial schema.</h3></div></div></div></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d2074e768>Methods: participants, interventions and outcomes</h2><p class="" id=d2074e771>This is protocol V6 (15-Jul-2019).</p><div class=section><a name=d2074e774 class=n-a></a><h3 class=section-title>Study setting</h3><p class="" id=d2074e779>Seven secondary care hospitals in the UK are recruiting participants into ACCEPT. A list of study sites is available via contacting <a href="mailto:accept@soton.ac.uk">accept@soton.ac.uk</a>.</p></div><div class=section><a name=d2074e786 class=n-a></a><h3 class=section-title>Eligibility criteria</h3><p class="" id=d2074e791><b><i>Inclusion criteria</i></b></p><p class="" id=d2074e796>Participants should fulfil the following criteria:</p><div class=list><a name=d2074e799 class=n-a></a><ul><li><p id=d2074e803>Histologically confirmed DLBCL, expressing CD20; sufficient tumour block should be available to forward to a central laboratory for gene expression profiling and pathology review; at a minimum, participants should have sufficient tumour material to test for: H/E morphological check of compatibility of DLBCL diagnosis, immunophenotyping and RNA for gene expression profiling</p></li><li><p id=d2074e809>Measurable disease of at least 15mm</p></li><li><p id=d2074e815>Not previously treated for lymphoma and fit enough to receive combination chemoimmunotherapy with curative intent</p></li><li><p id=d2074e821>Stage IAX (bulk defined as lymph node diameter &gt;10cm) to stage IV disease and deemed to require a full course of chemotherapy. Patients with non-bulky IE disease will not be eligible</p></li><li><p id=d2074e827>ECOG performance status 0–2 or 3 if this is directly attributable to lymphoma</p></li><li><p id=d2074e834>Adequate bone marrow function with platelets &gt; 100×10<sup>9</sup>/L; neutrophils &gt; 1.0×10<sup>9</sup>/L at study entry, unless lower figures are attributable to lymphoma</p></li><li><p id=d2074e846>Measured or calculated creatinine clearance &gt; 30mls/min, (calculated using the formula of Cockcroft and Gault [(140-Age) × Mass (kg) × (1.04 (for women) or 1.23 (for men))/Serum Creatinine (µmolL)]</p></li><li><p id=d2074e852>Serum bilirubin &lt; 35μmol/L and transaminases &lt; 2.5× upper limit of normal at time of study entry</p></li><li><p id=d2074e858>Cardiac function sufficient to tolerate 300mg/m<sup>2</sup> of doxorubicin. A pre-treatment echocardiogram or MUGA is required to establish baseline LVEF equal to or greater than institutional normal range.</p></li><li><p id=d2074e867>No concurrent uncontrolled medical condition</p></li><li><p id=d2074e873>Life expectancy &gt; 3 months</p></li><li><p id=d2074e880>Aged 16 years and above</p></li><li><p id=d2074e886>Willing and able to participate in all required evaluations and procedures in this study protocol including swallowing capsules without difficulty</p></li><li><p id=d2074e892>Ability to understand the purpose and risks of the study and provide signed and dated informed consent</p></li></ul></div><p class="" id=d2074e897><b><i>Exclusion criteria</i></b></p><p class="" id=d2074e903>Patients will be excluded from the study entry if any of the following criteria are met:</p><div class=list><a name=d2074e906 class=n-a></a><ul><li><p id=d2074e910>Previous history of treated or untreated indolent lymphoma; however newly diagnosed patients with DLBCL who are found to also have small cell infiltration of the bone marrow or other diagnostic material (discordant lymphoma) will be eligible</p></li><li><p id=d2074e916>Patients who have received immunisation with a live vaccine within four weeks prior to enrolment will be ineligible</p></li><li><p id=d2074e922>Diagnosis of primary mediastinal lymphoma</p></li><li><p id=d2074e928>Diagnosis of primary Central Nervous System lymphoma</p></li><li><p id=d2074e934>History of stroke or intracranial haemorrhage in preceding 6 months</p></li><li><p id=d2074e941>History of bleeding diathesis (e.g., haemophilia, von Willebrand disease)</p></li><li><p id=d2074e947>Requires or receiving anticoagulation with warfarin or equivalent antagonists (e.g. phenprocoumon) within 7 days of first dose of acalabrutinib; however, patients using therapeutic low molecule weight heparin or low dose aspirin will be eligible</p></li><li><p id=d2074e953>Prior exposure to a BCR inhibitor (e.g. Btk inhibitors, phosphoinositide-3 kinase (PI3K), or Syk inhibitors) or BCL-2 inhibitor (e.g. ABT-199)</p></li><li><p id=d2074e959>Requires treatment with a strong cytochrome P450 3A4 (CYP3A4) inhibitor/inducer.</p></li><li><p id=d2074e965>Requires treatment with proton pump inhibitors (e.g. omeprazole, esomeprazole, lansoprazole, dexlansoprazole, rabeprazole, or pantoprazole)</p><div class=list><a name=d2074e968 class=n-a></a><ul style="list-style-type: none"><li><p id=d2074e975><span class=label>○ </span> Patients receiving proton pump inhibitors should switch to short-acting H2-receptor antagonists or antacids prior to study entry to be eligible for enrolment into this study</p></li></ul></div></li><li><p id=d2074e983>Uncontrolled systemic infection.</p></li><li><p id=d2074e990>Major surgery in the preceding 4 weeks of first dose of study drug. If a subject had major surgery, they must have recovered adequately from any toxicity and/or complications from the intervention before the first dose of study drug</p></li><li><p id=d2074e996>Significant cardiovascular disease such as uncontrolled or symptomatic arrhythmias, congestive heart failure, or myocardial infarction within 6 months of screening, or any Class 3 or 4 cardiac disease as defined by the New York Heart Association Functional Classification, or corrected QT interval (QTc) &gt; 480 msec at screening. QTc interval should be calculated using Fridericia’s formula</p></li><li><p id=d2074e1002>Serological positivity for Hepatitis B (HBV), C (HCV), or known HIV infection. As per standard of care, prior to initiation of immunochemotherapy, the results of hepatitis serology should be known prior to commencement of therapy.</p><div class=list><a name=d2074e1005 class=n-a></a><ul style="list-style-type: none"><li><p id=d2074e1012><span class=label>- </span> Positive test results for chronic HBV infection (defined as positive HBsAg serology) will not be eligible. Patients with occult or prior HBV infection (defined as negative HBsAg and positive total HBcAb) will not be eligible. Patients who have protective titres of hepatitis B surface antibody (HBsAb) after vaccination will be eligible</p></li><li><p id=d2074e1021><span class=label>- </span> Positive test results for HCV (HCV antibody serology testing) will not be eligible</p></li></ul></div></li><li><p id=d2074e1029>Women who can bear children must agree to use two highly effective forms of contraception or abstinence during the study and for 12 months after the last treatment dose (contraception is discussed under ‘5. Relevant concomitant care permitted or prohibited during the trial’)</p></li><li><p id=d2074e1035>Breastfeeding or pregnant women</p></li><li><p id=d2074e1041>Men who can father children must agree to use two highly effective forms of contraception with additional barrier or abstinence during the study and for 12 months after the last treatment dose (contraception is discussed under ‘Relevant concomitant care permitted or prohibited during the trial’)</p></li><li><p id=d2074e1048>Men must agree to refrain from sperm donation during the study and for 12 months after the last treatment dose</p></li><li><p id=d2074e1054>Serious medical or psychiatric illness likely to affect participation or that may compromise the ability to give informed consent</p></li><li><p id=d2074e1060>Prior malignancy (other than DLBCL), except for adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, or other cancer from which the subject has been disease free for ≥ 2 years or which will not limit survival to &lt; 2 years. Note: these cases must be discussed with Southampton Clinical Trials Unit (SCTU)</p></li><li><p id=d2074e1066>Malabsorption syndrome, disease significantly affecting gastrointestinal function, resection of the stomach or small bowel, gastric bypass, symptomatic inflammatory bowel disease, or partial or complete bowel obstruction or gastric restrictions and bariatric surgery, such as gastric bypass</p></li><li><p id=d2074e1072>Any immunotherapy within 4 weeks of 1<sup>st</sup> dose of the study</p></li><li><p id=d2074e1081>Concurrent participation in another therapeutic clinical trial</p></li></ul></div></div><div class=section><a name=d2074e1087 class=n-a></a><h3 class=section-title>Consent</h3><p class="" id=d2074e1092><b><i>Who will take informed consent?</i></b></p><p class="" id=d2074e1097>Consent to enter the trial will be sought from each participant only after a full explanation has been given, a Patient Information Sheet (PIS) offered (<i>Extended data</i><sup><a href="#ref-14">14</a></sup>) and time allowed for consideration. Signed participant consent will be obtained. Only site staff named on the Delegation Log and authorised to do so may obtain consent. Patients may refuse to participate without giving reasons and this will not prejudice their future treatment.</p><p class="" id=d2074e1106><b><i>Additional consent provisions for collection and use of participant data and biological specimens</i></b></p><p class="" id=d2074e1111>The trial’s Informed Consent Forms detail the consent provisions for collection and use of participant data and biological specimens in future research (<i>Extended data</i><sup><a href="#ref-14">14</a></sup>).</p></div><div class=section><a name=d2074e1122 class=n-a></a><h3 class=section-title>Interventions</h3><p class="" id=d2074e1127><b><i>Explanation for the choice of comparators</i></b></p><p class="" id=d2074e1132><i>Rationale for combination of acalabrutinib in combination with R-CHOP in DLBCL</i></p><p class="" id=d2074e1136>Dysregulation of BCR signalling is well recognised in DLBCL and other B-cell malignancies. Btk is central to signalling through the BCR. The safety and efficacy of a first generation Btk inhibitor, ibrutinib, in combination with R-CHOP has already been investigated by a Phase Ib study in patients with DLBCL, demonstrating that it is well tolerated with an overall response rate (ORR) of 91% (CR 70%)<sup><a href="#ref-10">10</a></sup>.</p><p class="" id=d2074e1143>Acalabrutinib is a second generation Btk inhibitor with enhanced kinase selectivity and potential for better efficacy and tolerability over first-generation inhibitors. It has a number of preclinical properties that would indicate the potential for favourable efficacy and safety over ibrutinib. These include preferential selectivity for Btk with the potential for less off-target effects (e.g. Epidermal Growth Factor Receptor and diarrhoea). Acalabrutinib does not appear to abrogate thrombus formation, compared to ibrutinib, mediated by off-target kinase activity, and would therefore potentially reduce the risk of bleeding and also compared to ibrutinib does not have a negative effect on ADCC, an important mediator of rituximab function.</p><p class="" id=d2074e1147>Results from the study of acalabrutinib in patients with chronic lymphocytic leukaemia (CLL) demonstrate a favourable toxicity profile with an emergent lower rate of haematological toxicity compared to ibrutinib. No DLTs were reached and no SAEs reported to date at doses ≤400mg<sup><a href="#ref-15">15</a></sup>.</p><p class="" id=d2074e1154><i>Rationale for dose selection</i></p><p class="" id=d2074e1158>Results from the study of ibrutinib in combination with R-CHOP indicated that the maximal tolerated dose was not reached and the recommended Phase II dose of ibrutinib was 560mg od<sup><a href="#ref-10">10</a></sup>. This is the licensed single agent dose for use in mantle cell lymphoma. Given the favourable single agent toxicity profile of acalabrutinib in the CLL study compared to ibrutinib, it is anticipated that acalabrutinib may safely be given in combination with R-CHOP at doses close or equivalent to those being investigated as a single agent.</p><p class="" id=d2074e1165>Preliminary data from the ongoing Phase I/II study in patients with relapsed/refractory or previously untreated CLL have shown that acalabrutinib is well tolerated at dosages of 100 to 400 mg od and 100 to 200 mg bd<sup><a href="#ref-15">15</a></sup>. These data suggest that <i>de novo</i> synthesis of Btk can occur within 24 hours in peripheral blood cells. Twice daily dosing may ensure Btk inhibition for the entire 24 hours and thus may be beneficial in terms of increasing efficacy and/or decreasing development of resistance to acalabrutinib.</p><p class="" id=d2074e1175>Taken together, the proposed starting dose of 100mg od is considered represent one where there is good pharmacodynamic evidence that the target is being suitably occupied without safety concerns in single agent studies and one supported by our pharmacokinetic knowledge of acalabrutinib. Escalation to twice daily dosing in the second cohort, addresses the continued inhibition of Btk based upon concerns about <i>de novo</i> synthesis during the 24-hour period.</p><p class="" id=d2074e1181><b><i>Intervention description</i></b></p><p class="" id=d2074e1187>All participants will receive 6 cycles of R-CHOP on a standard 21 day schedule with the addition of acalabrutinib in cycles 2–6. This will be followed by a continuation period of acalabrutinib only for 2 cycles each of 28 days. The Schedule of Events (<a href="#T2">Table 2</a>) describes the trial interventions.</p><a name=T2 class=n-a></a><div class="table-wrap panel clearfix"><div class=caption><h3>Table 2. Schedule of observations and procedures.</h3></div><table xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class=article-table frame=below><a name=d2074e1204 class=n-a></a><thead><a name=d2074e1206 class=n-a></a><tr><a name=d2074e1208 class=n-a></a><th align=left colspan=13 rowspan=1><a name=d2074e1210 class=n-a></a>R<span style="font-variant: small-caps">egistration and</span> C<span style="font-variant: small-caps">ycle</span> 1</th></tr><tr><a name=d2074e1220 class=n-a></a><th align=center colspan=1 rowspan=1><a name=d2074e1222 class=n-a></a>Visit</th><th align=center colspan=11 rowspan=2><a name=d2074e1225 class=n-a></a>Screening <sup><a href="#FN1">a</a></sup></th><th align=center colspan=1 rowspan=1><a name=d2074e1231 class=n-a></a>Cycle 1</th></tr><tr><a name=d2074e1235 class=n-a></a><th align=center colspan=1 rowspan=1><a name=d2074e1237 class=n-a></a>Weeks</th><th align=center colspan=1 rowspan=1><a name=d2074e1240 class=n-a></a>1</th></tr><tr><a name=d2074e1244 class=n-a></a><th align=center colspan=1 rowspan=1><a name=d2074e1246 class=n-a></a>Days</th><th align=center colspan=2 rowspan=1><a name=d2074e1249 class=n-a></a>Within 90<br class=br>days of<br class=br>treatment</th><th align=center colspan=2 rowspan=1><a name=d2074e1256 class=n-a></a>Within 35 days<br class=br>of treatment</th><th align=center colspan=2 rowspan=1><a name=d2074e1261 class=n-a></a>Within 28 days<br class=br>of treatment</th><th align=center colspan=2 rowspan=1><a name=d2074e1266 class=n-a></a>Within 14 days<br class=br>of treatment</th><th align=center colspan=2 rowspan=1><a name=d2074e1272 class=n-a></a>Within 72<br class=br>hours of<br class=br>treatment</th><th align=center colspan=1 rowspan=1><a name=d2074e1279 class=n-a></a>Prior to<br class=br>treatment</th><th align=center colspan=1 rowspan=1><a name=d2074e1284 class=n-a></a>R-CHOP</th></tr></thead><tbody><a name=d2074e1289 class=n-a></a><tr><a name=d2074e1291 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d2074e1293 class=n-a></a>Informed consent</td><td align=left colspan=2 rowspan=1 valign=top><a name=d2074e1296 class=n-a></a></td><td align=left colspan=2 rowspan=1 valign=top><a name=d2074e1298 class=n-a></a></td><td align=center colspan=2 rowspan=1 valign=top><a name=d2074e1300 class=n-a></a>X</td><td align=left colspan=2 rowspan=1 valign=top><a name=d2074e1303 class=n-a></a></td><td align=left colspan=2 rowspan=1 valign=top><a name=d2074e1306 class=n-a></a></td><td align=left colspan=1 rowspan=1 valign=top><a name=d2074e1308 class=n-a></a></td><td align=left colspan=1 rowspan=1 valign=top><a name=d2074e1310 class=n-a></a></td></tr><tr><a name=d2074e1313 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d2074e1315 class=n-a></a>Inclusion/Exclusion<br class=br>criteria</td><td align=left colspan=2 rowspan=1 valign=top><a name=d2074e1320 class=n-a></a></td><td align=left colspan=2 rowspan=1 valign=top><a name=d2074e1322 class=n-a></a></td><td align=left colspan=2 rowspan=1 valign=top><a name=d2074e1324 class=n-a></a></td><td align=center colspan=2 rowspan=1 valign=top><a name=d2074e1326 class=n-a></a>X</td><td align=left colspan=2 rowspan=1 valign=top><a name=d2074e1330 class=n-a></a></td><td align=left colspan=1 rowspan=1 valign=top><a name=d2074e1332 class=n-a></a></td><td align=left colspan=1 rowspan=1 valign=top><a name=d2074e1334 class=n-a></a></td></tr><tr><a name=d2074e1337 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d2074e1339 class=n-a></a>Medical History</td><td align=left colspan=2 rowspan=1 valign=top><a name=d2074e1342 class=n-a></a></td><td align=left colspan=2 rowspan=1 valign=top><a name=d2074e1344 class=n-a></a></td><td align=left colspan=2 rowspan=1 valign=top><a name=d2074e1346 class=n-a></a></td><td align=center colspan=2 rowspan=1 valign=top><a name=d2074e1348 class=n-a></a>X</td><td align=left colspan=2 rowspan=1 valign=top><a name=d2074e1352 class=n-a></a></td><td align=left colspan=1 rowspan=1 valign=top><a name=d2074e1354 class=n-a></a></td><td align=left colspan=1 rowspan=1 valign=top><a name=d2074e1356 class=n-a></a></td></tr><tr><a name=d2074e1359 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d2074e1361 class=n-a></a>Physical Exam</td><td align=left colspan=2 rowspan=1 valign=top><a name=d2074e1364 class=n-a></a></td><td align=left colspan=2 rowspan=1 valign=top><a name=d2074e1366 class=n-a></a></td><td align=left colspan=2 rowspan=1 valign=top><a name=d2074e1368 class=n-a></a></td><td align=center colspan=2 rowspan=1 valign=top><a name=d2074e1370 class=n-a></a>X</td><td align=left colspan=2 rowspan=1 valign=top><a name=d2074e1374 class=n-a></a></td><td align=left colspan=1 rowspan=1 valign=top><a name=d2074e1376 class=n-a></a></td><td align=left colspan=1 rowspan=1 valign=top><a name=d2074e1378 class=n-a></a></td></tr><tr><a name=d2074e1381 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d2074e1383 class=n-a></a>IPI and NCCN-IPI<br class=br>(<i>Extended data</i>)</td><td align=left colspan=2 rowspan=1 valign=top><a name=d2074e1391 class=n-a></a></td><td align=left colspan=2 rowspan=1 valign=top><a name=d2074e1393 class=n-a></a></td><td align=left colspan=2 rowspan=1 valign=top><a name=d2074e1395 class=n-a></a></td><td align=center colspan=2 rowspan=1 valign=top><a name=d2074e1397 class=n-a></a>X</td><td align=left colspan=2 rowspan=1 valign=top><a name=d2074e1401 class=n-a></a></td><td align=left colspan=1 rowspan=1 valign=top><a name=d2074e1403 class=n-a></a></td><td align=left colspan=1 rowspan=1 valign=top><a name=d2074e1405 class=n-a></a></td></tr><tr><a name=d2074e1409 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d2074e1411 class=n-a></a>Vital signs <sup><a href="#FN2">b</a></sup></td><td align=left colspan=2 rowspan=1 valign=top><a name=d2074e1417 class=n-a></a></td><td align=left colspan=2 rowspan=1 valign=top><a name=d2074e1419 class=n-a></a></td><td align=left colspan=2 rowspan=1 valign=top><a name=d2074e1421 class=n-a></a></td><td align=center colspan=2 rowspan=1 valign=top><a name=d2074e1423 class=n-a></a>X</td><td align=left colspan=2 rowspan=1 valign=top><a name=d2074e1427 class=n-a></a></td><td align=left colspan=1 rowspan=1 valign=top><a name=d2074e1429 class=n-a></a></td><td align=center colspan=1 rowspan=1 valign=top><a name=d2074e1431 class=n-a></a>X</td></tr><tr><a name=d2074e1435 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d2074e1437 class=n-a></a>ECOG performance<br class=br>Status</td><td align=left colspan=2 rowspan=1 valign=top><a name=d2074e1442 class=n-a></a></td><td align=left colspan=2 rowspan=1 valign=top><a name=d2074e1444 class=n-a></a></td><td align=left colspan=2 rowspan=1 valign=top><a name=d2074e1446 class=n-a></a></td><td align=center colspan=2 rowspan=1 valign=top><a name=d2074e1448 class=n-a></a>X</td><td align=left colspan=2 rowspan=1 valign=top><a name=d2074e1452 class=n-a></a></td><td align=left colspan=1 rowspan=1 valign=top><a name=d2074e1454 class=n-a></a></td><td align=center colspan=1 rowspan=1 valign=top><a name=d2074e1456 class=n-a></a>X</td></tr><tr><a name=d2074e1460 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d2074e1462 class=n-a></a>PET-CT or contrast<br class=br>enhanced CT with<br class=br>separate PET <sup><a href="#FN3">c</a></sup></td><td align=left colspan=2 rowspan=1 valign=top><a name=d2074e1472 class=n-a></a></td><td align=center colspan=2 rowspan=1 valign=top><a name=d2074e1474 class=n-a></a>X</td><td align=left colspan=2 rowspan=1 valign=top><a name=d2074e1477 class=n-a></a></td><td align=left colspan=2 rowspan=1 valign=top><a name=d2074e1479 class=n-a></a></td><td align=left colspan=2 rowspan=1 valign=top><a name=d2074e1482 class=n-a></a></td><td align=left colspan=1 rowspan=1 valign=top><a name=d2074e1484 class=n-a></a></td><td align=left colspan=1 rowspan=1 valign=top><a name=d2074e1486 class=n-a></a></td></tr><tr><a name=d2074e1489 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d2074e1491 class=n-a></a>Bone marrow<br class=br>biopsy <sup><a href="#FN4">d</a></sup></td><td align=center colspan=2 rowspan=1 valign=top><a name=d2074e1499 class=n-a></a>X</td><td align=left colspan=2 rowspan=1 valign=top><a name=d2074e1502 class=n-a></a></td><td align=left colspan=2 rowspan=1 valign=top><a name=d2074e1504 class=n-a></a></td><td align=left colspan=2 rowspan=1 valign=top><a name=d2074e1506 class=n-a></a></td><td align=left colspan=2 rowspan=1 valign=top><a name=d2074e1509 class=n-a></a></td><td align=left colspan=1 rowspan=1 valign=top><a name=d2074e1511 class=n-a></a></td><td align=left colspan=1 rowspan=1 valign=top><a name=d2074e1513 class=n-a></a></td></tr><tr><a name=d2074e1516 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d2074e1518 class=n-a></a>Biochemistry: renal<br class=br>and liver function <sup><a href="#FN5">e</a></sup></td><td align=left colspan=2 rowspan=1 valign=top><a name=d2074e1526 class=n-a></a></td><td align=left colspan=2 rowspan=1 valign=top><a name=d2074e1528 class=n-a></a></td><td align=left colspan=2 rowspan=1 valign=top><a name=d2074e1530 class=n-a></a></td><td align=center colspan=2 rowspan=1 valign=top><a name=d2074e1532 class=n-a></a>X</td><td align=left colspan=2 rowspan=1 valign=top><a name=d2074e1536 class=n-a></a></td><td align=left colspan=1 rowspan=1 valign=top><a name=d2074e1538 class=n-a></a></td><td align=left colspan=1 rowspan=1 valign=top><a name=d2074e1540 class=n-a></a></td></tr><tr><a name=d2074e1543 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d2074e1545 class=n-a></a>Biochemistry:<br class=br>Additional baseline<br class=br>panel <sup><a href="#FN6">f</a></sup></td><td align=left colspan=2 rowspan=1 valign=top><a name=d2074e1555 class=n-a></a></td><td align=left colspan=2 rowspan=1 valign=top><a name=d2074e1557 class=n-a></a></td><td align=left colspan=2 rowspan=1 valign=top><a name=d2074e1559 class=n-a></a></td><td align=left colspan=2 rowspan=1 valign=top><a name=d2074e1561 class=n-a></a></td><td align=center colspan=2 rowspan=1 valign=top><a name=d2074e1564 class=n-a></a>X</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2074e1567 class=n-a></a></td><td align=left colspan=1 rowspan=1 valign=top><a name=d2074e1569 class=n-a></a></td></tr><tr><a name=d2074e1573 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d2074e1575 class=n-a></a>Haematology <sup><a href="#FN7">g</a></sup></td><td align=left colspan=2 rowspan=1 valign=top><a name=d2074e1581 class=n-a></a></td><td align=left colspan=2 rowspan=1 valign=top><a name=d2074e1583 class=n-a></a></td><td align=left colspan=2 rowspan=1 valign=top><a name=d2074e1585 class=n-a></a></td><td align=left colspan=2 rowspan=1 valign=top><a name=d2074e1587 class=n-a></a></td><td align=center colspan=2 rowspan=1 valign=top><a name=d2074e1590 class=n-a></a>X</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2074e1593 class=n-a></a></td><td align=left colspan=1 rowspan=1 valign=top><a name=d2074e1595 class=n-a></a></td></tr><tr><a name=d2074e1598 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d2074e1600 class=n-a></a>Immunoglobulins</td><td align=left colspan=2 rowspan=1 valign=top><a name=d2074e1603 class=n-a></a></td><td align=left colspan=2 rowspan=1 valign=top><a name=d2074e1605 class=n-a></a></td><td align=left colspan=2 rowspan=1 valign=top><a name=d2074e1607 class=n-a></a></td><td align=left colspan=2 rowspan=1 valign=top><a name=d2074e1609 class=n-a></a></td><td align=center colspan=2 rowspan=1 valign=top><a name=d2074e1612 class=n-a></a>X</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2074e1615 class=n-a></a></td><td align=left colspan=1 rowspan=1 valign=top><a name=d2074e1617 class=n-a></a></td></tr><tr><a name=d2074e1620 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d2074e1622 class=n-a></a>Hepatitis B, C and<br class=br>HIV serology <sup><a href="#FN8">h</a></sup></td><td align=left colspan=2 rowspan=1 valign=top><a name=d2074e1630 class=n-a></a></td><td align=left colspan=2 rowspan=1 valign=top><a name=d2074e1632 class=n-a></a></td><td align=center colspan=2 rowspan=1 valign=top><a name=d2074e1634 class=n-a></a>X</td><td align=left colspan=2 rowspan=1 valign=top><a name=d2074e1637 class=n-a></a></td><td align=left colspan=2 rowspan=1 valign=top><a name=d2074e1640 class=n-a></a></td><td align=left colspan=1 rowspan=1 valign=top><a name=d2074e1642 class=n-a></a></td><td align=left colspan=1 rowspan=1 valign=top><a name=d2074e1644 class=n-a></a></td></tr><tr><a name=d2074e1647 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d2074e1649 class=n-a></a>Pregnancy test <sup><a href="#FN9">i</a></sup></td><td align=left colspan=2 rowspan=1 valign=top><a name=d2074e1655 class=n-a></a></td><td align=left colspan=2 rowspan=1 valign=top><a name=d2074e1657 class=n-a></a></td><td align=left colspan=2 rowspan=1 valign=top><a name=d2074e1659 class=n-a></a></td><td align=left colspan=2 rowspan=1 valign=top><a name=d2074e1661 class=n-a></a></td><td align=left colspan=2 rowspan=1 valign=top><a name=d2074e1664 class=n-a></a></td><td align=center colspan=1 rowspan=1 valign=top><a name=d2074e1666 class=n-a></a>X</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2074e1669 class=n-a></a></td></tr><tr><a name=d2074e1672 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d2074e1674 class=n-a></a>Electrocardiogram <sup><a href="#FN34">j</a></sup></td><td align=left colspan=2 rowspan=1 valign=top><a name=d2074e1680 class=n-a></a></td><td align=left colspan=2 rowspan=1 valign=top><a name=d2074e1682 class=n-a></a></td><td align=center colspan=2 rowspan=1 valign=top><a name=d2074e1684 class=n-a></a>X</td><td align=left colspan=2 rowspan=1 valign=top><a name=d2074e1687 class=n-a></a></td><td align=left colspan=2 rowspan=1 valign=top><a name=d2074e1690 class=n-a></a></td><td align=left colspan=1 rowspan=1 valign=top><a name=d2074e1692 class=n-a></a></td><td align=left colspan=1 rowspan=1 valign=top><a name=d2074e1694 class=n-a></a></td></tr><tr><a name=d2074e1697 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d2074e1699 class=n-a></a>Echocardiogram/<br class=br>MUGA <sup><a href="#FN10">k</a></sup></td><td align=left colspan=2 rowspan=1 valign=top><a name=d2074e1707 class=n-a></a></td><td align=left colspan=2 rowspan=1 valign=top><a name=d2074e1709 class=n-a></a></td><td align=center colspan=2 rowspan=1 valign=top><a name=d2074e1711 class=n-a></a>X</td><td align=left colspan=2 rowspan=1 valign=top><a name=d2074e1714 class=n-a></a></td><td align=left colspan=2 rowspan=1 valign=top><a name=d2074e1717 class=n-a></a></td><td align=left colspan=1 rowspan=1 valign=top><a name=d2074e1719 class=n-a></a></td><td align=left colspan=1 rowspan=1 valign=top><a name=d2074e1721 class=n-a></a></td></tr><tr><a name=d2074e1725 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d2074e1727 class=n-a></a>Cerebrospinal fluid<br class=br>examination <sup><a href="#FN11">l</a></sup> <sup>(if clinically indicated)</sup></td><td align=left colspan=2 rowspan=1 valign=top><a name=d2074e1738 class=n-a></a></td><td align=left colspan=2 rowspan=1 valign=top><a name=d2074e1740 class=n-a></a></td><td align=center colspan=2 rowspan=1 valign=top><a name=d2074e1742 class=n-a></a>X</td><td align=left colspan=2 rowspan=1 valign=top><a name=d2074e1745 class=n-a></a></td><td align=left colspan=2 rowspan=1 valign=top><a name=d2074e1748 class=n-a></a></td><td align=left colspan=1 rowspan=1 valign=top><a name=d2074e1750 class=n-a></a></td><td align=left colspan=1 rowspan=1 valign=top><a name=d2074e1752 class=n-a></a></td></tr><tr><a name=d2074e1755 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d2074e1757 class=n-a></a>Tumour material <sup><a href="#FN12">m</a></sup></td><td align=left colspan=2 rowspan=1 valign=top><a name=d2074e1763 class=n-a></a></td><td align=left colspan=2 rowspan=1 valign=top><a name=d2074e1765 class=n-a></a></td><td align=center colspan=2 rowspan=1 valign=top><a name=d2074e1767 class=n-a></a>X</td><td align=left colspan=2 rowspan=1 valign=top><a name=d2074e1770 class=n-a></a></td><td align=left colspan=2 rowspan=1 valign=top><a name=d2074e1773 class=n-a></a></td><td align=left colspan=1 rowspan=1 valign=top><a name=d2074e1775 class=n-a></a></td><td align=left colspan=1 rowspan=1 valign=top><a name=d2074e1777 class=n-a></a></td></tr><tr><a name=d2074e1780 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d2074e1782 class=n-a></a>Streck Plasma DNA<br class=br>Sample<sup><a href="#FN13">n</a></sup></td><td align=left colspan=2 rowspan=1 valign=top><a name=d2074e1790 class=n-a></a></td><td align=left colspan=2 rowspan=1 valign=top><a name=d2074e1792 class=n-a></a></td><td align=center colspan=2 rowspan=1 valign=top><a name=d2074e1794 class=n-a></a>X</td><td align=left colspan=2 rowspan=1 valign=top><a name=d2074e1797 class=n-a></a></td><td align=left colspan=2 rowspan=1 valign=top><a name=d2074e1800 class=n-a></a></td><td align=left colspan=1 rowspan=1 valign=top><a name=d2074e1802 class=n-a></a></td><td align=left colspan=1 rowspan=1 valign=top><a name=d2074e1804 class=n-a></a></td></tr><tr><a name=d2074e1807 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d2074e1809 class=n-a></a>EDTA Sample<sup><a href="#FN13">n</a></sup></td><td align=left colspan=2 rowspan=1 valign=top><a name=d2074e1815 class=n-a></a></td><td align=left colspan=2 rowspan=1 valign=top><a name=d2074e1817 class=n-a></a></td><td align=left colspan=2 rowspan=1 valign=top><a name=d2074e1819 class=n-a></a></td><td align=left colspan=2 rowspan=1 valign=top><a name=d2074e1821 class=n-a></a></td><td align=left colspan=2 rowspan=1 valign=top><a name=d2074e1824 class=n-a></a></td><td align=center colspan=1 rowspan=1 valign=top><a name=d2074e1826 class=n-a></a>X</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2074e1829 class=n-a></a></td></tr><tr><a name=d2074e1832 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d2074e1834 class=n-a></a>Concomitant<br class=br>Medications</td><td align=left colspan=2 rowspan=1 valign=top><a name=d2074e1839 class=n-a></a></td><td align=left colspan=2 rowspan=1 valign=top><a name=d2074e1841 class=n-a></a></td><td align=left colspan=2 rowspan=1 valign=top><a name=d2074e1843 class=n-a></a></td><td align=center colspan=2 rowspan=1 valign=top><a name=d2074e1845 class=n-a></a>X</td><td align=left colspan=2 rowspan=1 valign=top><a name=d2074e1849 class=n-a></a></td><td align=left colspan=1 rowspan=1 valign=top><a name=d2074e1851 class=n-a></a></td><td align=center colspan=1 rowspan=1 valign=top><a name=d2074e1853 class=n-a></a>X</td></tr><tr><a name=d2074e1857 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d2074e1859 class=n-a></a>Adverse Events <sup><a href="#FN14">o</a></sup></td><td align=left colspan=2 rowspan=1 valign=top><a name=d2074e1865 class=n-a></a></td><td align=left colspan=2 rowspan=1 valign=top><a name=d2074e1867 class=n-a></a></td><td align=center colspan=2 rowspan=1 valign=top><a name=d2074e1869 class=n-a></a>X</td><td align=center colspan=2 rowspan=1 valign=top><a name=d2074e1872 class=n-a></a>X</td><td align=center colspan=2 rowspan=1 valign=top><a name=d2074e1876 class=n-a></a>X</td><td align=center colspan=1 rowspan=1 valign=top><a name=d2074e1879 class=n-a></a>X</td><td align=center colspan=1 rowspan=1 valign=top><a name=d2074e1882 class=n-a></a>X</td></tr><tr><a name=d2074e1887 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d2074e1889 class=n-a></a>R-CHOP</td><td align=left colspan=2 rowspan=1 valign=top><a name=d2074e1892 class=n-a></a></td><td align=left colspan=2 rowspan=1 valign=top><a name=d2074e1894 class=n-a></a></td><td align=left colspan=2 rowspan=1 valign=top><a name=d2074e1896 class=n-a></a></td><td align=left colspan=2 rowspan=1 valign=top><a name=d2074e1898 class=n-a></a></td><td align=left colspan=2 rowspan=1 valign=top><a name=d2074e1901 class=n-a></a></td><td align=left colspan=1 rowspan=1 valign=top><a name=d2074e1903 class=n-a></a></td><td align=center colspan=1 rowspan=1 valign=top><a name=d2074e1905 class=n-a></a>X</td></tr><tr><a name=d2074e1909 class=n-a></a><th align=left colspan=13 rowspan=1 valign=top><a name=d2074e1911 class=n-a></a><b>C<span style="font-variant: small-caps">ycles</span> 2 – E<span style="font-variant: small-caps">nd of</span> T<span style="font-variant: small-caps">reatment</span></b></th></tr><tr><a name=d2074e1924 class=n-a></a><th align=left colspan=1 rowspan=1 valign=top><a name=d2074e1926 class=n-a></a>Visit</th><th align=center colspan=1 rowspan=1 valign=top><a name=d2074e1929 class=n-a></a>Cycle<br class=br>2<br class=br>Day 1</th><th align=center colspan=1 rowspan=1 valign=top><a name=d2074e1936 class=n-a></a>Cycle<br class=br>2 Day<br class=br>8</th><th align=center colspan=1 rowspan=1 valign=top><a name=d2074e1943 class=n-a></a>Cycle 2<br class=br>Day 15</th><th align=center colspan=1 rowspan=1 valign=top><a name=d2074e1948 class=n-a></a>Cycle 3<br class=br>Day 1</th><th align=center colspan=1 rowspan=1 valign=top><a name=d2074e1954 class=n-a></a>Cycle 4<br class=br>Day1</th><th align=center colspan=1 rowspan=1 valign=top><a name=d2074e1959 class=n-a></a>Cycle 4<br class=br>Day 8</th><th align=center colspan=1 rowspan=1 valign=top><a name=d2074e1964 class=n-a></a>Cycle 5<br class=br>Day 1</th><th align=center colspan=1 rowspan=1 valign=top><a name=d2074e1969 class=n-a></a>Cycle 6<br class=br>Day 1</th><th align=center colspan=1 rowspan=1 valign=top><a name=d2074e1974 class=n-a></a>Cycle<br class=br>7<sup><a href="#FN23">x</a></sup></th><th align=center colspan=1 rowspan=1 valign=top><a name=d2074e1982 class=n-a></a>Cycle 8<sup><a href="#FN23">x</a></sup></th><th align=center colspan=2 rowspan=1 valign=top><a name=d2074e1989 class=n-a></a>End of Treatment<sup><a href="#FN27">bb</a></sup></th></tr><tr><a name=d2074e1996 class=n-a></a><th align=left colspan=1 rowspan=1 valign=top><a name=d2074e1998 class=n-a></a>Weeks</th><th align=center colspan=1 rowspan=1 valign=top><a name=d2074e2001 class=n-a></a>4</th><th align=center colspan=1 rowspan=1 valign=top><a name=d2074e2004 class=n-a></a>5</th><th align=center colspan=1 rowspan=1 valign=top><a name=d2074e2007 class=n-a></a>6</th><th align=center colspan=1 rowspan=1 valign=top><a name=d2074e2010 class=n-a></a>7</th><th align=center colspan=1 rowspan=1 valign=top><a name=d2074e2014 class=n-a></a>10</th><th align=center colspan=1 rowspan=1 valign=top><a name=d2074e2017 class=n-a></a>11</th><th align=center colspan=1 rowspan=1 valign=top><a name=d2074e2020 class=n-a></a>13</th><th align=center colspan=1 rowspan=1 valign=top><a name=d2074e2023 class=n-a></a>16</th><th align=center colspan=1 rowspan=1 valign=top><a name=d2074e2026 class=n-a></a>19<sup><a href="#FN22">w</a></sup></th><th align=center colspan=1 rowspan=1 valign=top><a name=d2074e2032 class=n-a></a>23</th><th align=center colspan=2 rowspan=1 valign=top><a name=d2074e2036 class=n-a></a>27–30</th></tr><tr><a name=d2074e2040 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d2074e2042 class=n-a></a>Physical Exam <sup><a href="#FN24">y</a></sup></td><td align=center colspan=1 rowspan=1 valign=top><a name=d2074e2048 class=n-a></a>X</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2074e2051 class=n-a></a></td><td align=left colspan=1 rowspan=1 valign=top><a name=d2074e2053 class=n-a></a></td><td align=center colspan=1 rowspan=1 valign=top><a name=d2074e2055 class=n-a></a>X</td><td align=center colspan=1 rowspan=1 valign=top><a name=d2074e2059 class=n-a></a>X</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2074e2062 class=n-a></a></td><td align=center colspan=1 rowspan=1 valign=top><a name=d2074e2064 class=n-a></a>X</td><td align=center colspan=1 rowspan=1 valign=top><a name=d2074e2067 class=n-a></a>X</td><td align=center colspan=1 rowspan=1 valign=top><a name=d2074e2070 class=n-a></a>X</td><td align=center colspan=1 rowspan=1 valign=top><a name=d2074e2073 class=n-a></a>X</td><td align=center colspan=2 rowspan=1 valign=top><a name=d2074e2077 class=n-a></a>X</td></tr><tr><a name=d2074e2081 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d2074e2083 class=n-a></a>Vital Signs <sup><a href="#FN15">p</a></sup></td><td align=center colspan=1 rowspan=1 valign=top><a name=d2074e2089 class=n-a></a>X</td><td align=center colspan=1 rowspan=1 valign=top><a name=d2074e2092 class=n-a></a>X</td><td align=center colspan=1 rowspan=1 valign=top><a name=d2074e2095 class=n-a></a>X</td><td align=center colspan=1 rowspan=1 valign=top><a name=d2074e2098 class=n-a></a>X</td><td align=center colspan=1 rowspan=1 valign=top><a name=d2074e2102 class=n-a></a>X</td><td align=center colspan=1 rowspan=1 valign=top><a name=d2074e2105 class=n-a></a>X</td><td align=center colspan=1 rowspan=1 valign=top><a name=d2074e2108 class=n-a></a>X</td><td align=center colspan=1 rowspan=1 valign=top><a name=d2074e2111 class=n-a></a>X</td><td align=center colspan=1 rowspan=1 valign=top><a name=d2074e2114 class=n-a></a>X</td><td align=center colspan=1 rowspan=1 valign=top><a name=d2074e2117 class=n-a></a>X</td><td align=center colspan=2 rowspan=1 valign=top><a name=d2074e2121 class=n-a></a>X</td></tr><tr><a name=d2074e2126 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d2074e2128 class=n-a></a>ECOG performance<br class=br>Status <sup><a href="#FN24">y</a></sup></td><td align=center colspan=1 rowspan=1 valign=top><a name=d2074e2136 class=n-a></a>X</td><td align=center colspan=1 rowspan=1 valign=top><a name=d2074e2139 class=n-a></a>X</td><td align=center colspan=1 rowspan=1 valign=top><a name=d2074e2142 class=n-a></a>X</td><td align=center colspan=1 rowspan=1 valign=top><a name=d2074e2145 class=n-a></a>X</td><td align=center colspan=1 rowspan=1 valign=top><a name=d2074e2149 class=n-a></a>X</td><td align=center colspan=1 rowspan=1 valign=top><a name=d2074e2152 class=n-a></a>X</td><td align=center colspan=1 rowspan=1 valign=top><a name=d2074e2155 class=n-a></a>X</td><td align=center colspan=1 rowspan=1 valign=top><a name=d2074e2158 class=n-a></a>X</td><td align=center colspan=1 rowspan=1 valign=top><a name=d2074e2161 class=n-a></a>X</td><td align=center colspan=1 rowspan=1 valign=top><a name=d2074e2164 class=n-a></a>X</td><td align=center colspan=2 rowspan=1 valign=top><a name=d2074e2168 class=n-a></a>X</td></tr><tr><a name=d2074e2172 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d2074e2174 class=n-a></a>Contrast enhanced<br class=br>CT</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2074e2179 class=n-a></a></td><td align=left colspan=1 rowspan=1 valign=top><a name=d2074e2181 class=n-a></a></td><td align=left colspan=1 rowspan=1 valign=top><a name=d2074e2183 class=n-a></a></td><td align=left colspan=1 rowspan=1 valign=top><a name=d2074e2185 class=n-a></a></td><td align=left colspan=1 rowspan=1 valign=top><a name=d2074e2188 class=n-a></a></td><td align=left colspan=1 rowspan=1 valign=top><a name=d2074e2190 class=n-a></a></td><td align=left colspan=1 rowspan=1 valign=top><a name=d2074e2192 class=n-a></a></td><td align=left colspan=1 rowspan=1 valign=top><a name=d2074e2194 class=n-a></a></td><td align=center colspan=1 rowspan=1 valign=top><a name=d2074e2196 class=n-a></a>X<sup><a href="#FN26">aa</a></sup></td><td align=left colspan=1 rowspan=1 valign=top><a name=d2074e2202 class=n-a></a></td><td align=center colspan=2 rowspan=1 valign=top><a name=d2074e2205 class=n-a></a></td></tr><tr><a name=d2074e2208 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d2074e2210 class=n-a></a>PET-CT or contrast<br class=br>enhanced CT and<br class=br>separate PET <sup><a href="#FN16">q</a></sup></td><td align=left colspan=1 rowspan=1 valign=top><a name=d2074e2220 class=n-a></a></td><td align=left colspan=1 rowspan=1 valign=top><a name=d2074e2222 class=n-a></a></td><td align=left colspan=1 rowspan=1 valign=top><a name=d2074e2224 class=n-a></a></td><td align=left colspan=1 rowspan=1 valign=top><a name=d2074e2226 class=n-a></a></td><td align=left colspan=1 rowspan=1 valign=top><a name=d2074e2229 class=n-a></a></td><td align=left colspan=1 rowspan=1 valign=top><a name=d2074e2231 class=n-a></a></td><td align=left colspan=1 rowspan=1 valign=top><a name=d2074e2233 class=n-a></a></td><td align=left colspan=1 rowspan=1 valign=top><a name=d2074e2235 class=n-a></a></td><td align=left colspan=1 rowspan=1 valign=top><a name=d2074e2237 class=n-a></a></td><td align=left colspan=1 rowspan=1 valign=top><a name=d2074e2239 class=n-a></a></td><td align=center colspan=2 rowspan=1 valign=top><a name=d2074e2242 class=n-a></a>X <sup><a href="#FN16">q</a></sup></td></tr><tr><a name=d2074e2249 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d2074e2251 class=n-a></a>Bone marrow<br class=br>biopsy <sup><a href="#FN17">r</a></sup></td><td align=left colspan=1 rowspan=1 valign=top><a name=d2074e2259 class=n-a></a></td><td align=left colspan=1 rowspan=1 valign=top><a name=d2074e2261 class=n-a></a></td><td align=left colspan=1 rowspan=1 valign=top><a name=d2074e2263 class=n-a></a></td><td align=left colspan=1 rowspan=1 valign=top><a name=d2074e2265 class=n-a></a></td><td align=left colspan=1 rowspan=1 valign=top><a name=d2074e2268 class=n-a></a></td><td align=left colspan=1 rowspan=1 valign=top><a name=d2074e2270 class=n-a></a></td><td align=left colspan=1 rowspan=1 valign=top><a name=d2074e2272 class=n-a></a></td><td align=left colspan=1 rowspan=1 valign=top><a name=d2074e2274 class=n-a></a></td><td align=left colspan=1 rowspan=1 valign=top><a name=d2074e2276 class=n-a></a></td><td align=left colspan=1 rowspan=1 valign=top><a name=d2074e2278 class=n-a></a></td><td align=center colspan=2 rowspan=1 valign=top><a name=d2074e2281 class=n-a></a>(X) <sup><a href="#FN17">r</a></sup></td></tr><tr><a name=d2074e2288 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d2074e2290 class=n-a></a>Biochemistry: renal<br class=br>and liver function <sup><a href="#FN18">s</a></sup></td><td align=center colspan=1 rowspan=1 valign=top><a name=d2074e2298 class=n-a></a>X</td><td align=center colspan=1 rowspan=1 valign=top><a name=d2074e2301 class=n-a></a>X</td><td align=center colspan=1 rowspan=1 valign=top><a name=d2074e2304 class=n-a></a>X</td><td align=center colspan=1 rowspan=1 valign=top><a name=d2074e2307 class=n-a></a>X</td><td align=center colspan=1 rowspan=1 valign=top><a name=d2074e2311 class=n-a></a>X</td><td align=center colspan=1 rowspan=1 valign=top><a name=d2074e2314 class=n-a></a>X</td><td align=center colspan=1 rowspan=1 valign=top><a name=d2074e2317 class=n-a></a>X</td><td align=center colspan=1 rowspan=1 valign=top><a name=d2074e2320 class=n-a></a>X</td><td align=center colspan=1 rowspan=1 valign=top><a name=d2074e2323 class=n-a></a>X</td><td align=center colspan=1 rowspan=1 valign=top><a name=d2074e2326 class=n-a></a>X</td><td align=center colspan=2 rowspan=1 valign=top><a name=d2074e2330 class=n-a></a>X</td></tr><tr><a name=d2074e2334 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d2074e2336 class=n-a></a>Haematology <sup><a href="#FN19">t</a></sup></td><td align=center colspan=1 rowspan=1 valign=top><a name=d2074e2342 class=n-a></a>X</td><td align=center colspan=1 rowspan=1 valign=top><a name=d2074e2345 class=n-a></a>X</td><td align=center colspan=1 rowspan=1 valign=top><a name=d2074e2348 class=n-a></a>X</td><td align=center colspan=1 rowspan=1 valign=top><a name=d2074e2351 class=n-a></a>X</td><td align=center colspan=1 rowspan=1 valign=top><a name=d2074e2355 class=n-a></a>X</td><td align=center colspan=1 rowspan=1 valign=top><a name=d2074e2358 class=n-a></a>X</td><td align=center colspan=1 rowspan=1 valign=top><a name=d2074e2361 class=n-a></a>X</td><td align=center colspan=1 rowspan=1 valign=top><a name=d2074e2364 class=n-a></a>X</td><td align=center colspan=1 rowspan=1 valign=top><a name=d2074e2367 class=n-a></a>X</td><td align=center colspan=1 rowspan=1 valign=top><a name=d2074e2370 class=n-a></a>X</td><td align=center colspan=2 rowspan=1 valign=top><a name=d2074e2374 class=n-a></a>X</td></tr><tr><a name=d2074e2379 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d2074e2381 class=n-a></a>Electrocardiogram <sup><a href="#FN25">z</a></sup></td><td align=left colspan=1 rowspan=1 valign=top><a name=d2074e2387 class=n-a></a></td><td align=left colspan=1 rowspan=1 valign=top><a name=d2074e2389 class=n-a></a></td><td align=left colspan=1 rowspan=1 valign=top><a name=d2074e2391 class=n-a></a></td><td align=center colspan=1 rowspan=1 valign=top><a name=d2074e2393 class=n-a></a>X</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2074e2397 class=n-a></a></td><td align=left colspan=1 rowspan=1 valign=top><a name=d2074e2399 class=n-a></a></td><td align=center colspan=1 rowspan=1 valign=top><a name=d2074e2401 class=n-a></a>X</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2074e2404 class=n-a></a></td><td align=center colspan=1 rowspan=1 valign=top><a name=d2074e2406 class=n-a></a>X</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2074e2409 class=n-a></a></td><td align=center colspan=2 rowspan=1 valign=top><a name=d2074e2412 class=n-a></a>X</td></tr><tr><a name=d2074e2416 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d2074e2418 class=n-a></a>Echocardiogram <sup><a href="#FN25">z</a></sup></td><td align=left colspan=1 rowspan=1 valign=top><a name=d2074e2424 class=n-a></a></td><td align=left colspan=1 rowspan=1 valign=top><a name=d2074e2426 class=n-a></a></td><td align=left colspan=1 rowspan=1 valign=top><a name=d2074e2428 class=n-a></a></td><td align=left colspan=1 rowspan=1 valign=top><a name=d2074e2430 class=n-a></a></td><td align=center colspan=1 rowspan=1 valign=top><a name=d2074e2433 class=n-a></a>X</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2074e2436 class=n-a></a></td><td align=left colspan=1 rowspan=1 valign=top><a name=d2074e2438 class=n-a></a></td><td align=left colspan=1 rowspan=1 valign=top><a name=d2074e2440 class=n-a></a></td><td align=left colspan=1 rowspan=1 valign=top><a name=d2074e2442 class=n-a></a></td><td align=left colspan=1 rowspan=1 valign=top><a name=d2074e2444 class=n-a></a></td><td align=center colspan=2 rowspan=1 valign=top><a name=d2074e2447 class=n-a></a>X</td></tr><tr><a name=d2074e2451 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d2074e2453 class=n-a></a>Pharmacokinetic<br class=br>samples<sup><a href="#FN28">cc</a></sup></td><td align=center colspan=1 rowspan=1 valign=top><a name=d2074e2461 class=n-a></a>X</td><td align=center colspan=1 rowspan=1 valign=top><a name=d2074e2464 class=n-a></a>X</td><td align=center colspan=1 rowspan=1 valign=top><a name=d2074e2467 class=n-a></a>X</td><td align=center colspan=1 rowspan=1 valign=top><a name=d2074e2470 class=n-a></a>X</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2074e2474 class=n-a></a></td><td align=left colspan=1 rowspan=1 valign=top><a name=d2074e2476 class=n-a></a></td><td align=left colspan=1 rowspan=1 valign=top><a name=d2074e2478 class=n-a></a></td><td align=left colspan=1 rowspan=1 valign=top><a name=d2074e2480 class=n-a></a></td><td align=left colspan=1 rowspan=1 valign=top><a name=d2074e2482 class=n-a></a></td><td align=left colspan=1 rowspan=1 valign=top><a name=d2074e2484 class=n-a></a></td><td align=center colspan=2 rowspan=1 valign=top><a name=d2074e2487 class=n-a></a></td></tr><tr><a name=d2074e2490 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d2074e2492 class=n-a></a>Pharmacodynamic<br class=br>samples<sup><a href="#FN28">cc</a></sup></td><td align=center colspan=1 rowspan=1 valign=top><a name=d2074e2500 class=n-a></a>X</td><td align=center colspan=1 rowspan=1 valign=top><a name=d2074e2503 class=n-a></a>X</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2074e2506 class=n-a></a></td><td align=left colspan=1 rowspan=1 valign=top><a name=d2074e2508 class=n-a></a></td><td align=center colspan=1 rowspan=1 valign=top><a name=d2074e2511 class=n-a></a>X</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2074e2514 class=n-a></a></td><td align=left colspan=1 rowspan=1 valign=top><a name=d2074e2516 class=n-a></a></td><td align=left colspan=1 rowspan=1 valign=top><a name=d2074e2518 class=n-a></a></td><td align=left colspan=1 rowspan=1 valign=top><a name=d2074e2520 class=n-a></a></td><td align=left colspan=1 rowspan=1 valign=top><a name=d2074e2522 class=n-a></a></td><td align=center colspan=2 rowspan=1 valign=top><a name=d2074e2525 class=n-a></a></td></tr><tr><a name=d2074e2528 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d2074e2530 class=n-a></a>R-CHOP +<br class=br>acalabrutinib</td><td align=center colspan=1 rowspan=1 valign=top><a name=d2074e2535 class=n-a></a>X</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2074e2538 class=n-a></a></td><td align=left colspan=1 rowspan=1 valign=top><a name=d2074e2540 class=n-a></a></td><td align=center colspan=1 rowspan=1 valign=top><a name=d2074e2542 class=n-a></a>X</td><td align=center colspan=1 rowspan=1 valign=top><a name=d2074e2546 class=n-a></a>X</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2074e2549 class=n-a></a></td><td align=center colspan=1 rowspan=1 valign=top><a name=d2074e2551 class=n-a></a>X</td><td align=center colspan=1 rowspan=1 valign=top><a name=d2074e2554 class=n-a></a>X</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2074e2557 class=n-a></a></td><td align=left colspan=1 rowspan=1 valign=top><a name=d2074e2559 class=n-a></a></td><td align=center colspan=2 rowspan=1 valign=top><a name=d2074e2562 class=n-a></a></td></tr><tr><a name=d2074e2565 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d2074e2567 class=n-a></a>Acalabrutinib<br class=br>(only)<sup><a href="#FN23">x</a></sup></td><td align=left colspan=1 rowspan=1 valign=top><a name=d2074e2575 class=n-a></a></td><td align=left colspan=1 rowspan=1 valign=top><a name=d2074e2577 class=n-a></a></td><td align=left colspan=1 rowspan=1 valign=top><a name=d2074e2579 class=n-a></a></td><td align=left colspan=1 rowspan=1 valign=top><a name=d2074e2581 class=n-a></a></td><td align=left colspan=1 rowspan=1 valign=top><a name=d2074e2584 class=n-a></a></td><td align=left colspan=1 rowspan=1 valign=top><a name=d2074e2586 class=n-a></a></td><td align=left colspan=1 rowspan=1 valign=top><a name=d2074e2588 class=n-a></a></td><td align=left colspan=1 rowspan=1 valign=top><a name=d2074e2590 class=n-a></a></td><td align=center colspan=1 rowspan=1 valign=top><a name=d2074e2592 class=n-a></a>X</td><td align=center colspan=1 rowspan=1 valign=top><a name=d2074e2595 class=n-a></a>X</td><td align=center colspan=2 rowspan=1 valign=top><a name=d2074e2599 class=n-a></a></td></tr><tr><a name=d2074e2603 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d2074e2605 class=n-a></a>Compliance <sup><a href="#FN20">u</a></sup></td><td align=center colspan=1 rowspan=1 valign=top><a name=d2074e2611 class=n-a></a>X</td><td align=center colspan=1 rowspan=1 valign=top><a name=d2074e2614 class=n-a></a>X</td><td align=center colspan=1 rowspan=1 valign=top><a name=d2074e2617 class=n-a></a>X</td><td align=center colspan=1 rowspan=1 valign=top><a name=d2074e2620 class=n-a></a>X</td><td align=center colspan=1 rowspan=1 valign=top><a name=d2074e2624 class=n-a></a>X</td><td align=center colspan=1 rowspan=1 valign=top><a name=d2074e2627 class=n-a></a>X</td><td align=center colspan=1 rowspan=1 valign=top><a name=d2074e2630 class=n-a></a>X</td><td align=center colspan=1 rowspan=1 valign=top><a name=d2074e2633 class=n-a></a>X</td><td align=center colspan=1 rowspan=1 valign=top><a name=d2074e2636 class=n-a></a>X</td><td align=center colspan=1 rowspan=1 valign=top><a name=d2074e2639 class=n-a></a>X</td><td align=center colspan=2 rowspan=1 valign=top><a name=d2074e2643 class=n-a></a>X</td></tr><tr><a name=d2074e2647 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d2074e2649 class=n-a></a>Concomitant<br class=br>medications</td><td align=center colspan=1 rowspan=1 valign=top><a name=d2074e2654 class=n-a></a>X</td><td align=center colspan=1 rowspan=1 valign=top><a name=d2074e2657 class=n-a></a>X</td><td align=center colspan=1 rowspan=1 valign=top><a name=d2074e2660 class=n-a></a>X</td><td align=center colspan=1 rowspan=1 valign=top><a name=d2074e2663 class=n-a></a>X</td><td align=center colspan=1 rowspan=1 valign=top><a name=d2074e2667 class=n-a></a>X</td><td align=center colspan=1 rowspan=1 valign=top><a name=d2074e2670 class=n-a></a>X</td><td align=center colspan=1 rowspan=1 valign=top><a name=d2074e2673 class=n-a></a>X</td><td align=center colspan=1 rowspan=1 valign=top><a name=d2074e2676 class=n-a></a>X</td><td align=center colspan=1 rowspan=1 valign=top><a name=d2074e2679 class=n-a></a>X</td><td align=center colspan=1 rowspan=1 valign=top><a name=d2074e2682 class=n-a></a>X</td><td align=center colspan=2 rowspan=1 valign=top><a name=d2074e2686 class=n-a></a>X</td></tr><tr><a name=d2074e2690 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d2074e2692 class=n-a></a>Adverse Events</td><td align=center colspan=1 rowspan=1 valign=top><a name=d2074e2695 class=n-a></a>X</td><td align=center colspan=1 rowspan=1 valign=top><a name=d2074e2698 class=n-a></a>X</td><td align=center colspan=1 rowspan=1 valign=top><a name=d2074e2701 class=n-a></a>X</td><td align=center colspan=1 rowspan=1 valign=top><a name=d2074e2704 class=n-a></a>X</td><td align=center colspan=1 rowspan=1 valign=top><a name=d2074e2708 class=n-a></a>X</td><td align=center colspan=1 rowspan=1 valign=top><a name=d2074e2711 class=n-a></a>X</td><td align=center colspan=1 rowspan=1 valign=top><a name=d2074e2714 class=n-a></a>X</td><td align=center colspan=1 rowspan=1 valign=top><a name=d2074e2717 class=n-a></a>X</td><td align=center colspan=1 rowspan=1 valign=top><a name=d2074e2720 class=n-a></a>X</td><td align=center colspan=1 rowspan=1 valign=top><a name=d2074e2723 class=n-a></a>X</td><td align=center colspan=2 rowspan=1 valign=top><a name=d2074e2727 class=n-a></a>X</td></tr><tr><a name=d2074e2731 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d2074e2733 class=n-a></a>Streck Plasma DNA<br class=br>Sample<sup><a href="#FN21">v</a></sup></td><td align=center colspan=1 rowspan=1 valign=top><a name=d2074e2741 class=n-a></a>X</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2074e2744 class=n-a></a></td><td align=left colspan=1 rowspan=1 valign=top><a name=d2074e2746 class=n-a></a></td><td align=center colspan=1 rowspan=1 valign=top><a name=d2074e2748 class=n-a></a>X</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2074e2752 class=n-a></a></td><td align=left colspan=1 rowspan=1 valign=top><a name=d2074e2754 class=n-a></a></td><td align=left colspan=1 rowspan=1 valign=top><a name=d2074e2756 class=n-a></a></td><td align=left colspan=1 rowspan=1 valign=top><a name=d2074e2758 class=n-a></a></td><td align=left colspan=1 rowspan=1 valign=top><a name=d2074e2760 class=n-a></a></td><td align=left colspan=1 rowspan=1 valign=top><a name=d2074e2762 class=n-a></a></td><td align=center colspan=2 rowspan=1 valign=top><a name=d2074e2765 class=n-a></a>X</td></tr><tr><a name=d2074e2769 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d2074e2771 class=n-a></a>Immunoglobulins</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2074e2774 class=n-a></a></td><td align=left colspan=1 rowspan=1 valign=top><a name=d2074e2776 class=n-a></a></td><td align=left colspan=1 rowspan=1 valign=top><a name=d2074e2778 class=n-a></a></td><td align=center colspan=1 rowspan=1 valign=top><a name=d2074e2780 class=n-a></a>X</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2074e2784 class=n-a></a></td><td align=left colspan=1 rowspan=1 valign=top><a name=d2074e2786 class=n-a></a></td><td align=left colspan=1 rowspan=1 valign=top><a name=d2074e2788 class=n-a></a></td><td align=left colspan=1 rowspan=1 valign=top><a name=d2074e2790 class=n-a></a></td><td align=left colspan=1 rowspan=1 valign=top><a name=d2074e2792 class=n-a></a></td><td align=left colspan=1 rowspan=1 valign=top><a name=d2074e2794 class=n-a></a></td><td align=center colspan=2 rowspan=1 valign=top><a name=d2074e2797 class=n-a></a>X</td></tr><tr><a name=d2074e2801 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d2074e2803 class=n-a></a>Pregnancy Test</td><td align=center colspan=1 rowspan=1 valign=top><a name=d2074e2806 class=n-a></a>X</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2074e2809 class=n-a></a></td><td align=left colspan=1 rowspan=1 valign=top><a name=d2074e2811 class=n-a></a></td><td align=center colspan=1 rowspan=1 valign=top><a name=d2074e2813 class=n-a></a>X</td><td align=center colspan=1 rowspan=1 valign=top><a name=d2074e2817 class=n-a></a>X</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2074e2820 class=n-a></a></td><td align=center colspan=1 rowspan=1 valign=top><a name=d2074e2822 class=n-a></a>X</td><td align=center colspan=1 rowspan=1 valign=top><a name=d2074e2825 class=n-a></a>X</td><td align=center colspan=1 rowspan=1 valign=top><a name=d2074e2828 class=n-a></a>X</td><td align=center colspan=1 rowspan=1 valign=top><a name=d2074e2831 class=n-a></a>X</td><td align=center colspan=2 rowspan=1 valign=top><a name=d2074e2835 class=n-a></a>X</td></tr><tr><a name=d2074e2840 class=n-a></a><th align=left colspan=13 rowspan=1 valign=top><a name=d2074e2842 class=n-a></a><b>S<span style="font-variant: small-caps">chedule of</span> F<span style="font-variant: small-caps">ollow</span>-U<span style="font-variant: small-caps">p</span> V<span style="font-variant: small-caps">isits</span></b> (<span style="font-variant: small-caps">begin 3</span> <span style="font-variant: small-caps">months following cycle</span> 8 <span style="font-variant: small-caps">- at the end of the acalabrutinib</span><br class=br><span style="font-variant: small-caps">continuation phase- at week</span> 39)</th></tr><tr><a name=d2074e2871 class=n-a></a><th align=left colspan=1 rowspan=1 valign=top><a name=d2074e2872 class=n-a></a>Months following<br class=br>last therapy <sup><a href="#FN32">gg</a></sup></th><th align=center colspan=2 rowspan=1 valign=top><a name=d2074e2880 class=n-a></a>3</th><th align=center colspan=1 rowspan=1 valign=top><a name=d2074e2883 class=n-a></a>6</th><th align=center colspan=2 rowspan=1 valign=top><a name=d2074e2886 class=n-a></a>9</th><th align=center colspan=1 rowspan=1 valign=top><a name=d2074e2889 class=n-a></a>12</th><th align=center colspan=1 rowspan=1 valign=top><a name=d2074e2892 class=n-a></a>16</th><th align=center colspan=2 rowspan=1 valign=top><a name=d2074e2896 class=n-a></a>20</th><th align=center colspan=3 rowspan=1 valign=top><a name=d2074e2899 class=n-a></a>24</th></tr><tr><a name=d2074e2903 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d2074e2905 class=n-a></a>Physical Exam</td><td align=center colspan=2 rowspan=1 valign=top><a name=d2074e2908 class=n-a></a>X</td><td align=center colspan=1 rowspan=1 valign=top><a name=d2074e2911 class=n-a></a>X</td><td align=center colspan=2 rowspan=1 valign=top><a name=d2074e2914 class=n-a></a>X</td><td align=center colspan=1 rowspan=1 valign=top><a name=d2074e2917 class=n-a></a>X</td><td align=center colspan=1 rowspan=1 valign=top><a name=d2074e2921 class=n-a></a>X</td><td align=center colspan=2 rowspan=1 valign=top><a name=d2074e2924 class=n-a></a>X</td><td align=center colspan=3 rowspan=1 valign=top><a name=d2074e2927 class=n-a></a>X</td></tr><tr><a name=d2074e2931 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d2074e2933 class=n-a></a>ECOG performance<br class=br>status</td><td align=center colspan=2 rowspan=1 valign=top><a name=d2074e2938 class=n-a></a>X</td><td align=center colspan=1 rowspan=1 valign=top><a name=d2074e2941 class=n-a></a>X</td><td align=center colspan=2 rowspan=1 valign=top><a name=d2074e2944 class=n-a></a>X</td><td align=center colspan=1 rowspan=1 valign=top><a name=d2074e2947 class=n-a></a>X</td><td align=center colspan=1 rowspan=1 valign=top><a name=d2074e2951 class=n-a></a>X</td><td align=center colspan=2 rowspan=1 valign=top><a name=d2074e2954 class=n-a></a>X</td><td align=center colspan=3 rowspan=1 valign=top><a name=d2074e2957 class=n-a></a>X</td></tr><tr><a name=d2074e2961 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d2074e2963 class=n-a></a>Haematology</td><td align=center colspan=2 rowspan=1 valign=top><a name=d2074e2966 class=n-a></a>X</td><td align=center colspan=1 rowspan=1 valign=top><a name=d2074e2969 class=n-a></a>X</td><td align=center colspan=2 rowspan=1 valign=top><a name=d2074e2972 class=n-a></a>X</td><td align=center colspan=1 rowspan=1 valign=top><a name=d2074e2975 class=n-a></a>X</td><td align=center colspan=1 rowspan=1 valign=top><a name=d2074e2979 class=n-a></a>X</td><td align=center colspan=2 rowspan=1 valign=top><a name=d2074e2982 class=n-a></a>X</td><td align=center colspan=3 rowspan=1 valign=top><a name=d2074e2985 class=n-a></a>X</td></tr><tr><a name=d2074e2989 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d2074e2991 class=n-a></a>Biochemistry <sup><a href="#FN29">dd</a></sup></td><td align=center colspan=2 rowspan=1 valign=top><a name=d2074e2997 class=n-a></a>X</td><td align=center colspan=1 rowspan=1 valign=top><a name=d2074e3000 class=n-a></a>X</td><td align=center colspan=2 rowspan=1 valign=top><a name=d2074e3003 class=n-a></a>X</td><td align=center colspan=1 rowspan=1 valign=top><a name=d2074e3006 class=n-a></a>X</td><td align=center colspan=1 rowspan=1 valign=top><a name=d2074e3010 class=n-a></a>X</td><td align=center colspan=2 rowspan=1 valign=top><a name=d2074e3013 class=n-a></a>X</td><td align=center colspan=3 rowspan=1 valign=top><a name=d2074e3016 class=n-a></a>X</td></tr><tr><a name=d2074e3021 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d2074e3023 class=n-a></a>CT <sup><a href="#FN30">ee</a></sup></td><td align=center colspan=2 rowspan=1 valign=top><a name=d2074e3029 class=n-a></a></td><td align=left colspan=1 rowspan=1 valign=top><a name=d2074e3031 class=n-a></a></td><td align=center colspan=2 rowspan=1 valign=top><a name=d2074e3033 class=n-a></a></td><td align=center colspan=1 rowspan=1 valign=top><a name=d2074e3035 class=n-a></a>X</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2074e3039 class=n-a></a></td><td align=center colspan=2 rowspan=1 valign=top><a name=d2074e3041 class=n-a></a></td><td align=center colspan=3 rowspan=1 valign=top><a name=d2074e3043 class=n-a></a>X</td></tr><tr><a name=d2074e3047 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d2074e3049 class=n-a></a>Adverse Events</td><td align=center colspan=2 rowspan=1 valign=top><a name=d2074e3052 class=n-a></a>X</td><td align=center colspan=1 rowspan=1 valign=top><a name=d2074e3055 class=n-a></a>X</td><td align=center colspan=2 rowspan=1 valign=top><a name=d2074e3058 class=n-a></a>X</td><td align=center colspan=1 rowspan=1 valign=top><a name=d2074e3061 class=n-a></a>X</td><td align=center colspan=1 rowspan=1 valign=top><a name=d2074e3065 class=n-a></a>X</td><td align=center colspan=2 rowspan=1 valign=top><a name=d2074e3068 class=n-a></a>X</td><td align=center colspan=3 rowspan=1 valign=top><a name=d2074e3071 class=n-a></a>X</td></tr><tr><a name=d2074e3075 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d2074e3077 class=n-a></a>Streck Plasma DNA<br class=br>Sample <sup><a href="#FN31">ff</a></sup></td><td align=center colspan=2 rowspan=1 valign=top><a name=d2074e3085 class=n-a></a>X</td><td align=center colspan=1 rowspan=1 valign=top><a name=d2074e3088 class=n-a></a>X</td><td align=center colspan=2 rowspan=1 valign=top><a name=d2074e3091 class=n-a></a>X</td><td align=center colspan=1 rowspan=1 valign=top><a name=d2074e3094 class=n-a></a>X</td><td align=center colspan=1 rowspan=1 valign=top><a name=d2074e3098 class=n-a></a>X</td><td align=center colspan=2 rowspan=1 valign=top><a name=d2074e3101 class=n-a></a>X</td><td align=center colspan=3 rowspan=1 valign=top><a name=d2074e3104 class=n-a></a>X</td></tr><tr><a name=d2074e3108 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d2074e3110 class=n-a></a>Immunoglobulins</td><td align=center colspan=2 rowspan=1 valign=top><a name=d2074e3113 class=n-a></a></td><td align=center colspan=1 rowspan=1 valign=top><a name=d2074e3115 class=n-a></a>X</td><td align=center colspan=2 rowspan=1 valign=top><a name=d2074e3118 class=n-a></a></td><td align=center colspan=1 rowspan=1 valign=top><a name=d2074e3120 class=n-a></a>X</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2074e3124 class=n-a></a></td><td align=center colspan=2 rowspan=1 valign=top><a name=d2074e3126 class=n-a></a></td><td align=center colspan=3 rowspan=1 valign=top><a name=d2074e3128 class=n-a></a>X</td></tr><tr><a name=d2074e3132 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d2074e3134 class=n-a></a>Pregnancy Test</td><td align=center colspan=2 rowspan=1 valign=top><a name=d2074e3137 class=n-a></a>X</td><td align=center colspan=1 rowspan=1 valign=top><a name=d2074e3140 class=n-a></a>X</td><td align=center colspan=2 rowspan=1 valign=top><a name=d2074e3143 class=n-a></a>X</td><td align=center colspan=1 rowspan=1 valign=top><a name=d2074e3146 class=n-a></a>X</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2074e3150 class=n-a></a></td><td align=center colspan=2 rowspan=1 valign=top><a name=d2074e3152 class=n-a></a></td><td align=center colspan=3 rowspan=1 valign=top><a name=d2074e3154 class=n-a></a></td></tr></tbody></table><div class=table-wrap-foot><div class=footnote><a name=d2074e3161 class=n-a></a><p id=FN1> <sup>a</sup> Screening investigations to be performed within 14 days of starting study medication with the exception of informed consent, CT, Electrocardiogram and Bone marrow biopsy</p><p id=FN2><sup>b</sup> Blood pressure, pulse, temperature, height and weight. Assessment to be performed pre-dose and as per local practice during rituximab infusion</p><p id=FN3><sup>c</sup> PET and Contrast Enhanced CT of chest, abdomen and pelvis (neck if indicated) should be carried out within 35 days of planned treatment. The PET-CT hybrid scanners may be used to acquire the required CT images only if the CT produced by the scanner is of diagnostic quality and includes the use of intravenous (IV) contrast. If this cannot be achieved, a PET and separate Contrast Enhanced CT scan should be performed. Bi-dimensional measurements are expected.</p><p id=FN4><sup>d</sup> Bone marrow aspirate and trephine biopsy (single site with adequate trephine) (within 90 days of first treatment).</p><p id=FN5><sup>e</sup> Serum chemistry to include sodium, potassium, urea, creatinine, bilirubin, alanine or aspartate transaminase, alkaline phosphatase and albumin.</p><p id=FN6><sup>f</sup> Additional serum chemistry to be performed only at baseline: LDH, calcium, phosphate, β2-microglobulin and uric acid.</p><p id=FN7><sup>g</sup> Full blood count to include haemoglobin, white blood cell count, absolute neutrophil, lymphocytes and platelets counts. To be taken within 72 hours of chemotherapy administration on each cycle</p><p id=FN8><sup>h</sup> As per standard of care, sites should have hepatitis results available prior to initiation of immunochemotherapy.</p><p id=FN9><sup>i</sup> Only required in females of child bearing potential on day 1 before treatment commences</p><p id=FN34><sup>j</sup> A 12 lead ECG should be performed on all patients.</p><p id=FN10><sup>k</sup> In addition, an Echocardiogram or MUGA will be performed for all patients to establish a left ventricular ejection fraction equal to or greater than institutional normal range. Patients should be considered suitable to receive 300mg/m<sup>2</sup> doxorubicin</p><p id=FN11><sup>l</sup> Cerebrospinal fluid examination should be performed if clinically indicated or lymphomatous involvement of peripheral blood, nasal/paranasal sinuses or testis. CNS prophylaxis may be given according to local policy</p><p id=FN12><sup>m</sup> Diagnostic tumour block to be forwarded immediately upon obtaining either Tissue Block Screening consent or main study consent (for those patients whose tissue sample is easily accessible) to HMDS, Leeds, according to study procedure outlined in Investigator Site File.</p><p id=FN13><sup>n</sup> 20ml Blood sample in 2x10ml Streck tubes and 1x7.5ml EDTA Blood sample to be forwarded immediately to HMDS, Leeds prior to treatment start.</p><p id=FN14><sup>o</sup> Adverse Events to be collected from date of consent. Only Adverse Events related to study procedures should be reported prior to start of treatment.</p><p id=FN15><sup>p</sup> Blood pressure, pulse and temperature. Assessment to be performed pre-dose and as per local practice during rituximab infusion</p><p id=FN16><sup>q</sup> PET and Contrast Enhanced CT of chest, abdomen and pelvis (neck if indicated) needs to be completed within 3 weeks of the patient completing last treatment cycle. The PET-CT hybrid scanners may be used to acquire the required CT images only if the CT produced by the scanner is of diagnostic quality and includes the use of intravenous (IV) contrast. If this cannot be achieved, a PET and separate Contrast Enhanced CT scan should be performed. Bi-dimensional measurements are expected.</p><p id=FN17><sup>r</sup> Bone marrow biopsy to be repeated at the end of treatment if initially involved (to confirm CR)</p><p id=FN18><sup>s</sup> Serum chemistry to include sodium, potassium, urea, creatinine, bilirubin, alanine or aspartate transaminase, alkaline phosphatase, LDH and albumin. To be taken within 72 hours of administration of each cycle</p><p id=FN19><sup>t</sup> Full blood count including haemoglobin, white cell count, absolute neutrophil count, lymphocytes and platelets. To be taken within 72 hours of chemotherapy administration on each cycle</p><p id=FN20><sup>u</sup> Compliance will be assessed by patient’s diary with date and time of acalabrutinib administration, and the count of remaining capsules</p><p id=FN21><sup>v</sup> 20ml Blood sample in 2x10ml Streck tubes to be forwarded immediately to HMDS, Leeds</p><p id=FN22><sup>w</sup> End of RCHOP + acalabrutinib treatment at week 19 is also the start of the continuation phase of acalabrutinib. The dosing of acalabrutinib is continued after the last day of treatment (cycle 6 day 21) for 56 days further.</p><p id=FN23><sup>x</sup> Acalabrutinib only is given for cycles 7 and 8 as a continuation phase on a 28 days per cycle schedule - a total of 56 days continuation phase.</p><p id=FN24><sup>y</sup> Physical exam and ECOG performance status. To be taken within 48 hours of acalabrutinib administration.</p><p id=FN25><sup>z</sup> Electrocardiogram and Echocardiogram to be taken within 48 hours of acalabrutinib administration.</p><p id=FN26><sup>aa</sup>CT scan to be completed during Week 19 (+/- 1 week)</p><p id=FN27><sup>bb.</sup> EoT visit should take place within 3 weeks from the final dose of acalabrutinib.</p><p id=FN28><sup>cc</sup> Post dose samples should be taken at the protocol specified time ± 5 minutes.</p><p id=FN29><sup>dd</sup> Serum chemistry to include sodium, potassium, urea, creatinine, bilirubin, alanine or aspartate transaminase, alkaline phosphatase, LDH and albumin.</p><p id=FN30><sup><b>ee</b></sup> A contrast enhanced CT scan of the neck, chest, abdomen and pelvis will be performed at 12 months and 24 months following completion of protocol specified therapy. Bi-dimensional measurements are expected.</p><p id=FN31><sup>ff</sup> 20 ml Blood sample in 2x10ml Streck tubes to be forwarded immediately to HMDS, Leeds.</p><p id=FN32><sup>gg</sup> A visit window of +/- 2 weeks is permitted for follow-up visits.</p><p id=FN33>NB: The Participant/legal representative is free to withdraw consent at any time without providing a reason. When withdrawn, the participant will continue to receive standard clinical care. Follow up data will continue to be collected (unless the participant/legal representative has specifically stated that they do not want this to happen.</p></div></div></div><p class="" id=d2074e3343><i>Phase I - Dose Escalation</i></p><p class="" id=d2074e3347><i>Stage 1:</i></p><p class="" id=d2074e3351><span style="text-decoration: underline">R-CHOP + Acalabrutinib (Cycle 2–6)</span></p><div class=list><a name=d2074e3355 class=n-a></a><ul style="list-style-type: none"><li><p id=d2074e3362><span class=label>- </span> Rituximab 375mg/m<sup>2</sup> IV, on day 1</p></li><li><p id=d2074e3374><span class=label>- </span> Cyclophosphamide 750mg/m<sup>2</sup> IV, on day 1</p></li><li><p id=d2074e3386><span class=label>- </span> Doxorubicin 50mg/m<sup>2</sup> IV, on day 1</p></li><li><p id=d2074e3398><span class=label>- </span> Vincristine 1.4mg/m<sup>2</sup> (max 2mg) IV, on day 1</p></li><li><p id=d2074e3410><span class=label>- </span> Prednisolone 100mg po, on day 1–5</p></li><li><p id=d2074e3420><span class=label>- </span> Acalabrutinib, 100mg once daily taken orally, days 1–21</p></li></ul></div><p class="" id=d2074e3426><span style="text-decoration: underline">Cycle 7 (28 days) and 8 (28 days) - Acalabrutinib only</span></p><div class=list><a name=d2074e3430 class=n-a></a><ul style="list-style-type: none"><li><p id=d2074e3437><span class=label>- </span> Acalabrutinib, 100mg once daily taken orally for 56 days</p></li></ul></div><p class="" id=d2074e3442><span style="text-decoration: underline">Acalabrutinib dosage</span>:</p><p class="" id=d2074e3447>The first six participants enrolled in the study (cohort 1) will receive 100mg od started on day 1 of the 2<sup>nd</sup> cycle of R-CHOP. When participants of the first cohort have completed their third cycle, and their safety data has been reviewed by the Safety Review Committee, the decision for dose escalation to 100mg bd for cohort 2 could be taken.</p><p class="" id=d2074e3453><i>Stage 2:</i></p><p class="" id=d2074e3457><span style="text-decoration: underline">R-CHOP + Acalabrutinib (Cycle 2–6)</span></p><div class=list><a name=d2074e3462 class=n-a></a><ul style="list-style-type: none"><li><p id=d2074e3469><span class=label>- </span> Rituximab 375mg/m<sup>2</sup> IV, on day 1</p></li><li><p id=d2074e3481><span class=label>- </span> Cyclophosphamide 750mg/m<sup>2</sup> IV, on day 1</p></li><li><p id=d2074e3493><span class=label>- </span> Doxorubicin 50mg/m<sup>2</sup> IV, on day 1</p></li><li><p id=d2074e3505><span class=label>- </span> Vincristine 1.4mg/m<sup>2</sup> (max 2mg) IV, on day 1</p></li><li><p id=d2074e3517><span class=label>- </span> Prednisolone 100mg po, on day1–5</p></li><li><p id=d2074e3527><span class=label>- </span> Acalabrutinib 100mg twice daily, orally days 1–21</p></li></ul></div><p class="" id=d2074e3532><span style="text-decoration: underline">Cycle 7 (28 days) and 8 (28 days) - Acalabrutinib only</span></p><div class=list><a name=d2074e3536 class=n-a></a><ul style="list-style-type: none"><li><p id=d2074e3543><span class=label>- </span> Acalabrutinib, 100mg twice daily taken orally for 56 days following end of treatment with 6 cycles R-CHOP.</p></li></ul></div><p class="" id=d2074e3548><i>Phase II – Dose Expansion</i></p><p class="" id=d2074e3552><span style="text-decoration: underline">R-CHOP + Acalabrutinib (Cycle 2–6)</span></p><div class=list><a name=d2074e3556 class=n-a></a><ul style="list-style-type: none"><li><p id=d2074e3563><span class=label>- </span> Rituximab 375mg/m<sup>2</sup> IV, on day 1</p></li><li><p id=d2074e3575><span class=label>- </span> Cyclophosphamide 750mg/m<sup>2</sup> IV, on day 1</p></li><li><p id=d2074e3587><span class=label>- </span> Doxorubicin 50mg/m<sup>2</sup> IV, on day 1</p></li><li><p id=d2074e3599><span class=label>- </span> Vincristine 1.4mg/m<sup>2</sup> (max 2mg) IV, on day 1</p></li><li><p id=d2074e3611><span class=label>- </span> Prednisolone 100mg po, on day 1–5</p></li><li><p id=d2074e3621><span class=label>- </span> Acalabrutinib at a Recommended Phase II dose</p></li></ul></div><p class="" id=d2074e3627><span style="text-decoration: underline">Cycle 7 (28 days) and 8 (28 days) - Acalabrutinib only</span></p><p class="" id=d2074e3631>Acalabrutinib, at RP2D taken orally for 56 days following end of treatment with 6 cycles R-CHOP.</p><p class="" id=d2074e3634><b><i>Criteria for discontinuing or modifying allocated interventions</i></b></p><p class="" id=d2074e3639>After the participant has entered the trial, the clinician remains free to give alternative treatment to that specified in the protocol at any stage if he/she feels it is in the participant’s best interest, but the reasons for doing so should be recorded. In these cases, participants will be withdrawn from protocol treatment but remain within the trial for the purposes of follow-up and data analysis. All participants are free to withdraw at any time from the protocol treatment without giving reasons and without prejudicing further treatment.</p><p class="" id=d2074e3642><b><i>Strategies to improve adherence to interventions</i></b></p><p class="" id=d2074e3647>The investigator and/or study personnel will assess participant compliance with acalabrutinib at each study visit using direct questioning, examination of participants’ drug administration diaries and pill counts.</p></div><div class=section><a name=d2074e3651 class=n-a></a><h3 class=section-title>Relevant concomitant care permitted or prohibited during the trial</h3><p class="" id=d2074e3656><b><i>Supportive care</i></b></p><div class=list><a name=d2074e3661 class=n-a></a><ul><li><p id=d2074e3665>Live vaccination whilst on rituximab is prohibited and for participants who have peripheral B cell depletion must not have a live vaccination within three months of last rituximab dose</p></li><li><p id=d2074e3671>Participants will receive standard anti-emetic as per local policy</p></li><li><p id=d2074e3677>Allopurinol 300mg orally od should be given as per local practice; rasburicase may be administered if high risk of tumour lysis syndrome</p></li><li><p id=d2074e3683>Mouth care therapies are given according to local policy</p></li><li><p id=d2074e3689>Antacids and calcium supplements should be avoided for a period of at least 2 hours before and after taking acalabrutinib; short acting H2 receptor antagonists should only be taken at least 2 hours following acalabrutinib administration</p></li><li><p id=d2074e3696>Diarrhoea and constipation are both recognised side effects of therapy in this protocol, diarrhoea is the most common; treatment should be given according to local policy, although prophylactic anti-diarrhoeal agents are not recommended</p></li><li><p id=d2074e3702>Granulocyte-colony stimulating factor (GCSF) is mandated for all participants receiving R-CHOP and acalabrutinib; the formulation and duration will be according to local policy for primary prophylaxis but should be for at least seven days or until neutrophil recovery for those participants receiving the non-pegylated formulation</p></li><li><p id=d2074e3708>Antimicrobial prophylaxis given against <i>Pneumocystis jirovecii</i> pneumonia is mandated</p></li><li><p id=d2074e3717>Suitable infective prophylaxis to be given to participant’s aged 65 and over as per local policy; ciprofloxacin prophylaxis should be avoided due to possible interactions with acalabrutinib</p></li></ul></div><p class="" id=d2074e3722><b><i>Prohibited therapies</i></b></p><p class="" id=d2074e3727>Acalabrutinib is not a strong direct inhibitor or inducer or CYP isoforms; thus, acalabrutinib, at the currently used clinical doses, is unlikely to be a perpetrator of a drug interaction at the level of inhibition or induction of CYP isoforms. Acalabrutinib is partially metabolised by CYP3A; its exposure is affected when co-administered with strong CYP3A4 inducers or inhibitors. Consequently, the concomitant use of strong inhibitors/inducers of CYP3A4 (see <a href="#T3">Table 3</a>) should be avoided when possible.</p><a name=T3 class=n-a></a><div class="table-wrap panel clearfix"><div class=caption><h3>Table 3. Known strong <i>in vivo</i> inhibitors and inducers of CYP3A4.</h3></div><table xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class=article-table frame=below><a name=d2074e3748 class=n-a></a><thead><a name=d2074e3750 class=n-a></a><tr><a name=d2074e3752 class=n-a></a><th align=left colspan=1 rowspan=1 valign=top><a name=d2074e3754 class=n-a></a>Strong Inhibitors of CYP3A<sup><a href="#FN35">a</a></sup></th><th align=left colspan=1 rowspan=1 valign=top><a name=d2074e3760 class=n-a></a>Strong Inducers of CYP3A<sup><a href="#FN39">e</a></sup></th></tr></thead><tbody><a name=d2074e3768 class=n-a></a><tr><a name=d2074e3770 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d2074e3772 class=n-a></a>boceprevir<br class=br>clarithromycin<sup><a href="#FN36">b</a></sup><br class=br>conivaptin<sup><a href="#FN36">b</a></sup><br class=br>grapefruit juice<sup><a href="#FN37">c</a></sup><br class=br>itraconazole<sup><a href="#FN36">b</a></sup><br class=br>ketoconazole<sup><a href="#FN36">b</a></sup><br class=br>indinavir<br class=br>lopinavir/ritonavirb (combination<br class=br>drug)<br class=br>mibefradild<br class=br>nefazodone <br class=br>nelfinavir<br class=br>posaconazole<br class=br>ritonavirb<br class=br>saquinavir<br class=br>telaprevir<br class=br>telithromycin<br class=br>voriconazole</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2074e3827 class=n-a></a>carbamazepine<sup><a href="#FN40">f</a></sup><br class=br>phenytoin<sup><a href="#FN40">f</a></sup><br class=br>rifampin<sup><a href="#FN40">f</a></sup><br class=br>St John's wort<sup><a href="#FN40">f</a></sup></td></tr></tbody></table><div class=table-wrap-foot><div class=footnote><a name=FN35 class=n-a></a><p id=d2074e3855> a. A strong inhibitor for CYP3A is defined as an inhibitor that increases the AUC of a substrate for CYP3A by ≥ 5-fold.</p></div><div class=footnote><a name=FN36 class=n-a></a><p id=d2074e3861> b. In vivo inhibitor of P-glycoprotein.</p></div><div class=footnote><a name=FN37 class=n-a></a><p id=d2074e3867> c. The effect of grapefruit juice varies widely among brands and is concentration-, dose-, and preparation dependent. Studies have shown that it can be classified as a “strong CYP3A inhibitor” when a certain preparation was used (eg, high dose, double strength) or as a “moderate CYP3A inhibitor” when another preparation was used (eg, low dose, single strength).</p></div><div class=footnote><a name=FN38 class=n-a></a><p id=d2074e3873> d. Withdrawn from the United States market because of safety reasons.</p></div><div class=footnote><a name=FN39 class=n-a></a><p id=d2074e3879> e. A strong inducer for CYP3A is defined as an inducer that results in ≥ 80% decrease in the AUC of a substrate for CYP3A.</p></div><div class=footnote><a name=FN40 class=n-a></a><p id=d2074e3886> f. In vivo inducer of P-glycoprotein.</p></div><div class=footnote><a name=FN41 class=n-a></a><p id=d2074e3892> Note: The list of drugs in these tables is not exhaustive. Any questions about drugs not on this list should be addressed to the SCTU</p><p id=d2074e3895>Source: FDA Drug Development and Drug Interactions: Table of Substrates, Inhibitors and Inducers. Web link Accessed 21 January 2015:</p><p id=d2074e3898><a target=xrefwindow href="https://www.fda.gov/drugs/drug-interactions-labeling/drug-development-and-drug-interactions-table-substrates-inhibitors-and-inducers#inVivo" id=d2074e3899>http://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/DrugInteractionsLabeling/ucm093664.htm#inVivo</a></p></div></div></div><p class="" id=d2074e3905>Based on these considerations, patients who require therapy with drugs listed in <a href="#T3">Table 3</a> should not be enrolled into the study. If medically justified, patients may be enrolled if such inhibitors or inducers can be discontinued or alternative drugs that do not affect these enzymes can be substituted within 7 days before first dose of study drug. If a subject requires a strong CYP3A4 while on study, the subject will be monitored closely for potential drug-related toxicities.</p><p class="" id=d2074e3911>The effect of agents that reduce gastric acidity (e.g., proton pump inhibitors, H2 receptor antagonists or antacids) on acalabrutinib absorption was evaluated in a healthy volunteer study (ACE-HV-004; Acalabrutinib Investigator Brochure v8 ACERTA PHARMA B.V.). Results from this study indicate that participants should avoid the use of calcium carbonate containing drugs or supplements (e.g., antacids and calcium supplements) for a period of at least 2 hours before and after taking acalabrutinib. Similarly, participants should avoid the use of H2-receptor antagonists for a period of 2 hours after taking the study drugs. Use of omeprazole, esomeprazole, lansoprazole or any other proton pump inhibitors while taking acalabrutinib is not recommended due to a potential decrease in study drug exposure. However, if a subject requires the use of a proton pump inhibitor while on study (e.g., to treat a gastric ulcer) treatment options will be discussed with SCTU.</p><p class="" id=d2074e3914>In circumstances where treatment with ciprofloxacin is needed, the dose of acalabrutinib should be reduced to 100mg od.</p><p class="" id=d2074e3917>Warfarin and equivalent Vitamin K antagonists are prohibited. However, participants may use therapeutic low molecule weight heparin or low dose aspirin.</p><p class="" id=d2074e3920><b><i>Dietary restrictions</i></b></p><p class="" id=d2074e3926>Acalabrutinib can be taken with or without food. Because acalabrutinib may be metabolized by CYP3A4, participants should be strongly cautioned against consumption of grapefruit, grapefruit juice, or Seville orange juice (which contain potent CYP3A4 inhibitors) or using herbal remedies or dietary supplements (in particular, St John’s Wort, which is a potent CYP3A4 inducer). Otherwise, participants should maintain a normal diet unless modifications are required to manage an AE such as diarrhoea, nausea or vomiting.</p><p class="" id=d2074e3929><b><i>Contraception</i></b></p><p class="" id=d2074e3934>Contraception is mandated from trial entry until 12 months after the last treatment dose for participants of reproductive potential.</p><p class="" id=d2074e3937>Participants with reproductive potential must use two highly effective methods of contraception during the study, with male participants also agreeing to use additional barrier or abstinence due to the risk of exposure to a developing foetus if the female partner is already pregnant.</p><p class="" id=d2074e3940>Hormonal contraception may be susceptible to interaction with study or other drugs, which may reduce the efficacy of the contraception method.</p><p class="" id=d2074e3943>Both male and female patients must be counselled about future fertility prospects and sperm/ovarian preservation prior to study entry. Male patients must refrain from donating sperm once on study and during treatment and the 12 month follow-up period. Acalabrutinib is not known to confer long term reduction in fertility, however the cytotoxic drugs used in this protocol, i.e. doxorubicin and cyclophosphamide, may do.</p><p class="" id=d2074e3947><b><i>Provisions for post-trial care</i></b></p><p class="" id=d2074e3952>Participants completing the trial, or who withdraw their consent for follow-up, will be managed by standard clinical care from their usual treating clinician.</p></div><div class=section><a name=d2074e3956 class=n-a></a><h3 class=section-title>Outcomes</h3><p class="" id=d2074e3961><b><i>Primary outcomes</i></b></p><p class="" id=d2074e3966>The Phase I study will be dose escalation that will proceed until an MTD is defined or the MAD is determined in order to define the RP2D of acalabrutinib in combined with R-CHOP. This dose will be used in the Phase II evaluation of acalabrutinib in combination with R-CHOP in participants with DLBCL.</p><p class="" id=d2074e3969>The DLT will be defined using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse events (CTCAE) version 4.03. The MTD is defined as the highest dose level at which none of the first six treated participants, or no more than 2 of the first 12 treated participants, experiences a DLT.</p><p class="" id=d2074e3972>The DLT reporting period is from the start of treatment until the end of cycle 3. Events meeting the below criteria following the end of cycle 3 will not be recorded as DLTs.</p><p class="" id=d2074e3976>A DLT will be defined as the occurrence of the following:</p><div class=list><a name=d2074e3979 class=n-a></a><ul style="list-style-type: none"><li><p id=d2074e3986><span class=label>- </span> Grade 2 or greater haemorrhagic event requiring medical intervention or any intracranial haemorrhage</p><div class=list><a name=d2074e3989 class=n-a></a><ul style="list-style-type: none"><li><p id=d2074e3996><span class=label>- </span> Grade 3 or greater non-haematological toxicity at least possibly related to acalabrutinib (including grade 3 or 4 biochemical AEs). The following will be excluded; Grade 3 or 4 nausea in participants who have not received optimal treatment with anti-emetics, Grade 3 or 4 diarrhoea in participants who have not received optimal treatment with anti-diarrhoeal therapy, alopecia and those participants experiencing grade 3 or 4 administration reactions from rituximab.</p></li></ul></div></li><li><p id=d2074e4007><span class=label>- </span> Grade 4 thrombocytopenia or neutropenia for more than 7 days despite GCSF use.</p></li><li><p id=d2074e4016><span class=label>- </span> Any complete, continuous dose interruption more than 7 days for acalabrutinib related toxicities of grade 2 or greater within cycle 2.</p></li></ul></div><p class="" id=d2074e4021>If a DLT attributed to acalabrutinib per the investigator’s assessment occurred, dosing with acalabrutinib will be withheld. Acalabrutinib treatment will be resumed at a lower dose only after toxicity has resolved to ≤ grade 1. There will be no dose re-escalation for acalabrutinib after recovery from toxicity, and no intra-cohort participants dose escalation will be allowed. The study will terminate early if three DLT occur for the first six participants in Phase I (<a href="#T4">Table 4</a>).</p><a name=T4 class=n-a></a><div class="table-wrap panel clearfix"><div class=caption><h3>Table 4. Cohort size assessment actions.</h3></div><table xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class=article-table frame=below><a name=d2074e4038 class=n-a></a><thead><a name=d2074e4040 class=n-a></a><tr><a name=d2074e4042 class=n-a></a><th align=left colspan=1 rowspan=1><a name=d2074e4044 class=n-a></a>Cohort size</th><th align=left colspan=1 rowspan=1><a name=d2074e4047 class=n-a></a>Assessment</th><th align=left colspan=1 rowspan=1><a name=d2074e4050 class=n-a></a>Actions</th></tr></thead><tbody><a name=d2074e4055 class=n-a></a><tr><a name=d2074e4057 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d2074e4059 class=n-a></a>6 participants</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2074e4062 class=n-a></a>0 DLTs</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2074e4065 class=n-a></a>If cohort 1: proceed to the next cohort and escalate dose<br class=br>If cohort 2: RP2D is established as this dose</td></tr><tr><a name=d2074e4071 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d2074e4073 class=n-a></a>6 participants</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2074e4076 class=n-a></a>1–2 DLTs</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2074e4079 class=n-a></a>If cohort 1 or 2: Expand cohort to include up to 12 evaluable patients and re-evaluate</td></tr><tr><a name=d2074e4083 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d2074e4085 class=n-a></a>6 participants</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2074e4088 class=n-a></a>≥ 3 DLTs</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2074e4091 class=n-a></a>If cohort 1: Dose will be considered non-tolerated dose (NTD)<br class=br>No further recruitment to this cohort and dose escalation will cease<br class=br>If cohort 2: The RP2D will be defined as the dose in the previous cohort or further assessment may be<br class=br>required of an intermediate dose</td></tr><tr><a name=d2074e4101 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d2074e4103 class=n-a></a>12 participants</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2074e4106 class=n-a></a>1–2 DLTs</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2074e4109 class=n-a></a>If cohort 1: dose escalation may occur by proceeding to the next cohort, at the safety committee’s discretion<br class=br>If cohort 2: RP2D may be established at this dose, at the safety committee’s discretion</td></tr><tr><a name=d2074e4115 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d2074e4117 class=n-a></a>12 participants</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2074e4120 class=n-a></a>≥ 3 DLTs</td><td align=left colspan=1 rowspan=1 valign=top><a name=d2074e4123 class=n-a></a>If cohort 1: Dose will be considered non-tolerated dose (NTD)<br class=br>No further recruitment to this cohort and dose escalation will cease<br class=br>If cohort 2: The RP2D will be defined as the dose in the previous cohort or further assessment may be<br class=br>required of an intermediate dose</td></tr></tbody></table></div><p class="" id=d2074e4136>Dose adjustments for R-CHOP components, will follow conventional dose modification schedules.</p><p class="" id=d2074e4139>Phase II will use ORR to document the anti-tumour activity of the acalabrutinib and R-CHOP combination therapy, as well as investigating treatment safety. Safety will be assessed throughout via:</p><div class=list><a name=d2074e4143 class=n-a></a><ul><li><p id=d2074e4147>The reporting of adverse events using the NCI CTCAE v4.03.</p></li><li><p id=d2074e4153>Regular haematological and biochemistry evaluation</p></li><li><p id=d2074e4159>DLT defined using the NCI CTCAE v4.03.</p></li></ul></div><p class="" id=d2074e4164><b><i>Secondary outcomes</i></b></p><div class=list><a name=d2074e4169 class=n-a></a><ul><li><p id=d2074e4173>Pharmacokinetics of acalabrutinib, area under the curve (AUC), maximum concentration (C<sub>max</sub>), time to maximum concentration (T<sub>max</sub>), half-life (T<sub>1/2</sub>) and other PK parameters</p></li><li><p id=d2074e4188>Overall response rate of the combination acalabrutinib and R-CHOP according to cell of origin</p><p class="" id=d2074e4191>Progression-free survival at 2 years</p></li><li><p id=d2074e4197>Overall survival (death from any cause) at 2 years</p></li></ul></div><p class="" id=d2074e4202><b><i>Tertiary outcomes</i></b></p><div class=list><a name=d2074e4207 class=n-a></a><ul><li><p id=d2074e4211>Btk occupancy by acalabrutinib on peripheral blood using fluorescent affinity probe assay</p></li><li><p id=d2074e4217>Antibody-dependent cell-mediated cytotoxicity of R-CHOP when combined to acalabrutinib, post 1st R-CHOP and at day 8, 2nd cycle acalabrutinib + R-CHOP</p></li><li><p id=d2074e4223>CD86 and CD69 expression as a function of BCR activation by flow cytometry.</p></li><li><p id=d2074e4229>Tumour-specific DNA in plasma will be sequenced throughout treatment and clinical course</p></li><li><p id=d2074e4235>Apply the following techniques to formalin fixed paraffin embedded (FFPE) tumour material: mutational panel, Fluorescence In Situ Hybridization (FISH) analysis, immunohistochemical analysis for dual protein expression of Myc and Bcl2 and gene expression profiling using whole transcriptome profiling</p></li></ul></div></div><div class=section><a name=d2074e4241 class=n-a></a><h3 class=section-title>Participant timeline</h3><p class="" id=d2074e4246>The time schedule of enrolment, interventions, assessments, and visits for participants are fully detailed in the schedule of events (<a href="#T2">Table 2</a>).</p></div><div class=section><a name=d2074e4253 class=n-a></a><h3 class=section-title>Sample size</h3><p class="" id=d2074e4258>There is no formal sample size calculation given the modified 6+6 classical design. Sample size for Phase I is based upon anticipated numbers to complete schedule of dose escalation to DLT or MAD (n=6 - 24 participants). For Phase II, the sample size (n=15) permits sufficient numbers of participants to gain additional safety information and to look for exploratory signal of efficacy in biological subgroups in a pooled analysis of both stages.</p></div><div class=section><a name=d2074e4262 class=n-a></a><h3 class=section-title>Recruitment</h3><p class="" id=d2074e4267>Patients are approached within a hospital setting and screened for eligibility by research staff to ensure all inclusion and exclusion criteria are met. Clinicians will seek informed consent to enter the trial from a patient only after the patient has received a full explanation of the trial, the patient has read the PIS and had enough time to consider taking part.</p><p class="" id=d2074e4270>After the participant has entered the trial the clinician remains free to give alternative treatment to that specified in the protocol at any stage if he/she feels it is in the participant’s best interest, but the reasons for doing so should be recorded. In these cases, participants will be withdrawn from protocol treatment but remain within the trial for the purposes of follow-up and data analysis.</p></div><div class=section><a name=d2074e4275 class=n-a></a><h3 class=section-title>Assignment of interventions</h3><p class="" id=d2074e4280>ACCEPT is a non-randomised open-label study, consequently there is no allocation sequence and no-one involved in the trial is blinded to the intervention.</p></div><div class=section><a name=d2074e4284 class=n-a></a><h3 class=section-title>Data collection and management</h3><p class="" id=d2074e4289><b><i>Plans for assessment and collection of outcomes</i></b></p><p class="" id=d2074e4294>Hospital research staff will enter participant data into the study eCRFs via a remote data collection tool (Medidata Rave). Only trained personnel with specific roles in the study will be granted access to the eCRFs. SCTU trial staff will regularly check the data for missing or anomalous values. Data queries will either be automatically generated within the eCRF, or manually raised with site by the SCTU team. Site staff will respond to explain or resolve the discrepancies.</p><p class="" id=d2074e4297><b><i>Plans to promote participant retention and complete follow-up</i></b></p><p class="" id=d2074e4302>ACCEPT has no specific plans for promoting retention to the trial. Participants who do not complete six cycles of treatment for reasons other than toxicity will be replaced.</p><p class="" id=d2074e4306><b><i>Data management</i></b></p><p class="" id=d2074e4311>Full details of the data management strategy for the study are available as <i>Extended data</i><sup><a href="#ref-14">14</a></sup>.</p><p class="" id=d2074e4320><b><i>Confidentiality</i></b></p><p class="" id=d2074e4325>Participant data is pseudonymised by assigning each participant a participant identifier code, which is used to identify the participant during the study and for any participant- specific communication between SCTU and site.</p></div><div class=section><a name=d2074e4329 class=n-a></a><h3 class=section-title>Plans for collection, laboratory evaluation and storage of biological specimens for genetic or molecular analysis in this trial/future use</h3><p class="" id=d2074e4334><b><i>Pharmacokinetic sampling</i></b></p><p class="" id=d2074e4339>Acalabrutinib pharmacokinetics will be assessed in all participants by determination of serum concentrations of acalabrutinib by a fully validated assay that has already been used in human studies. The samples will be taken from participants as explained in <a href="#T5">Table 5</a>.</p><a name=T5 class=n-a></a><div class="table-wrap panel clearfix"><div class=caption><h3>Table 5. Schedule for pharmacokinetic sampling.</h3></div><table xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class=article-table frame=below><a name=d2074e4356 class=n-a></a><thead><a name=d2074e4358 class=n-a></a><tr><a name=d2074e4360 class=n-a></a><th align=center colspan=3 rowspan=1 valign=top><a name=d2074e4362 class=n-a></a></th><th align=center colspan=6 rowspan=1 valign=top><a name=d2074e4364 class=n-a></a>Hours post dose<sup><a href="#FN42">a</a></sup></th></tr><tr><a name=d2074e4371 class=n-a></a><th align=center colspan=1 rowspan=1 valign=top><a name=d2074e4373 class=n-a></a>Cycle</th><th align=center colspan=1 rowspan=1 valign=top><a name=d2074e4376 class=n-a></a>Day</th><th align=center colspan=1 rowspan=1 valign=top><a name=d2074e4379 class=n-a></a>Predose</th><th align=center colspan=1 rowspan=1 valign=top><a name=d2074e4382 class=n-a></a>0.5</th><th align=center colspan=1 rowspan=1 valign=top><a name=d2074e4385 class=n-a></a>0.75</th><th align=center colspan=1 rowspan=1 valign=top><a name=d2074e4389 class=n-a></a>1</th><th align=center colspan=1 rowspan=1 valign=top><a name=d2074e4392 class=n-a></a>2</th><th align=center colspan=1 rowspan=1 valign=top><a name=d2074e4395 class=n-a></a>4</th><th align=center colspan=1 rowspan=1 valign=top><a name=d2074e4398 class=n-a></a>6</th></tr></thead><tbody><a name=d2074e4403 class=n-a></a><tr><a name=d2074e4405 class=n-a></a><td align=center colspan=1 rowspan=1 valign=top><a name=d2074e4407 class=n-a></a>2</td><td align=center colspan=1 rowspan=1 valign=top><a name=d2074e4410 class=n-a></a>1</td><td align=center colspan=1 rowspan=1 valign=top><a name=d2074e4413 class=n-a></a>X</td><td align=center colspan=1 rowspan=1 valign=top><a name=d2074e4416 class=n-a></a>X</td><td align=center colspan=1 rowspan=1 valign=top><a name=d2074e4419 class=n-a></a>X</td><td align=center colspan=1 rowspan=1 valign=top><a name=d2074e4423 class=n-a></a>X</td><td align=center colspan=1 rowspan=1 valign=top><a name=d2074e4426 class=n-a></a>X</td><td align=center colspan=1 rowspan=1 valign=top><a name=d2074e4429 class=n-a></a>X</td><td align=center colspan=1 rowspan=1 valign=top><a name=d2074e4432 class=n-a></a>X</td></tr><tr><a name=d2074e4436 class=n-a></a><td align=center colspan=1 rowspan=1 valign=top><a name=d2074e4438 class=n-a></a></td><td align=center colspan=1 rowspan=1 valign=top><a name=d2074e4440 class=n-a></a>8</td><td align=center colspan=1 rowspan=1 valign=top><a name=d2074e4443 class=n-a></a>X</td><td align=center colspan=1 rowspan=1 valign=top><a name=d2074e4446 class=n-a></a>X</td><td align=center colspan=1 rowspan=1 valign=top><a name=d2074e4449 class=n-a></a>X</td><td align=center colspan=1 rowspan=1 valign=top><a name=d2074e4453 class=n-a></a>X</td><td align=center colspan=1 rowspan=1 valign=top><a name=d2074e4456 class=n-a></a>X</td><td align=center colspan=1 rowspan=1 valign=top><a name=d2074e4459 class=n-a></a>X</td><td align=center colspan=1 rowspan=1 valign=top><a name=d2074e4462 class=n-a></a>X</td></tr><tr><a name=d2074e4466 class=n-a></a><td align=center colspan=1 rowspan=1 valign=top><a name=d2074e4468 class=n-a></a></td><td align=center colspan=1 rowspan=1 valign=top><a name=d2074e4470 class=n-a></a>15</td><td align=center colspan=1 rowspan=1 valign=top><a name=d2074e4473 class=n-a></a>X</td><td align=center colspan=1 rowspan=1 valign=top><a name=d2074e4476 class=n-a></a>X</td><td align=center colspan=1 rowspan=1 valign=top><a name=d2074e4479 class=n-a></a>X</td><td align=center colspan=1 rowspan=1 valign=top><a name=d2074e4483 class=n-a></a>X</td><td align=center colspan=1 rowspan=1 valign=top><a name=d2074e4486 class=n-a></a>X</td><td align=center colspan=1 rowspan=1 valign=top><a name=d2074e4489 class=n-a></a></td><td align=center colspan=1 rowspan=1 valign=top><a name=d2074e4491 class=n-a></a></td></tr><tr><a name=d2074e4494 class=n-a></a><td align=center colspan=1 rowspan=1 valign=top><a name=d2074e4496 class=n-a></a>3</td><td align=center colspan=1 rowspan=1 valign=top><a name=d2074e4499 class=n-a></a>1</td><td align=center colspan=1 rowspan=1 valign=top><a name=d2074e4502 class=n-a></a>X</td><td align=center colspan=1 rowspan=1 valign=top><a name=d2074e4505 class=n-a></a></td><td align=center colspan=1 rowspan=1 valign=top><a name=d2074e4507 class=n-a></a></td><td align=center colspan=1 rowspan=1 valign=top><a name=d2074e4510 class=n-a></a></td><td align=center colspan=1 rowspan=1 valign=top><a name=d2074e4512 class=n-a></a></td><td align=center colspan=1 rowspan=1 valign=top><a name=d2074e4514 class=n-a></a></td><td align=center colspan=1 rowspan=1 valign=top><a name=d2074e4516 class=n-a></a></td></tr></tbody></table><div class=table-wrap-foot><div class=footnote><a name=FN42 class=n-a></a><p id=d2074e4525> <sup>a</sup>Post dose samples should be taken at the above specified times ± 5 minutes after study drug administration</p></div></div></div><p class="" id=d2074e4533><b><i>Pharmocodynamic sampling</i></b></p><p class="" id=d2074e4539>Acalabrutinib pharmacodynamics will be assessed in all participants by measurements of the following:</p><p class="" id=d2074e4542>1. <span style="text-decoration: underline">Evaluation of BTK occupancy in PBMCs.</span></p><p class="" id=d2074e4547>PBMC will be incubated with a fluorescently-tagged analogue of acalabrutinib. Acalabrutinib and the probe bind covalently to Btk, with binding of the probe being prevented by acalabrutinib occupancy. Probe-binding will be detected by flow cytometry. PMBCs will be collected by blood sample on day 1 of cycle 2 pre-dose and at 4 hours post-dose and on day 8 of cycle 2 pre-dose, at 2 and 4 hours post dose (<a href="#T6">Table 6</a>).</p><a name=T6 class=n-a></a><div class="table-wrap panel clearfix"><div class=caption><h3>Table 6. Schedule for pharmacodynamic sampling.</h3></div><table xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class=article-table frame=below><a name=d2074e4564 class=n-a></a><thead><a name=d2074e4566 class=n-a></a><tr><a name=d2074e4568 class=n-a></a><th align=center colspan=1 rowspan=1><a name=d2074e4570 class=n-a></a></th><th align=center colspan=1 rowspan=1><a name=d2074e4572 class=n-a></a></th><th align=center colspan=3 rowspan=1><a name=d2074e4574 class=n-a></a></th><th align=center colspan=1 rowspan=1><a name=d2074e4576 class=n-a></a>Hours post dose<sup><a href="#FN44">a</a></sup></th></tr><tr><a name=d2074e4583 class=n-a></a><th align=center colspan=1 rowspan=1><a name=d2074e4585 class=n-a></a></th><th align=center colspan=1 rowspan=1><a name=d2074e4587 class=n-a></a>Baseline</th><th align=center colspan=1 rowspan=1><a name=d2074e4590 class=n-a></a>Cycle</th><th align=center colspan=1 rowspan=1><a name=d2074e4593 class=n-a></a>Day</th><th align=center colspan=1 rowspan=1><a name=d2074e4596 class=n-a></a>Predose</th><th align=center colspan=1 rowspan=1><a name=d2074e4600 class=n-a></a>4</th></tr></thead><tbody><a name=d2074e4605 class=n-a></a><tr><a name=d2074e4607 class=n-a></a><td align=left colspan=1 rowspan=2 valign=top><a name=d2074e4609 class=n-a></a>BTK occupancy PBMCs</td><td align=center colspan=1 rowspan=1 valign=top><a name=d2074e4612 class=n-a></a></td><td align=center colspan=1 rowspan=1 valign=top><a name=d2074e4614 class=n-a></a>2</td><td align=center colspan=1 rowspan=1 valign=top><a name=d2074e4617 class=n-a></a>1</td><td align=center colspan=1 rowspan=1 valign=top><a name=d2074e4620 class=n-a></a>X</td><td align=center colspan=1 rowspan=1 valign=top><a name=d2074e4624 class=n-a></a>X</td></tr><tr><a name=d2074e4628 class=n-a></a><td align=center colspan=1 rowspan=1 valign=top><a name=d2074e4630 class=n-a></a></td><td align=center colspan=1 rowspan=1 valign=top><a name=d2074e4632 class=n-a></a>2</td><td align=center colspan=1 rowspan=1 valign=top><a name=d2074e4635 class=n-a></a>8</td><td align=center colspan=1 rowspan=1 valign=top><a name=d2074e4638 class=n-a></a>X</td><td align=center colspan=1 rowspan=1 valign=top><a name=d2074e4641 class=n-a></a></td></tr><tr><a name=d2074e4644 class=n-a></a><td align=left colspan=1 rowspan=2 valign=top><a name=d2074e4646 class=n-a></a>ADCC</td><td align=center colspan=1 rowspan=1 valign=top><a name=d2074e4649 class=n-a></a></td><td align=center colspan=1 rowspan=1 valign=top><a name=d2074e4651 class=n-a></a>2</td><td align=center colspan=1 rowspan=1 valign=top><a name=d2074e4654 class=n-a></a>1</td><td align=center colspan=1 rowspan=1 valign=top><a name=d2074e4657 class=n-a></a>X</td><td align=center colspan=1 rowspan=1 valign=top><a name=d2074e4661 class=n-a></a>X</td></tr><tr><a name=d2074e4665 class=n-a></a><td align=center colspan=1 rowspan=1 valign=top><a name=d2074e4667 class=n-a></a></td><td align=center colspan=1 rowspan=1 valign=top><a name=d2074e4669 class=n-a></a>2</td><td align=center colspan=1 rowspan=1 valign=top><a name=d2074e4672 class=n-a></a>8</td><td align=center colspan=1 rowspan=1 valign=top><a name=d2074e4675 class=n-a></a>X</td><td align=center colspan=1 rowspan=1 valign=top><a name=d2074e4678 class=n-a></a>X</td></tr><tr><a name=d2074e4682 class=n-a></a><td align=left colspan=1 rowspan=3 valign=top><a name=d2074e4684 class=n-a></a>CD86 and CD69 expression PBMCs</td><td align=center colspan=1 rowspan=1 valign=top><a name=d2074e4687 class=n-a></a></td><td align=center colspan=1 rowspan=1 valign=top><a name=d2074e4689 class=n-a></a>2</td><td align=center colspan=1 rowspan=1 valign=top><a name=d2074e4692 class=n-a></a>1</td><td align=center colspan=1 rowspan=1 valign=top><a name=d2074e4695 class=n-a></a>X</td><td align=center colspan=1 rowspan=1 valign=top><a name=d2074e4699 class=n-a></a></td></tr><tr><a name=d2074e4703 class=n-a></a><td align=center colspan=1 rowspan=1 valign=top><a name=d2074e4705 class=n-a></a></td><td align=center colspan=1 rowspan=1 valign=top><a name=d2074e4707 class=n-a></a>2</td><td align=center colspan=1 rowspan=1 valign=top><a name=d2074e4710 class=n-a></a>8</td><td align=center colspan=1 rowspan=1 valign=top><a name=d2074e4713 class=n-a></a>X</td><td align=center colspan=1 rowspan=1 valign=top><a name=d2074e4716 class=n-a></a></td></tr><tr><a name=d2074e4719 class=n-a></a><td align=center colspan=1 rowspan=1 valign=top><a name=d2074e4721 class=n-a></a></td><td align=center colspan=1 rowspan=1 valign=top><a name=d2074e4723 class=n-a></a>4</td><td align=center colspan=1 rowspan=1 valign=top><a name=d2074e4726 class=n-a></a>1</td><td align=center colspan=1 rowspan=1 valign=top><a name=d2074e4729 class=n-a></a>X</td><td align=center colspan=1 rowspan=1 valign=top><a name=d2074e4732 class=n-a></a></td></tr></tbody></table><div class=table-wrap-foot><div class=footnote><a name=FN43 class=n-a></a><p id=d2074e4741> ADCC, Antibody dependent cellular cytotoxicity; BTK, Bruton Tyrosine Kinase; PBMC, Peripheral Blood Mononuclear cells</p></div><div class=footnote><a name=FN44 class=n-a></a><p id=d2074e4747> <sup>a</sup>The post dose sample should be taken 4 hours ± 5 minutes after study drug administration.</p></div></div></div><p class="" id=d2074e4755>2. <span style="text-decoration: underline">Impact of the addition of acalabrutinib on R-CHOP mediated ADCC</span></p><p class="" id=d2074e4760>Blood samples will be collected on day 1 and day 8 cycle 2 pre- dose and 4 hours post dose. A fluorescent dye release assay measuring target cell lysis, coupled with flow cytometry will be employed to measure ADCC (<a href="#T6">Table 6</a>).</p><p class="" id=d2074e4767>3. <span style="text-decoration: underline">BCR activation before and after R-CHOP + acalabrutinib</span></p><p class="" id=d2074e4772>Blood samples for measurement of BCR activation will be collected on day 1 and day 8 cycle 2 pre-dose and on day 1 cycle 4 pre-dose. BCR activation will be determined by measurement of CD86 and CD69 expression on PBMC by flow cytometry (<a href="#T6">Table 6</a>).</p><p class="" id=d2074e4778><b><i>Translational research</i></b></p><p class="" id=d2074e4783>This study will prospectively validate the cell of origin (ABC versus GCB) model of DLBCL and its practicality and utility, as well as assessing the benefit/toxicity of the addition of acalabrutinib to R-CHOP.</p><p class="" id=d2074e4786>For all participants, sufficient diagnostic material should be available to forward to a central laboratory for pathological review and gene expression profiling. FFPE lymph node biopsies should be forwarded to Haematological Malignancy Diagnostic Service (HMDS) where molecular phenotyping will be performed using a reliable array platform requiring the extraction of RNA. Central pathological review will be performed as quality check but not fed back to site unless findings untoward. There must be sufficient tumour block to test for H/E morphological check of compatibility of DLBCL diagnosis, immunophenotyping, RNA for gene expression profiling. Additional material will be used for immunohistochemical, cytogenetic and molecular genetic studies FISH, DNA for mutation, Transcription Mediated Amplification. Material will only be retained if the sample size is sufficient for removal of material without compromising its value as archived diagnostic material. This may include the generation of extended full section immunohistochemical studies, tissue microarrays and DNA extraction. The remaining FFPE block will be returned to the local pathologist.</p><p class="" id=d2074e4789>DNA extracted from tumour material will be used to perform mutation detection on BCR pathway (e.g. Btk, PI3K, CD79b). Genetic abnormalities of BCR pathway will be correlated with clinical outcomes and the expression of BCR pathway target genes.</p></div><div class=section><a name=d2074e4793 class=n-a></a><h3 class=section-title>Statistical methods</h3><p class="" id=d2074e4798><b><i>Statistical methods for primary and secondary outcomes</i></b></p><p class="" id=d2074e4803>A full and detailed statistical analysis plan will be developed prior to the final analysis of the trial. The main features of the statistical analysis plan are:</p><div class=list><a name=d2074e4806 class=n-a></a><ul><li><p id=d2074e4810>Participants are required to receive 6 cycles of treatment to be included in the analysis, unless the cycles are not completed due to toxicity. The safety population will include all participants who receive any component of therapy.</p></li><li><p id=d2074e4816>Baseline characteristics will be summarised with means and standard deviations for continuous outcomes (if data is skewed medians and ranges will be presented) and frequencies and percentages for binary outcomes.</p></li><li><p id=d2074e4822>The primary analysis will be presented in a descriptive fashion, including a summary of any DLTs experienced by participants in Phase I and summary statistics for overall response rates for participants in Phase II, summarised with frequencies and percentages.</p></li><li><p id=d2074e4828>The safety component of the primary analysis will consist of all AEs and SAEs summarised by the CTCAE System Organ Class and term. SAEs by relatedness will also be listed.</p></li><li><p id=d2074e4834>Kaplan-Meier survival curves will be produced for the time to event secondary outcomes of progression-free survival and overall survival.</p></li><li><p id=d2074e4841>The final analysis will be conducted after one of the following conditions is met.</p><div class=list><a name=d2074e4844 class=n-a></a><ul style="list-style-type: none"><li><p id=d2074e4851><span class=label>○ </span> The trial is terminated early (for example, due to toxicity).</p></li><li><p id=d2074e4860><span class=label>○ </span> All participants have had the opportunity to complete protocol defined therapy and have completed the final follow-up visit, which will be 2 years after receiving the last study treatment, or sooner, if all participants have progressed, died or withdrawn from the study.</p></li><li><p id=d2074e4869><span class=label>○ </span> The predicted date for the final analysis is quarter 3 of 2022</p></li></ul></div></li></ul></div><p class="" id=d2074e4876><b><i>Interim analyses</i></b></p><p class="" id=d2074e4882>In Phase I the Safety Review Committee will review safety data and advise on dose escalation. The study will terminate early if three DLT occur for the first 6 participants in Phase I.</p><p class="" id=d2074e4885>In Phase II an independent Data Monitoring &amp; Ethics Committee (DMEC) will review outcome and safety data regularly during the trial advising the independent Trial Steering Committee (TSC) on continuation of the trial.</p><p class="" id=d2074e4888><b><i>Methods for additional analyses (e.g. subgroup analyses)</i></b></p><p class="" id=d2074e4893>Not applicable.</p><p class="" id=d2074e4896><b><i>Methods in analysis to handle protocol non-adherence and any statistical methods to handle missing data</i></b></p><p class="" id=d2074e4901>If the participant is discovered to be ineligible over the course of the study their participation will end. Where possible, participants who have withdrawn from trial treatment should remain in follow-up as per the trial schedule. If participants additionally withdraw consent for this, they should revert to standard clinical care as deemed by the responsible clinician. It would remain useful for the trial team to continue to collect survival follow-up data and unless the participant explicitly states otherwise, survival follow-up data will continue to be collected. Details of trial discontinuation (date, reason if known) should be recorded in the eCRF and medical record.</p><p class="" id=d2074e4905><b><i>Plans to give access to the full protocol, participant level-data and statistical code</i></b></p><p class="" id=d2074e4910>The full protocol is available as <i>Extended data</i><sup><a href="#ref-14">14</a></sup>. The ‘Dissemination plans’ section of this article describes how to access trial-related data.</p></div><div class=section><a name=d2074e4920 class=n-a></a><h3 class=section-title>Oversight and monitoring</h3><p class="" id=d2074e4925><b><i>Composition of the coordinating centre and trial steering committee</i></b></p><p class="" id=d2074e4930>An independent TSC has been set up to monitor trial progress. The ACCEPT TSC charter defines the membership, terms of reference, roles, responsibilities, authority, decision-making and relationships of the TSC, including the timing of meetings, frequency and format of meetings and relationships with other trial committees.</p><p class="" id=d2074e4933>The ACCEPT Trial Management Group includes representatives with expertise in haematology, oncology, translational science and medical statistics; as well as being supported by a Patient and Public Involvement contributor and CTU staff involved in the day-to-day running of the trial. Charters for these groups are available via <a href="mailto:accept@soton.ac.uk">accept@soton.ac.uk</a>.</p><p class="" id=d2074e4939><b><i>Composition of the data monitoring committee, its role and reporting structure</i></b></p><p class="" id=d2074e4945>An independent DMEC comprising three clinicians and a statistician experienced in this research area (but not directly involved in this trial apart from DMEC membership) has been set up to monitor trial progress and safety. The Charter for this group is also available via <a href="mailto:accept@soton.ac.uk">accept@soton.ac.uk</a>.</p><p class="" id=d2074e4951><b><i>Adverse event reporting and harms</i></b></p><p class="" id=d2074e4956>Data on AEs will be collected at treatment and follow-up visits. SAEs will be reported up to 30 days after the last administration of the trial drug to the SCTU safety desk. The trial also has a UK regulatory compliant real-time SAE reporting process to identify serious AEs and suspected unexpected SAEs that could suspend or stop the trial if warranted.</p><p class="" id=d2074e4959><b><i>Frequency and plans for auditing trial conduct</i></b></p><p class="" id=d2074e4964>The SCTU has undertaken a risk assessment for the ACCEPT trial, which includes the requirements for monitoring (both central and site). The SCTU undertakes a number of internal audits of its own systems and processes annually and has routine audits from both its sponsor and the independent Medicine and Health care products regulatory authority (MHRA).</p><p class="" id=d2074e4967><b><i>Plans for communicating important protocol amendments to relevant parties (e.g. trial participants, ethical committees)</i></b></p><p class="" id=d2074e4973>Research ethics committee/MHRA-approved protocol amendments will be communicated to sites via email and updated trial documentation provided centrally via the SCTU trial website (<a target=xrefwindow href="https://www.southampton.ac.uk/ctu" id=d2074e4975>https://www.southampton.ac.uk/ctu</a>). Trial registries will be amended where relevant with explanations for these changes.</p></div><div class=section><a name=d2074e4980 class=n-a></a><h3 class=section-title>End of the trial</h3><p class="" id=d2074e4985>The end of the study is defined as the date of the last follow-up visit of the last participant (expected to occur 24 months after the last participant receives their last study treatment). NB: The study will terminate early if three DLT occur for the first 6 participant in Phase I.</p></div></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d2074e4992>Dissemination plans</h2><p class="" id=d2074e4995>The results from the ACCEPT trial will be disseminated to patients and clinical teams through peer-reviewed journal articles authored by the members of the trial management group and presented at international conferences. We will also publicise our findings through existing networks and patient groups. Summary trial results will be available on the SCTU website.</p><p class="" id=d2074e4998>Pseudonymised individual participant data within the clinical trial dataset will be available for sharing via controlled access by authorised SCTU staff (as delegated to SCTU by the trial sponsor). Data access can be requested via a <a target=xrefwindow href="https://www.southampton.ac.uk/ctu/about/index.page" id=d2074e5000>SCTU Data Release application form</a>; detailing the specific requirements and the proposed research, statistical analysis, publication plan and evidence of research group qualifications. Please email the completed form to the SCTU Data Release Committee Coordinator at <a href="mailto:ctu@soton.ac.uk">ctu@soton.ac.uk</a>.</p><p class="" id=d2074e5007>Data access requests are reviewed against specific eligibility criteria by the SCTU data custodian and key members of the trial team, including a statistician and chief investigator or by an external Independent Review Panel. Decisions about requests are made promptly and usually no more than three months after receipt of request. Responses to all data requests, with a clear rationale for any refusals, will be sent promptly to the data requester.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d2074e5014>Trial status</h2><p class="" id=d2074e5017>Recruitment opened in May 2017 and finished January 2020; the trial is now closed to recruitment and is in follow-up. However, if any of the current participants (n=9) withdraw prior to receiving 6 cycles of R-CHOP, for reasons other than toxicity, we will need to replace them. If this situation arises, we will re-open recruitment to all sites.</p><p class="" id=d2074e5020>If the trial does not need to reopen, the last participants will reach cycle 6 on 20 April 2020 and will complete treatment on 6 July 2020. Participants enter a 24-month follow-up period after treatment and LPLV will be July 2022. The Phase I participants are nearing the end of their follow-up period and FPLV is due on 15 Feb 2020.</p><p class="" id=d2074e5023>This clinical trial was entered into EudraCT in December 2017 (EudraCT Number: 2015-003213-18) and is registered as ISRCTN 13626902.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d2074e5029>Discussion</h2><p class="" id=d2074e5032>ACCEPT aims to find out the maximum dose of acalabrutinib that can safely be given to patients in combination with R-CHOP as well as investigating the potential side effects and activity in patients with DLBCL.</p><div class=section><a name=d2074e5035 class=n-a></a><h3 class=section-title>First use of drug in combination with R-CHOP</h3><p class="" id=d2074e5040>This is the first use of the second generation Btk inhibitor acalabrutinib in combination with R-CHOP. This has been addressed through use of an appropriate Phase I trial design and monitoring during the study. The protocol contains stopping criteria in response to side effects which may occur with dose levels. To maintain safety during the trial, the data will be monitored closely by a Safety Review Committee and an independent DMEC on an on-going basis. First generation Btk inhibitors have been used safely in combination with R-CHOP in this patient group.</p></div><div class=section><a name=d2074e5044 class=n-a></a><h3 class=section-title>Uncertainty</h3><p class="" id=d2074e5049>Previous preclinical and clinical observations make a compelling case for the clinical investigation of R-CHOP in combination with acalabrutinib for the treatment of patients with DLBCL. However, the clinical effects of acalabrutinib on DLCBL are unknown and the initial group of patients in particular are unlikely to derive benefit from low dose acalabrutinib. It will be made clear to all patients that the benefit of acalabrutinib is uncertain.</p></div><div class=section><a name=d2074e5053 class=n-a></a><h3 class=section-title>Biological samples to be taken specifically for this study</h3><p class="" id=d2074e5058>Multiple blood samples will be taken in this study. Participants may also be subjected to up to two bone marrow biopsies and a lumbar puncture. These study procedures have been designed to be as limited as possible to gain the necessary information and to be conducted in the least distressing way by experienced health care professionals.</p></div><div class=section><a name=d2074e5063 class=n-a></a><h3 class=section-title>Ionising radiation</h3><p class="" id=d2074e5068>Participants will have two PET/CT scans and a separate CT with contrast (Cycle 7). These are standard of care in DLBCL. In addition, they will undergo two additional CT scans to look for progression as a research investigation (months 12 and 24). Patients will be made fully aware of this and the risks of these scans prior to giving consent to their participation in the trial.</p><p class="" id=d2074e5071>In addition, an Echocardiogram or MUGA will be performed for all patients to establish whether patients have a left ventricular ejection fraction of &gt;55% to ensure they are suitable to receive 300mg/m<sup>2</sup> doxorubicin.</p></div><div class=section><a name=d2074e5078 class=n-a></a><h3 class=section-title>Legal issues</h3><p class="" id=d2074e5083>There are no particular legal concerns arising from this study. The SCTU at the University of Southampton will be the UK coordinating trials unit and the University Hospital Southampton NHS Foundation Trust the sponsor in the UK and responsible for all legal requirements of conducting a non-commercial clinical trial of an investigation product. The drug for this trial is provided by ACERTA Pharma, BV who are responsible for the Good Manufacturing Practice quality drug and who is also providing research funding.</p></div></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d2074e5090>Data availability</h2><div class=section><a name=d2074e5093 class=n-a></a><h3 class=section-title>Underlying data</h3><p class="" id=d2074e5098>No underlying data is associated with this article.</p></div><div class=section><a name=d2074e5102 class=n-a></a><h3 class=section-title>Extended data</h3><p class="" id=d2074e5107>Figshare: ACCEPT - combining acalabrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone (R-CHOP) for Diffuse Large B-cell Lymphoma (DLBCL): study protocol for a phase Ib/II open-label non-randomised clinical trial, <a target=xrefwindow href="https://doi.org/10.6084/m9.figshare.11791275.v4" id=d2074e5109>https://doi.org/10.6084/m9.figshare.11791275.v4</a><sup><a href="#ref-14">14</a></sup>.</p><p class="" id=d2074e5116>This project contains the following extended data:</p><div class=list><a name=d2074e5119 class=n-a></a><ul style="list-style-type: none"><li><p id=d2074e5126><span class=label>- </span> Informed Consent Form and Patient Information Sheet – Tissue Block Screening; Phase I; Phase II; Pregnancy</p></li><li><p id=d2074e5135><span class=label>- </span> Full trial protocol</p></li><li><p id=d2074e5144><span class=label>- </span> Data Management Plan</p></li></ul></div><p class="" id=d2074e5149>Data are available under the terms of the <a target=xrefwindow href="https://creativecommons.org/licenses/by/4.0/legalcode" id=d2074e5151>Creative Commons Attribution 4.0 International license</a> (CC-BY 4.0).</p></div><div class=section><a name=d2074e5156 class=n-a></a><h3 class=section-title>Reporting guidelines</h3><p class="" id=d2074e5161>Figshare: SPIRIT checklist for ‘ACCEPT - combining acalabrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone (R-CHOP) for Diffuse Large B-cell Lymphoma (DLBCL): study protocol for a phase Ib/II open-label non-randomised clinical trial’, <a target=xrefwindow href="https://doi.org/10.6084/m9.figshare.11791275.v4" id=d2074e5163>https://doi.org/10.6084/m9.figshare.11791275.v4</a><sup><a href="#ref-14">14</a></sup>.</p><p class="" id=d2074e5170>Data are available under the terms of the <a target=xrefwindow href="https://creativecommons.org/licenses/by/4.0/legalcode" id=d2074e5172>Creative Commons Attribution 4.0 International license</a> (CC-BY 4.0).</p></div></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d2074e5180>Ethics approval and consent to participate</h2><p class="" id=d2074e5183>The study received ethical approval from South Central - Berkshire Research Ethics Committee on 26 January 2017 (ref: 16/SC/0657) and has Health Research Authority approval (IRAS 182046). Written informed consent for participation and publication of the participants/patients’ data was obtained from the participants. Participants are free to withdraw at any time. The Informed Consent Forms are provided as <i>Extended data.</i></p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d2074e5191>Consent for publication</h2><p class="" id=d2074e5194>Responsibility for publication has been delegated to Andrew Davies (Chief Investigator) and Gareth Griffiths (Director of SCTU) who have consented to this publication.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d2074e5200>Sponsor information</h2><p class="" id=d2074e5203>Name and contact information for the trial sponsor: University Hospital Southampton NHS Foundation Trust (email: <a href="mailto:R&amp;Doffice@suht.swest.nhs.uk">R&amp;Doffice@suht.swest.nhs.uk</a>), sponsor reference number: RHM CAN 1129.</p><p class="" id=d2074e5209>The study sponsor was not involved in the study design; writing of the protocol paper; or the decision to submit the paper for publication.</p></div><div id=article1-back class=generated-article-footer><div class=back-section><a name=d2074e5216 class=n-a></a><span class="research-layout prime-recommended-wrapper reference-heading is-hidden"><span class=faculty-opinion-icon></span><span class="prime-red big">Faculty Opinions recommended</span></span><h2 class=main-title id=d2502>References</h2><div class="section ref-list"><a name=d2074e5216 class=n-a></a><ul><li><a name=ref-1 class=n-a></a><span class=label>1. </span>&nbsp;<span class=citation><a name=d2074e5223 class=n-a></a>Cancer Research UK: UK Non-Hodgkin’s Lymphoma Statistics. (Accessed February 2019). <a target=xrefwindow id=d2074e5225 href="http://info.cancerresearchuk.org/cancerstats/types/nhl/?a=5441">Reference Source</a></span></li><li><a name=ref-2 class=n-a></a><span class=label>2. </span>&nbsp;<span class=citation><a name=d2074e5234 class=n-a></a>A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin’s lymphoma. The Non-Hodgkin’s Lymphoma Classification Project. <i>Blood.</i> 1997; <b>89</b>(11): 3909–18. <a target=xrefwindow id=d2074e5242 href="http://www.ncbi.nlm.nih.gov/pubmed/9166827">PubMed Abstract </a> | <a target=xrefwindow id=d2074e5245 href="https://doi.org/10.1182/blood.V89.11.3909">Publisher Full Text </a></span></li><li><a name=ref-3 class=n-a></a><span class=label>3. </span>&nbsp;<span class=citation><a name=d2074e5254 class=n-a></a>Fisher RI, Gaynor ER, Dahlberg S, <i> et al.</i>: Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin’s lymphoma. <i>N Engl J Med.</i> 1993; <b>328</b>(14): 1002–1006. <a target=xrefwindow id=d2074e5265 href="http://www.ncbi.nlm.nih.gov/pubmed/7680764">PubMed Abstract </a> | <a target=xrefwindow id=d2074e5268 href="https://doi.org/10.1056/NEJM199304083281404">Publisher Full Text </a></span></li><li><a name=ref-4 class=n-a></a><span class=label>4. </span>&nbsp;<span class=citation><a name=d2074e5277 class=n-a></a>Coiffier B, Lepage E, Bière J, <i> et al.</i>: CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. <i>N Engl J Med.</i> 2002; <b>346</b>(4): 235–242. <a target=xrefwindow id=d2074e5288 href="http://www.ncbi.nlm.nih.gov/pubmed/11807147">PubMed Abstract </a> | <a target=xrefwindow id=d2074e5291 href="https://doi.org/10.1056/NEJMoa011795">Publisher Full Text </a></span></li><li><a name=ref-5 class=n-a></a><span class=label>5. </span>&nbsp;<span class=citation><a name=d2074e5300 class=n-a></a>Habermann TM, Weller EA, Morrison VA, <i> et al.</i>: Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. <i>J Clin Oncol.</i> 2006; <b>24</b>(19): 312–7. <a target=xrefwindow id=d2074e5311 href="http://www.ncbi.nlm.nih.gov/pubmed/16754935">PubMed Abstract </a> | <a target=xrefwindow id=d2074e5314 href="https://doi.org/10.1200/JCO.2005.05.1003">Publisher Full Text </a></span></li><li><a name=ref-6 class=n-a></a><span class=label>6. </span>&nbsp;<span class=citation><a name=d2074e5324 class=n-a></a>Pfreundschuh M, Schubert J, Ziepert M, <i> et al.</i>: Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60). <i>Lancet Oncol.</i> 2008; <b>9</b>(2): 105–116. <a target=xrefwindow id=d2074e5335 href="http://www.ncbi.nlm.nih.gov/pubmed/18226581">PubMed Abstract </a> | <a target=xrefwindow id=d2074e5338 href="https://doi.org/10.1016/S1470-2045(08)70002-0">Publisher Full Text </a></span></li><li><a name=ref-7 class=n-a></a><span class=label>7. </span>&nbsp;<span class=citation><a name=d2074e5347 class=n-a></a>Pfreundschuh M, Trumper L, Osterborg A, <i> et al.</i>: CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. <i>Lancet Oncol.</i> 2006; <b>7</b>(5): 379–391. <a target=xrefwindow id=d2074e5358 href="http://www.ncbi.nlm.nih.gov/pubmed/16648042">PubMed Abstract </a> | <a target=xrefwindow id=d2074e5361 href="https://doi.org/10.1016/S1470-2045(06)70664-7">Publisher Full Text </a></span></li><li><a name=ref-8 class=n-a></a><span class=label>8. </span>&nbsp;<span class=citation><a name=d2074e5370 class=n-a></a>Sehn LH, Donaldson J, Chhanabhai M, <i> et al.</i>: Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia. <i>J Clin Oncol.</i> 2005; <b>23</b>(22): 5027–5033. <a target=xrefwindow id=d2074e5381 href="http://www.ncbi.nlm.nih.gov/pubmed/15955905">PubMed Abstract </a> | <a target=xrefwindow id=d2074e5384 href="https://doi.org/10.1200/JCO.2005.09.137">Publisher Full Text </a></span></li><li><a name=ref-9 class=n-a></a><span class=label>9. </span>&nbsp;<span class=citation><a name=d2074e5393 class=n-a></a>Gisselbrecht C, Glass B, Mounier N, <i> et al.</i>: R-ICE versus R-DHAP in relapsed patients with CD20 diffuse large B-cell lymphoma (DLBCL) followed by autologous stem cell transplantation: CORAL study. <i>J Clin Oncol.</i> 2005; (27): abstr. 8509. <a target=xrefwindow id=d2074e5401 href="https://ascopubs.org/doi/abs/10.1200/jco.2009.27.15_suppl.8509">Reference Source</a></span></li><li><a name=ref-10 class=n-a></a><span class=label>10. </span>&nbsp;<span class=citation><a name=d2074e5410 class=n-a></a>Davis RE, Ngo VN, Lenz G, <i> et al.</i>: Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma. <i>Nature.</i> 2010; <b>463</b>(7277): 88–92. <a target=xrefwindow id=d2074e5421 href="http://www.ncbi.nlm.nih.gov/pubmed/20054396">PubMed Abstract </a> | <a target=xrefwindow id=d2074e5424 href="https://doi.org/10.1038/nature08638">Publisher Full Text </a> | <a target=xrefwindow id=d2074e5428 href="http://www.ncbi.nlm.nih.gov/pmc/articles/2845535">Free Full Text </a></span></li><li><a name=ref-11 class=n-a></a><span class=label>11. </span>&nbsp;<span class=citation><a name=d2074e5437 class=n-a></a>Younes A, Thieblement C, Morschahauser F, <i> et al.</i>: Combination of ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for treatment-naive patients with CD20-positive B-cell non-Hodgkin lymphoma: a non-randomised, phase 1b study. <i>Lancet Oncol.</i> 2014; <b>15</b>(9): 1019–26. <a target=xrefwindow id=d2074e5448 href="http://www.ncbi.nlm.nih.gov/pubmed/25042202">PubMed Abstract </a> | <a target=xrefwindow id=d2074e5451 href="https://doi.org/10.1016/S1470-2045(14)70311-0">Publisher Full Text </a></span></li><li><a name=ref-12 class=n-a></a><span class=label>12. </span>&nbsp;<span class=citation><a name=d2074e5461 class=n-a></a>Barf T, Kaptein A: Irreversible protein kinase inhibitors: balancing the benefits and risks. <i>J Med Chem.</i> 2012; <b>55</b>(14): 6243–6262. <a target=xrefwindow id=d2074e5469 href="http://www.ncbi.nlm.nih.gov/pubmed/22621397">PubMed Abstract </a> | <a target=xrefwindow id=d2074e5472 href="https://doi.org/10.1021/jm3003203">Publisher Full Text </a></span></li><li><a name=ref-13 class=n-a></a><span class=label>13. </span>&nbsp;<span class=citation><a name=d2074e5481 class=n-a></a>Landau DB, Hughes L, Baker A, <i> et al.</i>: IDEAL-CRT: A Phase 1/2 Trial of Isotoxic Dose-Escalated Radiation Therapy and Concurrent Chemotherapy in Patients With Stage II/III Non-Small Cell Lung Cancer. <i>Int J Radiat Oncol Biol Phys.</i> 2016; <b>95</b>(5): 1367–77. <a target=xrefwindow id=d2074e5492 href="http://www.ncbi.nlm.nih.gov/pubmed/27296040">PubMed Abstract </a> | <a target=xrefwindow id=d2074e5495 href="https://doi.org/10.1016/j.ijrobp.2016.03.031">Publisher Full Text </a> | <a target=xrefwindow id=d2074e5499 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4959796">Free Full Text </a></span></li><li><a name=ref-14 class=n-a></a><span class=label>14. </span>&nbsp;<span class=citation><a name=d2074e5508 class=n-a></a>Davies A, Ardeshna K, Barrans S, <i> et al.</i>: ACCEPT - combining acalabrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone (R-CHOP) for Diffuse Large B-cell Lymphoma (DLBCL): study protocol for a phase Ib/II open-label non-randomised clinical trial. <i>figshare.</i> Journal contribution. 2020. <a target=xrefwindow id=d2074e5516 href="http://www.doi.org/10.6084/m9.figshare.11791275.v4">http://www.doi.org/10.6084/m9.figshare.11791275.v4</a></span></li><li><a name=ref-15 class=n-a></a><span class=label>15. </span>&nbsp;<span class=citation><a name=d2074e5525 class=n-a></a><a target=xrefwindow id=d2074e5526><a target=xrefwindow id=d2074e5526 href="https://clinicaltrials.gov/ct2/show/NCT02029443"> https://clinicaltrials.gov/ct2/show/NCT02029443</a></a></span></li></ul></div></div></div> </div> <div class=f1r-article-desk> <section class="o-box o-box--medium u-bg--2 u-mt--2"> <h4 class="u-mt--0 u-mb--2 t-h3 u-weight--md">Looking for the Open Peer Review Reports?</h4> <p class="u-mt--0 u-mb--0 t-h4">They can now be found at the top of the panel on the right, linked from the box entitled Open Peer Review. Choose the reviewer report you wish to read and click the 'read' link. You can also read all the peer review reports by <a target=_blank href="https://f1000research.com/articles/9-941/v1/pdf?article_uuid=89d4ae47-5192-48b1-a8fc-0cf781e1c908">downloading the PDF</a>.</p> </section> </div> <div id=article-comments class="article-comments padding-bottom-20"> <div class=current-article-comment-section> <h2 class=main-title name=add-new-comment id=add-new-comment> <span class="research-layout f1r-article-mobile-inline valign-middle"> <span class="f1r-icon icon-104_comments size30"></span> </span> <span class=f1r-article-desk-inline>Comments on this article</span> <span class=f1r-article-mobile-inline>Comments (0)</span> <span class="f1r-article-mobile-inline float-right"> <span class="f1r-icon icon-14_more_small"></span> <span class="f1r-icon icon-10_less_small"></span> </span> </h2> </div> <div class="f1r-article-desk-inline referee-report-info-box referee-report-version-box"> Version 1 </div> <div class="f1r-article-mobile research-layout mobile-version-info padding-top-30"> <span class=mversion>VERSION 1</span> <span class=details>PUBLISHED 07 Aug 2020</span> <span class="article-pubinfo-mobile versions-section"> </span> </div> <div class="f1r-article-mobile research-layout margin-top-20 is-centered"> <a href="/login?originalPath=/articles/9-941/v1&scrollTo=add-new-comment" class=register-report-comment-button data-test-id=add-comment_mob> <button class="primary orange extra-padding comment-on-this-report">ADD YOUR COMMENT</button> </a> </div> <a href="/login?originalPath=/articles/9-941/v1&scrollTo=add-new-comment" class="f1r-article-desk register-report-comment-button" data-test-id=add-comment> <span class=contracted></span>Comment </a> </div> <div class="f1r-article-mobile margin-bottom-30"> <div class=contracted-details> <a href="#" class="contracted-details-label author-affiliations"><span class=contracted></span>Author details</a> <a href="#" class=section-title>Author details</a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details affiliations is-hidden"> <sup>1</sup> Southampton Experimental Cancer Medicine Centre, University of Southampton and University Hospital Southampton NHS Foundation Trust, Southhampton, UK<br/> <sup>2</sup> Leeds Teaching Hospitals NHS Trust, Leeds, UK<br/> <sup>3</sup> Southampton Clinical Trials Unit, University of Southampton and University Hospital Southampton NHS Foundation Trust, Southampton, UK<br/> <sup>4</sup> University College London Hospitals NHS Foundation Trust, London, UK<br/> <sup>5</sup> Oxford University Hospitals NHS Trust, Oxford, UK<br/> <sup>6</sup> University of Manchester, Manchester, UK<br/> <sup>7</sup> Plymouth Hospitals NHS Trust and Plymouth University Peninsula School of Medicine and Dentistry, Plymouth, UK<br/> <sup>8</sup> Nottingham University Hospitals NHS Trust, Nottingham, UK<br/> <p> <div class=margin-bottom> Andrew Davies <br/> <span>Roles: </span> Conceptualization, Funding Acquisition, Methodology, Supervision </div> <div class=margin-bottom> Sharon Barrans <br/> <span>Roles: </span> Investigation, Project Administration, Resources </div> <div class=margin-bottom> Cathy Burton <br/> <span>Roles: </span> Investigation, Resources </div> <div class=margin-bottom> Katy Mercer <br/> <span>Roles: </span> Project Administration, Writing – Review & Editing </div> <div class=margin-bottom> Joshua Caddy <br/> <span>Roles: </span> Project Administration, Writing – Review & Editing </div> <div class=margin-bottom> Fay Chinnery <br/> <span>Roles: </span> Writing – Original Draft Preparation </div> <div class=margin-bottom> Laura Day <br/> <span>Roles: </span> Formal Analysis, Writing – Review & Editing </div> <div class=margin-bottom> Diana Fernando <br/> <span>Roles: </span> Data Curation </div> <div class=margin-bottom> Kirit Ardeshna <br/> <span>Roles: </span> Investigation, Resources </div> <div class=margin-bottom> Graham Collins <br/> <span>Roles: </span> Investigation, Resources </div> <div class=margin-bottom> John Radford <br/> <span>Roles: </span> Investigation, Resources </div> <div class=margin-bottom> Simon Rule <br/> <span>Roles: </span> Investigation, Resources </div> <div class=margin-bottom> Andrew McMillan <br/> <span>Roles: </span> Investigation, Resources </div> <div class=margin-bottom> Peter Johnson <br/> <span>Roles: </span> Conceptualization, Investigation, Methodology, Resources </div> <div class=margin-bottom> Gareth Griffiths <br/> <span>Roles: </span> Conceptualization </div> </p> </div> </div> <div class=contracted-details> <a href="#" class=section-title>Article Versions (1)</a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details grant-information article-page is-hidden"> <div> <a href="https://f1000research.com/articles/9-941/v1" title="Open version 1 of this article." class="" gahelper=1>version 1</a> <span class="article-pubinfo-mobile versions-section"> </span> </div> <div> Published: 07 Aug 2020, 9:941 </div> <div class=""><a href="https://doi.org/10.12688/f1000research.22318.1">https://doi.org/10.12688/f1000research.22318.1</a></div> </div> </div> <div class=contracted-details> <a href="#" class=section-title> <span class="f1r-icon icon-100_open_access"></span> Copyright </a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details grant-information article-page is-hidden"> © 2020 Davies A <em>et al</em>. This is an open access article distributed under the terms of the <a href="http://creativecommons.org/licenses/by/4.0/" target=_blank data-test-id=box-licence-link>Creative Commons Attribution License</a>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. </div> </div> <div class="padding-top-30 research-layout"> <div class=article-toolbox-wrapper-mobile> <div class=article-tools-icon-mobile data-section=download> <span class="f1r-icon icon-76_download_file white"></span> </div> <div class="article-tools-icon-mobile mobile-metrics article-metrics-wrapper metrics-icon-wrapper" data-section=metrics data-version-id=24618 data-id=22318 data-downloads="" data-views="" data-scholar="10.12688/f1000research.22318.1" data-recommended="" data-f1r-ga-helper="Article Page Metrics (Mobile)"> <span class="f1r-icon icon-89_metrics white"></span> </div> <div class=article-tools-divider-mobile></div> <div class=article-tools-icon-mobile data-section=cite> <span class="f1r-icon icon-82_quote white"></span> </div> <div class="article-tools-icon-mobile " data-section=track> <span class="f1r-icon icon-90_track white"></span> </div> <div class=article-tools-divider-mobile></div> <div class=article-tools-icon-mobile data-section=share> <span class="f1r-icon icon-34_share white"></span> </div> <span class=article-toolbox-stretch></span> </div> <div class=article-toolbox-content-mobile> <div class="toolbox-section download"> <div class=toolbox-section-heading>Download</div> <div class=toolbox-section-content> <a href="https://f1000research.com/articles/9-941/v1/pdf?article_uuid=89d4ae47-5192-48b1-a8fc-0cf781e1c908" title="Download PDF" class="no-decoration pdf-download-helper"> <span class="f1r-icon icon-102_download_pdf toolbox-section-icon"></span> </a> <div class=toolbox-section-option-divider>&nbsp;</div> <a id=mobile-download-xml class=no-decoration href="#" title="Download XML"> <span class="f1r-icon icon-103_download_xml toolbox-section-icon"></span> </a> </div> <div class=toolbox-section-divider></div> <div class=toolbox-section-heading>Export To</div> <div class=toolbox-section-content> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=WORKSPACE>Sciwheel</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=BIBTEX>Bibtex</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=ENDNOTE>EndNote</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=PROCITE>ProCite</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=REF_MANAGER>Ref. Manager (RIS)</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=SENTE>Sente</button> </div> </div> <div class="toolbox-section metrics"> <div class="toolbox-section-heading no-top-border">metrics</div> <div class="toolbox-section-divider toolbox-section-divider--no-height"></div> <div class=article-metrics-pageinfo> <div class=c-article-metrics-table> <table class=c-article-metrics-table__table> <thead> <tr> <th></th> <th><span class=c-article-metrics-table__heading>Views</span></th> <th><span class=c-article-metrics-table__heading>Downloads</span></th> </tr> </thead> <tbody> <tr> <th class=c-article-metrics-table__row-heading><span class="c-article-metrics-table__platform u-platform--" data-test-id=metrics_platform_name_mob>F1000Research</span></th> <td class="c-article-metrics-table__value js-article-views-count" data-test-id=metrics_platform_views_mob>-</td> <td class="c-article-metrics-table__value js-article-downloads-count" data-test-id=metrics_platform_downloads_mob>-</td> </tr> <tr> <th class=c-article-metrics-table__row-heading> <span class="u-ib u-middle c-article-metrics-table__pmc" data-test-id=metrics_pmc_name_mob>PubMed Central</span> <div class="c-block-tip c-block-tip--centered c-article-metrics-table__tooltip c-block-tip--md-padding c-block-tip--small-arrow u-ib u-middle"> <button type=button class="u-black--medium u-black--high@hover u-ib u-middle c-button--icon c-button--text c-block-tip__toggle"><i class="material-icons c-button--icon__icon">info_outline</i></button> <div class=c-block-tip__content>Data from PMC are received and updated monthly.</div> </div> </th> <td class="c-article-metrics-table__value js-pmc-views-count" data-test-id=metrics_pmc_views_mob>-</td> <td class="c-article-metrics-table__value js-pmc-downloads-count" data-test-id=metrics_pmc_downloads_mob>-</td> </tr> </tbody> </table> </div> </div> <span class=metrics-citations-container> <div class=toolbox-section-divider></div> <div class="toolbox-section-heading u-mb--1">Citations</div> <div> <div class=toolbox-section-colsplit> <div class=citations-scopus-logo> <a href="" target=_blank class="is-hidden metrics-citation-icon" title="View full citation details at www.scopus.com"><i class="material-icons scopus-icon">open_in_new</i></a> </div> <div class="toolbox-section-count scopus"> <a href='' class='scopus-citation-link is-hidden' target=_blank title='View full citation details at www.scopus.com'>0</a> </div> </div> <div class=toolbox-section-colsplit> <div class="citations-pubmed-logo f1000research"> <a href="" target=_blank class="is-hidden metrics-citation-icon f1000research" title="View full citation details"><i class="material-icons scopus-icon">open_in_new</i></a> </div> <div class="toolbox-section-count pubmed"> <a href='' class='pubmed-citation-link is-hidden' target=_blank title='View full citation details'>0</a> </div> </div> <div class=toolbox-section-divider></div> <div class=toolbox-section-content> <div class="citations-scholar-logo f1000research"> <a href="" target=_blank class="is-hidden metrics-citation-icon google-scholar f1000research" title="View full citation details" data-scholar="10.12688/f1000research.22318.1"><i class="material-icons scopus-icon">open_in_new</i></a> </div> </div> </div> </span> <span class=metrics-details-container> <div class=toolbox-section-divider></div> <div class="toolbox-section-content altmetric-section"> <div class=altmetrics-image></div> <div class=altmetrics-more-link> <a href="" target=_blank class=f1r-standard-link>SEE MORE DETAILS</a> </div> <div class=altmetric-mobile-column-counts></div> <div class=altmetric-mobile-column-readers></div> <div class=toolbox-section-divider></div> </div> </span> </div> <div class="toolbox-section cite"> <div class="toolbox-section-heading no-top-border">CITE</div> <div class=toolbox-section-divider></div> <div class=toolbox-section-heading>how to cite this article</div> <div id=citation-copy-mobile class="toolbox-section-content text-content heading9 small" data-test-id=mob_copy-citation_text> Davies A, Barrans S, Burton C <em>et al.</em> ACCEPT - combining acalabrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone (R-CHOP) for Diffuse Large B-cell Lymphoma (DLBCL): study protocol for a Phase Ib/II open-label non-randomised clinical trial [version 1; peer review: awaiting peer review] <i>F1000Research</i> 2020, <b>9</b>:941 (<a href="https://doi.org/10.12688/f1000research.22318.1" target=_blank>https://doi.org/10.12688/f1000research.22318.1</a>) </div> <div class=toolbox-section-divider></div> <div class="toolbox-section-content text-content heading9 small"> NOTE: <em>it is important to ensure the information in <b>square brackets after the title</b> is included in all citations of this article.</em> </div> <div class=toolbox-section-content> <button class="primary orange extra-padding copy-cite-article-mobile js-clipboard" data-clipboard-target="#citation-copy-mobile" title="Copy the current citation details." data-test-id=mob_copy-citation_button-mob>COPY CITATION DETAILS</button> </div> </div> <div class="toolbox-section track"> <div class="toolbox-section-heading no-top-border">track</div> <div class=toolbox-section-divider></div> <div class=toolbox-section-heading>receive updates on this article</div> <div class="toolbox-section-content padding-left-20 padding-right-20 heading9 small"> Track an article to receive email alerts on any updates to this article. </div> <div class=toolbox-section-content> <a data-article-id=22318 id=mobile-track-article-signin-22318 title="Receive updates on new activity such as publication of new versions, peer reviews or author responses." href="/login?originalPath=/trackArticle/22318?target=/articles/9-941/v1"> <button class="primary orange extra-padding"> TRACK THIS ARTICLE </button> </a> </div> </div> <div class="toolbox-section share"> <div class="toolbox-section-heading no-top-border">Share</div> <div class=toolbox-section-divider></div> <div class=toolbox-section-content> <a target=_blank class="f1r-shares-icon-square f1r-shares-email" title="Email this article"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-twitter" title="Share on Twitter"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-facebook" title="Share on Facebook"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-linkedin" title="Share on LinkedIn"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-reddit" title="Share on Reddit"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-mendelay" title="Share on Mendeley"></a> <div class="email-article-wrapper email-article-version-container"> <div class=toolbox-section-divider></div> <script src='https://www.recaptcha.net/recaptcha/api.js'></script> <form class="recommend-version-form-mobile research-layout"> <p>All fields are required.</p> <input name=versionId type=hidden value=24618 /> <input name=articleId type=hidden value=22318 /> <input name=senderName class="form-input-field reg-form" value="" type=text placeholder="Your name"/> <input name=senderEmail class="form-input-field reg-form margin-top" value="" type=text placeholder="Your email address"/> <textarea name=recipientEmails class="form-textarea-field ninetynine-percent-wide margin-top no-resize" placeholder="Recipient email address(es) (comma delimited)"></textarea> <input class="form-input-field reg-form margin-top" name=subject type=text value="Interesting article on F1000Research" placeholder=Subject /> <textarea name=message class="form-textarea-field reg-form margin-top no-resize">I thought this article from F1000Research (https://f1000research.com) would be of interest to you.</textarea> <div class="g-recaptcha margin-top" data-sitekey=6LcHqxoUAAAAANP3_0TzpGG6qFvl4DhbUcuRzw7W></div> <input value="" name=captcha type=hidden /> <p>A full article citation will be automatically included.</p> <p><img class="ticker-email-article-details hidden" src="/img/ticker.gif" alt=loading /></p> <button class="secondary orange margin-bottom" data-test-id=version_share_email_send>SEND EMAIL</button> <div class="orange-message margin-bottom is-hidden" data-test-id=version_share_email_message></div> </form> </div> </div> </div> </div> </div> <a name=article-reports></a> <div id=article-reports class="u-mt--3 reports-comments no-divider"> <div class="current-referee-status no-border-and-margin "> <h2 class=main-title id=current-referee-status> <span class="research-layout f1r-article-mobile-inline valign-middle"> <span class="f1r-icon icon-85_peer_review size30"></span> </span> Open Peer Review <span class="f1r-article-mobile-inline float-right"> <span class="f1r-icon icon-14_more_small"></span> <span class="f1r-icon icon-10_less_small"></span> </span> </h2> <a name=current-referee-status></a> <div class=current-referee-status__content name=add-new-report-comment id=add-new-report-comment> Current Reviewer Status: <div class=f1r-article-desk-inline><em>AWAITING PEER REVIEW</em></div> <div class="f1r-article-mobile-inline float-right"><em>AWAITING PEER REVIEW</em></div> <span class="circle-icon-small to-right" data-window=about-referee-status title=Help>?</span> <span class="research-layout f1r-article-mobile"> <div class=mobile-ref-status-help> Key to Reviewer Statuses <span class=referee-status-pointer></span> <span class="view-control float-right">VIEW</span> <span class="view-control float-right is-hidden">HIDE</span> <div class=mobile-ref-status-help-content> <div class="cf margin-top"> <span class="f1r-icon icon-86_approved status-green smaller float-left margin-bottom-40 margin-right" title=Approved></span> <span class=title>Approved</span>The paper is scientifically sound in its current form and only minor, if any, improvements are suggested </div> <div class="cf margin-top"> <span class="f1r-icon icon-87_approved_reservations status-green smaller float-left margin-bottom-40 margin-right" title="Approved with Reservations"></span> <span class=title>Approved with reservations</span> A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. </div> <div class="cf margin-top"> <span class="f1r-icon icon-88_not_approved status-red small float-left margin-bottom-30 margin-right" title="Not Approved"></span> <span class=title>Not approved</span>Fundamental flaws in the paper seriously undermine the findings and conclusions </div> </div> </div> </span> </div> </div> </div> <div class="f1r-article-mobile research-layout"> <div class="mobile-sections-divider before-comments"></div> </div> <div id=article-comments class="article-comments padding-bottom-20"> <div class=current-article-comment-section> <h2 class=main-title name=add-new-comment id=add-new-comment> <span class="research-layout f1r-article-mobile-inline valign-middle"> <span class="f1r-icon icon-104_comments size30"></span> </span> <span class=f1r-article-desk-inline>Comments on this article</span> <span class=f1r-article-mobile-inline>Comments (0)</span> <span class="f1r-article-mobile-inline float-right"> <span class="f1r-icon icon-14_more_small"></span> <span class="f1r-icon icon-10_less_small"></span> </span> </h2> </div> <div class="f1r-article-desk-inline referee-report-info-box referee-report-version-box"> Version 1 </div> <div class="f1r-article-mobile research-layout mobile-version-info padding-top-30"> <span class=mversion>VERSION 1</span> <span class=details>PUBLISHED 07 Aug 2020</span> <span class="article-pubinfo-mobile versions-section"> </span> </div> <div class="f1r-article-mobile research-layout margin-top-20 is-centered"> <a href="/login?originalPath=/articles/9-941/v1&scrollTo=add-new-comment" class=register-report-comment-button data-test-id=add-comment_mob> <button class="primary orange extra-padding comment-on-this-report">ADD YOUR COMMENT</button> </a> </div> <a href="/login?originalPath=/articles/9-941/v1&scrollTo=add-new-comment" class="f1r-article-desk register-report-comment-button" data-test-id=add-comment> <span class=contracted></span>Comment </a> </div> </div> </div> <div id=article_main-column class="p-article__sidebar o-layout__item u-1/3 not-expanded js-article-sidebar"> <div class="o-tab p-article__column-toggle-container"> <button class="c-tab c-tab--left js-column-toggle p-article__column-toggle not-expanded " type=button data-target-main=article_main-column data-target-secondary=article_secondary-column><i class="c-tab__icon material-icons u-hide@expanded">keyboard_arrow_left</i><i class="c-tab__icon material-icons u-show@expanded">keyboard_arrow_right</i></button> </div> <div class=p-article__sidebar-content> <div class="p-article__sidebar-scroller js-article-sidebar-scroller"> <section class="p-article__sidebar-view js-article-sidebar-view js-article-sidebar-main u-pt u-pb--8" data-view=peer-review> <div class="o-layout o-layout--flush"> <div class="o-layout__item u-pl"> <h3 class="u-mt--0 u-mb--2 t-h3 u-weight--md u-pl" data-test-id=article_sidebar_heading>Open Peer Review</h3> </div> <div class=o-layout__item> <div class="p-article__sidebar-highlight u-mb--2"> <h4 class="u-mt--0 u-mb--0 u-ib u-middle t-h4 u-weight--md u-mr--1/2">Reviewer Status</h4> <div class="u-ib u-middle"><em>AWAITING PEER REVIEW</em></div> </div> </div> <section class="o-layout__item u-pl"> <div class=u-pl> <hr class="c-hr c-hr--low c-hr--md u-mb--3"> <h4 class="t-h3 u-weight--md u-mt--0 u-mb--2">Comments on this article</h4> <div class=u-mb--4> <p class="u-mt--0 u-mb--1 t-h4"><a class=p-article__color--light href="#article-comments">All Comments</a><span class=" u-ib u-ml--1/2 p-article__color--light">(0)</span></p> <a class=t-h4 href="/login?originalPath=/articles/9-941/v1&scrollTo=add-new-comment" data-test-id=add-comment>Add a comment</a> </div> <hr class="c-hr c-hr--low c-hr--md u-mb--4"> <div class="research-layout f1r-article-desk"> <div class="heading6 c-ribbon-wrapper c-ribbon-wrapper--etoc f1000research "> <div class=c-ribbon-wrapper__body>Sign up for content alerts</div> </div> </div> <div class="research-layout sidebar-sign-up-form f1r-article-desk u-mb--4 "> <form class=js-email-alert-signup action="#" method=POST data-email=tocAlertWeekly> <input type=hidden name=isUserLoggedIn class=js-email-alert-signup-logged-in value=N /> <input type=hidden name=userId class=js-email-alert-signup-user-id value=""/> <input type=hidden name=frequency class=js-email-alert-signup-frequency value=WEEKLY /> <div class="o-actions o-actions--middle"> <div class=o-actions__primary> <input type=email name=emailAddress class="form-input-field js-email-alert-signup-address u-1/1 u-bb" required=required placeholder=Email /> </div> <div class=o-actions__secondary> <div class="_mdl-layout u-ml--1/2"> <button class="mdl-button mdl-js-button mdl-button--colored mdl-button--small mdl-button--filled js-email-alert-signup-submit">Sign Up</button> </div> </div> </div> </form> <div id=sidebar-sign-up-message class="section-text js-email-alert-signup-msg is-hidden">You are now signed up to receive this alert</div> </div> <section class=js-terms-container> <hr class="c-hr c-hr--low c-hr--md u-mb--3"> <h4 class="t-h3 u-weight--md u-mt--0 u-mb--1">Browse by related subjects</h4> <div class="article-subcontainer article-subcontainer--sidebar"> <ul class=js-terms-list></ul> </div> </section> </div> </section> </div> </section> </div> <script src="/js/shared_scripts/modal-dialogue.js"></script> <script src="/js/shared_scripts/read-more.js"></script> <script src="/js/article/article-router.js"></script> <script src="/js/article/article-sidebar.js"></script> <script src="/js/referee/new/referee_helpers.js"></script> <script src="/js/article/article-column-toggle.js"></script> </div> </div> </div> </main> <input type=hidden id=_articleVersionUrl value="https://f1000research.com/articles/9-941/v1/"> <div class=research-help id=about-referee-status> <div class="research-layout research-help-content about-referee-status"> <span class="close-research-help dark-cross" title=Close></span> Alongside their report, reviewers assign a status to the article: <div class="cf research-help-row"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> <span class=research-help-text>Approved - the paper is scientifically sound in its current form and only minor, if any, improvements are suggested</span> </div> <div class="cf research-help-row"> <span class="f1r-icon icon-87_approved_reservations status-green smaller" title="Approved with Reservations"></span> <span class=research-help-text>Approved with reservations - A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. </span> </div> <div class="cf research-help-row"> <span class="f1r-icon icon-88_not_approved status-red small" title="Not Approved"></span> <span class=research-help-text>Not approved - fundamental flaws in the paper seriously undermine the findings and conclusions</span> </div> </div> </div> <div id=datasets-info class=is-hidden> </div> <div class=article-interactive-content-container style="display: none;"> <a name=f-template class=n-a></a> <div class="interactive-content-wrapper padding-20"> <img src="" class=interactive-content-image title="Open the interactive image display"> <div class=interactive-content-title></div> <div class=interactive-content-text></div> <div class="f1r-article-desk interactive-content-ribbon" data-interactive-content-type=R-Script> <div class=interactive-content-label>Adjust parameters to alter display</div> <div class=interactive-content-button></div> </div> <div class="f1r-article-mobile mobile-interactive-note"> View on desktop for interactive features <img src="/img/icon/interactive_content.png" class="float-right margin-right-40"/> </div> <div class=clearfix></div> </div> </div> <div id=article-interactive-omero-container class=article-interactive-omero-container style="display: none;"> <div class=interactive-content-wrapper> <div class="interactive-omero-button omero-content" title="Open the interactive content window." data-interactive-content-type=Omero></div> <div class=has-interactive-content-image> <span class=box-arrow></span> <span class=box-middle>Includes Interactive Elements</span> <span class=box-end></span> </div> <div class="fig panel clearfix" style="margin: 0; padding-bottom: 20px;"> <a name=templatelink class=n-a></a> <a target=_blank href="" class=link-for-omero-image> <img src="" class=interactive-omero-image title="Open the image display window."> </a> <div class=caption> <div class=interactive-content-title></div> <div class=interactive-content-text></div> </div> <div class="is-hidden omero-image-list"></div> </div> <div class="f1r-article-mobile mobile-interactive-note omero"> View on desktop for interactive features <img src="/img/icon/interactive_content.png" class="float-right margin-right-40"/> </div> <div class=clearfix></div> </div> </div> <div class="add-comment-container shadow-box is-hidden" id=save-comment-container> <span id=save-comment-text class=intro-text>Edit comment</span> <textarea id=new-comment name=new-comment class="global-textarea comment margin-bottom margin-top"></textarea> <p><strong>Competing Interests</strong></p> <textarea id=new-competing-interests name=competing-interests class="global-textarea competing-interests margin-bottom check-xss"></textarea> <div class=clearfix></div> <button id=cancelComment type=button class="general-white-orange-button float-right no-background-button margin-left"> Cancel </button> <button id=save-comment-button commentId="" type=button class="general-white-orange-button float-right"> Save </button> <div class=clearfix></div> <div class="green-message margin-top is-hidden comment-is-saved">The comment has been saved.</div> <div class="red-message margin-top is-hidden comment-not-added">An error has occurred. Please try again.</div> <div class="red-message margin-top is-hidden comment-enter-text ucf">Your must enter a comment.</div> <div class="red-message margin-top is-hidden comment-references-error references">References error.</div> </div> <div class="modal-window-wrapper is-hidden"> <div id=conflicts-interests class="modal-window padding-20"> <div class=modal-window__content> <h2 class=h2-title>Competing Interests Policy</h2> <p> Provide sufficient details of any financial or non-financial competing interests to enable users to assess whether your comments might lead a reasonable person to question your impartiality. Consider the following examples, but note that this is not an exhaustive list: </p> <div class=heading5>Examples of 'Non-Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>Within the past 4 years, you have held joint grants, published or collaborated with any of the authors of the selected paper.</li> <li class=standard-padding>You have a close personal relationship (e.g. parent, spouse, sibling, or domestic partner) with any of the authors.</li> <li class=standard-padding>You are a close professional associate of any of the authors (e.g. scientific mentor, recent student).</li> <li class=standard-padding>You work at the same institute as any of the authors.</li> <li class=standard-padding>You hope/expect to benefit (e.g. favour or employment) as a result of your submission.</li> <li class=standard-padding>You are an Editor for the journal in which the article is published.</li> </ol> <div class="heading5 padding-top">Examples of 'Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>You expect to receive, or in the past 4 years have received, any of the following from any commercial organisation that may gain financially from your submission: a salary, fees, funding, reimbursements.</li> <li class=standard-padding>You expect to receive, or in the past 4 years have received, shared grant support or other funding with any of the authors.</li> <li class=standard-padding>You hold, or are currently applying for, any patents or significant stocks/shares relating to the subject matter of the paper you are commenting on.</li> </ol> </div> <div class="f1r-article-mobile research-layout"> <span class=modal-window-close-button></span> </div> </div> </div> <div class="o-modal c-email-alert-popup js-email-alert-popup is-hidden"> <div class="o-modal__body js-modal-body c-email-alert-popup__inner"> <h3 class=c-email-alert-popup__title>Stay Updated</h3> <p class=c-email-alert-popup__sub>Sign up for content alerts and receive a weekly or monthly email with all newly published articles</p> <p><a href="/register?originalPath=" class="c-email-alert-popup__lnk c-email-alert-popup__button js-email-alert-popup-action">Register with F1000Research</a></p> <p>Already registered? <a href="/login?originalPath=" class="c-email-alert-popup__lnk js-email-alert-popup-action">Sign in</a></p> <p class=c-email-alert-popup__footer><a class="c-email-alert-popup__lnk js-email-alert-popup-cancel" href="#">Not now, thanks</a></p> </div> </div> <div id=addCommentModal role=dialog aria-labelledby=addCommentModal_title aria-describedby=addCommentModal_description> <div class="c-modal js-modal is-closed p-article__add-comment-modal c-modal--xlarge js-article-comment-modal c-modal--scroll "> <aside class="c-modal__content u-black--high o-box u-pb--0 u-bg--2 c-modal--scroll-always "> <div class=c-modal__close> <button type=button class="c-button c-button--icon c-button--medium c-button--full@hover js-modal__close"><i class="c-button--icon__icon material-icons">close</i></button> </div> <div id=addCommentModal_description class="c-modal__description js-modal__content t-h4 u-mt--0 u-mb--2 u-black--medium"> <div class="js-add-comment-container t-caption u-black--high"> <div class=u-weight--bd>PLEASE NOTE</div> <div class=u-mt--1> <span class="red u-weight--bd">If you are an AUTHOR of this article,</span> please check that you signed in with the account associated with this article otherwise we cannot automatically identify your role as an author and your comment will be labelled as a &ldquo;User Comment&rdquo;. </div> <div class=u-mt--1> <span class="red u-weight--bd">If you are a REVIEWER of this article,</span> please check that you have signed in with the account associated with this article and then go to your <a href="/my/referee">account</a> to submit your report, please do not post your review here. </div> <div class="u-mt--1 u-mb--1"> If you do not have access to your original account, please <a href="mailto:research@f1000.com">contact us</a>. </div> <p class=no-top-margin>All commenters must hold a formal affiliation as per our <a href="/about/policies#commentspolicy" target=_blank>Policies</a>. The information that you give us will be displayed next to your comment.</p> <p>User comments must be in English, comprehensible and relevant to the article under discussion. We reserve the right to remove any comments that we consider to be inappropriate, offensive or otherwise in breach of the <a href="/about/legal/usercommenttermsandconditions" target=_blank>User Comment Terms and Conditions</a>. Commenters must not use a comment for personal attacks. When criticisms of the article are based on unpublished data, the data should be made available.</p> <div class="comments-note margin-bottom" id=accept-user-comments> <input class=js-add-comment-accept-terms type=checkbox id=acceptedTermsAndConditions name=acceptedTermsAndConditions> I accept the <a href="/about/legal/usercommenttermsandconditions" target=_blank> User Comment Terms and Conditions</a> <span class=required>&nbsp;</span> </div> <div class="default-error margin-top is-hidden comment-accept-conditions utac">Please confirm that you accept the User Comment Terms and Conditions.</div> <div class="research-layout registration-form u-mb--2"> <div class="u-mb--1 u-mt--2"> <strong>Affiliation</strong> </div> <div class=form-field> <input type=text name=institution class="form-input-field check-xss js-add-comment-institution" placeholder="Organization *" autocomplete=off /> <div class="default-error margin-top is-hidden comment-enter-institution institution">Please enter your organisation.</div> </div> <div class=form-field> <input type=text name=place class="form-input-field check-xss js-add-comment-place" placeholder=Place> </div> <div class=form-field> <div class="form-input-wrapper hundred-percent-wide"> <div class="new-select-standard-wrapper half-width inline-display heading10"> <select name=countryId id=country class="form-select-menu smaller js-add-comment-country"> <option value=-1>Country*</option> <option value=840>USA</option> <option value=826>UK</option> <option value=124>Canada</option> <option value=156>China</option> <option value=250>France</option> <option value=276>Germany</option> <optgroup label=-----------------------------------------------></optgroup> <option value=4>Afghanistan</option> <option value=248>Aland Islands</option> <option value=8>Albania</option> <option value=12>Algeria</option> <option value=16>American Samoa</option> <option value=20>Andorra</option> <option value=24>Angola</option> <option value=660>Anguilla</option> <option value=10>Antarctica</option> <option value=28>Antigua and Barbuda</option> <option value=32>Argentina</option> <option value=51>Armenia</option> <option value=533>Aruba</option> <option value=36>Australia</option> <option value=40>Austria</option> <option value=31>Azerbaijan</option> <option value=44>Bahamas</option> <option value=48>Bahrain</option> <option value=50>Bangladesh</option> <option value=52>Barbados</option> <option value=112>Belarus</option> <option value=56>Belgium</option> <option value=84>Belize</option> <option value=204>Benin</option> <option value=60>Bermuda</option> <option value=64>Bhutan</option> <option value=68>Bolivia</option> <option value=70>Bosnia and Herzegovina</option> <option value=72>Botswana</option> <option value=74>Bouvet Island</option> <option value=76>Brazil</option> <option value=86>British Indian Ocean Territory</option> <option value=92>British Virgin Islands</option> <option value=96>Brunei</option> <option value=100>Bulgaria</option> <option value=854>Burkina Faso</option> <option value=108>Burundi</option> <option value=116>Cambodia</option> <option value=120>Cameroon</option> <option value=124>Canada</option> <option value=132>Cape Verde</option> <option value=136>Cayman Islands</option> <option value=140>Central African Republic</option> <option value=148>Chad</option> <option value=152>Chile</option> <option value=156>China</option> <option value=162>Christmas Island</option> <option value=166>Cocos (Keeling) Islands</option> <option value=170>Colombia</option> <option value=174>Comoros</option> <option value=178>Congo</option> <option value=184>Cook Islands</option> <option value=188>Costa Rica</option> <option value=384>Cote d'Ivoire</option> <option value=191>Croatia</option> <option value=192>Cuba</option> <option value=196>Cyprus</option> <option value=203>Czech Republic</option> <option value=180>Democratic Republic of the Congo</option> <option value=208>Denmark</option> <option value=262>Djibouti</option> <option value=212>Dominica</option> <option value=214>Dominican Republic</option> <option value=218>Ecuador</option> <option value=818>Egypt</option> <option value=222>El Salvador</option> <option value=226>Equatorial Guinea</option> <option value=232>Eritrea</option> <option value=233>Estonia</option> <option value=231>Ethiopia</option> <option value=238>Falkland Islands</option> <option value=234>Faroe Islands</option> <option value=583>Federated States of Micronesia</option> <option value=242>Fiji</option> <option value=246>Finland</option> <option value=250>France</option> <option value=254>French Guiana</option> <option value=258>French Polynesia</option> <option value=260>French Southern Territories</option> <option value=266>Gabon</option> <option value=268>Georgia</option> <option value=276>Germany</option> <option value=288>Ghana</option> <option value=292>Gibraltar</option> <option value=300>Greece</option> <option value=304>Greenland</option> <option value=308>Grenada</option> <option value=312>Guadeloupe</option> <option value=316>Guam</option> <option value=320>Guatemala</option> <option value=831>Guernsey</option> <option value=324>Guinea</option> <option value=624>Guinea-Bissau</option> <option value=328>Guyana</option> <option value=332>Haiti</option> <option value=334>Heard Island and Mcdonald Islands</option> <option value=336>Holy See (Vatican City State)</option> <option value=340>Honduras</option> <option value=344>Hong Kong</option> <option value=348>Hungary</option> <option value=352>Iceland</option> <option value=356>India</option> <option value=360>Indonesia</option> <option value=364>Iran</option> <option value=368>Iraq</option> <option value=372>Ireland</option> <option value=376>Israel</option> <option value=380>Italy</option> <option value=388>Jamaica</option> <option value=392>Japan</option> <option value=832>Jersey</option> <option value=400>Jordan</option> <option value=398>Kazakhstan</option> <option value=404>Kenya</option> <option value=296>Kiribati</option> <option value=901>Kosovo (Serbia and Montenegro)</option> <option value=414>Kuwait</option> <option value=417>Kyrgyzstan</option> <option value=418>Lao People's Democratic Republic</option> <option value=428>Latvia</option> <option value=422>Lebanon</option> <option value=426>Lesotho</option> <option value=430>Liberia</option> <option value=434>Libya</option> <option value=438>Liechtenstein</option> <option value=440>Lithuania</option> <option value=442>Luxembourg</option> <option value=446>Macao</option> <option value=807>Macedonia</option> <option value=450>Madagascar</option> <option value=454>Malawi</option> <option value=458>Malaysia</option> <option value=462>Maldives</option> <option value=466>Mali</option> <option value=470>Malta</option> <option value=584>Marshall Islands</option> <option value=474>Martinique</option> <option value=478>Mauritania</option> <option value=480>Mauritius</option> <option value=175>Mayotte</option> <option value=484>Mexico</option> <option value=581>Minor Outlying Islands of the United States</option> <option value=498>Moldova</option> <option value=492>Monaco</option> <option value=496>Mongolia</option> <option value=499>Montenegro</option> <option value=500>Montserrat</option> <option value=504>Morocco</option> <option value=508>Mozambique</option> <option value=104>Myanmar</option> <option value=516>Namibia</option> <option value=520>Nauru</option> <option value=524>Nepal</option> <option value=530>Netherlands Antilles</option> <option value=540>New Caledonia</option> <option value=554>New Zealand</option> <option value=558>Nicaragua</option> <option value=562>Niger</option> <option value=566>Nigeria</option> <option value=570>Niue</option> <option value=574>Norfolk Island</option> <option value=580>Northern Mariana Islands</option> <option value=408>North Korea</option> <option value=578>Norway</option> <option value=512>Oman</option> <option value=586>Pakistan</option> <option value=585>Palau</option> <option value=275>Palestinian Territory</option> <option value=591>Panama</option> <option value=598>Papua New Guinea</option> <option value=600>Paraguay</option> <option value=604>Peru</option> <option value=608>Philippines</option> <option value=612>Pitcairn</option> <option value=616>Poland</option> <option value=620>Portugal</option> <option value=630>Puerto Rico</option> <option value=634>Qatar</option> <option value=638>Reunion</option> <option value=642>Romania</option> <option value=643>Russian Federation</option> <option value=646>Rwanda</option> <option value=654>Saint Helena</option> <option value=659>Saint Kitts and Nevis</option> <option value=662>Saint Lucia</option> <option value=666>Saint Pierre and Miquelon</option> <option value=670>Saint Vincent and the Grenadines</option> <option value=882>Samoa</option> <option value=674>San Marino</option> <option value=678>Sao Tome and Principe</option> <option value=682>Saudi Arabia</option> <option value=686>Senegal</option> <option value=688>Serbia</option> <option value=690>Seychelles</option> <option value=694>Sierra Leone</option> <option value=702>Singapore</option> <option value=703>Slovakia</option> <option value=705>Slovenia</option> <option value=90>Solomon Islands</option> <option value=706>Somalia</option> <option value=710>South Africa</option> <option value=239>South Georgia and the South Sandwich Is</option> <option value=410>South Korea</option> <option value=724>Spain</option> <option value=144>Sri Lanka</option> <option value=736>Sudan</option> <option value=740>Suriname</option> <option value=744>Svalbard and Jan Mayen</option> <option value=748>Swaziland</option> <option value=752>Sweden</option> <option value=756>Switzerland</option> <option value=760>Syria</option> <option value=158>Taiwan</option> <option value=762>Tajikistan</option> <option value=834>Tanzania</option> <option value=764>Thailand</option> <option value=270>The Gambia</option> <option value=528>The Netherlands</option> <option value=626>Timor-Leste</option> <option value=768>Togo</option> <option value=772>Tokelau</option> <option value=776>Tonga</option> <option value=780>Trinidad and Tobago</option> <option value=788>Tunisia</option> <option value=792>Turkey</option> <option value=795>Turkmenistan</option> <option value=796>Turks and Caicos Islands</option> <option value=798>Tuvalu</option> <option value=800>Uganda</option> <option value=826>UK</option> <option value=804>Ukraine</option> <option value=784>United Arab Emirates</option> <option value=850>United States Virgin Islands</option> <option value=858>Uruguay</option> <option value=840>USA</option> <option value=860>Uzbekistan</option> <option value=548>Vanuatu</option> <option value=862>Venezuela</option> <option value=704>Vietnam</option> <option value=876>Wallis and Futuna</option> <option value=905>West Bank and Gaza Strip</option> <option value=732>Western Sahara</option> <option value=887>Yemen</option> <option value=894>Zambia</option> <option value=716>Zimbabwe</option> </select> </div> </div> <div class="default-error margin-top is-hidden comment-enter-country country">Please select your country.</div> </div> </div> <textarea data-test-id=article_add-comment_comment name=new-comment class="js-add-comment-comment comment margin-bottom margin-top"></textarea> <div class="default-error margin-top comment-enter-text comment-error is-hidden ">You must enter a comment.</div> <label class="comments-note u-mt--2 u-mb--2" for=competingInterests_1> <div class="u-mb--1 u-mt--2"><strong data-test-id=article_report-add-comment_competing-interests-title>Competing Interests</strong></div> <p class="u-mb--2 u-mt--0" data-test-id=article_report-add-comment_competing-interests-description>Please disclose any <a href="#article-competing-intersts-policy" class=js-modal-competing-intersts-toggle>competing interests</a> that might be construed to influence your judgment of the article's or peer review report's validity or importance.</p> </label> <div id=article-competing-intersts-policy class=js-article-competing-interests-policy style="display: none;"> <h2 class="h2-title u-mt--0 u-pt--0">Competing Interests Policy</h2> <p> Provide sufficient details of any financial or non-financial competing interests to enable users to assess whether your comments might lead a reasonable person to question your impartiality. Consider the following examples, but note that this is not an exhaustive list: </p> <div class=heading5>Examples of 'Non-Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>Within the past 4 years, you have held joint grants, published or collaborated with any of the authors of the selected paper.</li> <li class=standard-padding>You have a close personal relationship (e.g. parent, spouse, sibling, or domestic partner) with any of the authors.</li> <li class=standard-padding>You are a close professional associate of any of the authors (e.g. scientific mentor, recent student).</li> <li class=standard-padding>You work at the same institute as any of the authors.</li> <li class=standard-padding>You hope/expect to benefit (e.g. favour or employment) as a result of your submission.</li> <li class=standard-padding>You are an Editor for the journal in which the article is published.</li> </ol> <div class="heading5 padding-top">Examples of 'Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>You expect to receive, or in the past 4 years have received, any of the following from any commercial organisation that may gain financially from your submission: a salary, fees, funding, reimbursements.</li> <li class=standard-padding>You expect to receive, or in the past 4 years have received, shared grant support or other funding with any of the authors.</li> <li class=standard-padding>You hold, or are currently applying for, any patents or significant stocks/shares relating to the subject matter of the paper you are commenting on.</li> </ol> </div> <div id=competingInterests_1 class="c-inline-editor js-inline-editor js-form_input u-bb--all u-mb--2 js-comment-competing-interests" data-name=competing-interests data-rows=3> <textarea id=competingInterests_1_input name=competing-interests placeholder="&nbsp;" required=false class="u-hide-visually js-inline-editor_input" tabindex=-1></textarea> <div class="c-inline-editor__editor js-inline-editor_editor o-box c-box o-box--tiny u-bg--11" data-target=competingInterests_1_input role=textbox required=false data-placeholder="&nbsp;" contenteditable=true></div> <span class="c-inline-editor__error js-inline-editor-message">Please state your competing interests</span> </div> <div data-test-id=article_add-comment_saved class="green-message comments is-hidden comment-is-saved">The comment has been saved.</div> <div data-test-id=article_add-comment_error class="default-error comments is-hidden comment-not-added">An error has occurred. Please try again.</div> <div class=clearfix></div> <div class=js-hook></div> </div> <div class="c-modal__extra-message js-modal__extra-message t-h4 u-black--medium"></div></div> <div class="c-modal__actions o-box__actions"> <a href="#" data-test-id=article_add-comment_cancel class="c-button c-button--full js-modal__close c-button--secondary">Cancel</a> <a href="#" data-test-id=article_add-comment_post class="c-button c-button--full js-modal__confirm c-button--primary">Post</a> </div> </aside> </div> </div> <style>
                .at-icon-wrapper {
        background-size: 100% !important;
    }
</style> <script src="/js/namespace.js"></script> <script src="/js/constants.js"></script> <script src="/js/utilities.js"></script> <script src="/js/article/alert-signup.js"></script> <script type='text/javascript'>
    var lTitle = "ACCEPT - combining acalabrutinib with rituximab,...".replace("'", '');
    var linkedInUrl = "http://www.linkedin.com/shareArticle?url=https://f1000research.com/articles/9-941/v1" + "&title=" + encodeURIComponent(lTitle) + "&summary=" + encodeURIComponent('Read the article by ');

    var deliciousUrl = "https://del.icio.us/post?url=https://f1000research.com/articles/9-941/v1&title=" + encodeURIComponent(lTitle);

    var redditUrl = "http://reddit.com/submit?url=https://f1000research.com/articles/9-941/v1" + "&title=" + encodeURIComponent(lTitle);

            linkedInUrl += encodeURIComponent('Davies A et al.');
    
    var offsetTop = /chrome/i.test( navigator.userAgent ) ? 4 : -10; 
    var addthis_config = {
            ui_offset_top: offsetTop,
                                    services_compact : "facebook,twitter,www.linkedin.com,www.mendeley.com,reddit.com",
            services_expanded : "facebook,twitter,www.linkedin.com,www.mendeley.com,reddit.com",
            services_custom : [
                {
                    name: "LinkedIn",
                    url:  linkedInUrl,
                    icon:"/img/icon/at_linkedin.svg"
                },
                {
                    name: "Mendeley",
                    url:  "http://www.mendeley.com/import/?url=https://f1000research.com/articles/9-941/v1/mendeley",
                    icon:"/img/icon/at_mendeley.svg"
                },
                {
                    name: "Reddit",
                    url:  redditUrl,
                    icon:"/img/icon/at_reddit.svg"
                },
            ]
        };


    var addthis_share = {
            url: "https://f1000research.com/articles/9-941",
            templates : {
                twitter : "ACCEPT - combining acalabrutinib with rituximab, cyclophosphamide,.... Davies A et al., published by " + 
               "@F1000Research"
       + ", https://f1000research.com/articles/9-941/v1"
            }
        };

    if (typeof(addthis) != "undefined"){
        addthis.addEventListener('addthis.ready', checkCount);
        addthis.addEventListener('addthis.menu.share', checkCount);
    }

        $(".f1r-shares-twitter").attr("href", "https://twitter.com/intent/tweet?text=" + addthis_share.templates.twitter);
    $(".f1r-shares-facebook").attr("href", "https://www.facebook.com/sharer/sharer.php?u=" + addthis_share.url);
    $(".f1r-shares-linkedin").attr("href", addthis_config.services_custom[0].url);
    $(".f1r-shares-reddit").attr("href", addthis_config.services_custom[2].url);
    $(".f1r-shares-mendelay").attr("href", addthis_config.services_custom[1].url);

    function checkCount(){
        setTimeout(function(){
            $(".addthis_button_expanded").each(function(){
                var count = $(this).text();
                if (count !== "" && count != "0")
                    $(this).removeClass("is-hidden");
                else
                    $(this).addClass("is-hidden");
            });
        }, 1000);
    }
</script> <div id=citeReportModal role=dialog aria-labelledby=citeReportModal_title aria-describedby=citeReportModal_description> <div class="c-modal js-modal is-closed c-modal--large js-cite-report-modal "> <aside class="c-modal__content u-black--high o-box u-pb--0 u-black--high "> <div class=c-modal__close> <button type=button class="c-button c-button--icon c-button--medium c-button--full@hover js-modal__close"><i class="c-button--icon__icon material-icons">close</i></button> </div> <h1 id=citeReportModal_title class="c-modal__title t-h3 u-mt--0 u-mb--2 u-weight--md">How to cite this report</h1> <div id=citeReportModal_description class="c-modal__description js-modal__content t-h4 u-mt--0 u-mb--2 u-black--medium"> <div id="" class=js-report-citation-container>{{reportCitation}}</div> <div class="c-modal__extra-message js-modal__extra-message t-h4 u-black--medium"></div></div> <div class="c-modal__actions o-box__actions"> <a href="#" class="c-button c-button--full js-modal__close c-button--secondary">Cancel</a> <a href="#" title="Copy the current citation details to the clipboard." data-clipboard-target="#referee-report-citation" data-test-id=report_copy-citation_button class="c-button c-button--full js-modal__confirm c-button--primary js-clipboard c-mini-tooltip--above">Copy Citation Details</a> </div> </aside> </div> </div> <script src="/js/referee/new/referee_validators.js"></script> <script src="/js/referee/new/referee_helpers.js"></script> <script src="/js/referee/new/referee_checkbox-input.js"></script> <script src="/js/referee/new/referee_inline-editor.js"></script> <script type="text/javascript">
    $(function(){
        var gaCat = "F1000Research";
        if (gaCat === "") {
            gaCat = $("body").hasClass("wellcome-brand") ? "Wellcome Open Research" : "F1000Research";
        }
        GAHelper.track({category: gaCat, action: "Article Page: ACCEPT - combining acalabrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone (R-CHOP) for Diffuse Large B-cell Lymphoma (DLBCL): study protocol for a Phase Ib\/II open-label non-randomised clinical trial", label: "pageviews"});
        GAHelper.track({category: gaCat, action: "Article Type: Study Protocol", label: "Article Page"});
        $(".f1r-article-desk .collection-image").each(function (idx, el) {
            var whatChannel = $(el).find("a").attr("href"),
                channelName = $.trim($(el).parent().find(".collection-detail a").text()),
                gaRef = "(ID: " + whatChannel.replace("/collections/", "") + ") " + channelName;
            GAHelper.track({category: 'ChannelStats', action: "Article Page: ACCEPT - combining acalabrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone (R-CHOP) for Diffuse Large B-cell Lymphoma (DLBCL): study protocol for a Phase Ib\/II open-label non-randomised clinical trial", label: gaRef});
        });
    });
</script> <script>
    $(function(){R.ui.buttonDropdowns('.dropdown-for-downloads');});
    $(function(){R.ui.toolbarDropdowns('.toolbar-dropdown-for-downloads');});
</script> <script src="/js/article/track_article.js" type="text/javascript"></script> <script type="text/javascript">
    $.get("/articles/acj/22318/24618")
</script> <script type="text/javascript" src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js"></script> <script type="text/javascript" src="/js/app/messenger.js"></script> <script type="text/javascript" src="/js/article/article_mobiles.js"></script> <script src="/js/vendor/clipboard.min.js"></script> <script src="/js/shared_scripts/modal-dialogue.js"></script> <script src="/js/shared_scripts/clipboard.js"></script> <script src="/js/article/thesaurus-terms-display.js"></script> <script>
    new F1000.Clipboard();
    new F1000.ThesaurusTermsDisplay("articles", "article", "24618");
</script> <script>
    $(document).ready(function() {
        $( "#frame1" ).on('load', function() {
            var mydiv = $(this).contents().find("div");
            var h     = mydiv.height();
            console.log(h)
        });

        
        var tooltipLivingFigure = jQuery(".interactive-living-figure-label .icon-more-info"),
            titleLivingFigure = tooltipLivingFigure.attr("title");
        tooltipLivingFigure.simpletip({
            fixed: true,
            position: ["-115", "30"],
            baseClass: 'small-tooltip',
            content:titleLivingFigure + "<div class='tooltip-arrow'></div>"
        });
        tooltipLivingFigure.removeAttr("title");

        $("body").on("click", ".cite-living-figure", function(e) {
            e.preventDefault();
            var ref = $(this).attr("data-ref");
            $(this).closest(".living-figure-list-container").find("#" + ref).fadeIn(200);
        });
        $("body").on("click", ".close-cite-living-figure", function(e) {
            e.preventDefault();
            $(this).closest(".popup-window-wrapper").fadeOut(200);
        });

                $(document).on("mouseup", function(e) {
            var metricsContainer = $(".article-metrics-popover-wrapper");
            if (!metricsContainer.is(e.target) && metricsContainer.has(e.target).length === 0) {
                $(".article-metrics-close-button").click();
            }
        });

        var articleId = $('#articleId').val();

        if($("#main-article-count-box").attachArticleMetrics) {
            $("#main-article-count-box").attachArticleMetrics(articleId, {
                articleMetricsView: true
            });
        }
    });

    var figshareWidget = $(".new_figshare_widget");
    if (figshareWidget.length > 0) {
        window.figshare.load("f1000", function(Widget) {
            // Select a tag/tags defined in your page. In this tag we will place the widget.
            _.map(figshareWidget, function(el){
                var widget = new Widget({
                    articleId: $(el).attr("figshare_articleId")
                    //height:300 // this is the height of the viewer part. [Default: 550]
                });
                widget.initialize(); // initialize the widget
                widget.mount(el); // mount it in a tag that's on your page
                // this will save the widget on the global scope for later use from
                // your JS scripts. This line is optional.
                //window.widget = widget;
            });
        });
    }
</script>

<script>
    $(document).ready(function () {

        
        var reportIds = {
                           "69041": 0,
                           "69040": 0,
                           "69028": 0,
                           "69033": 0,
                           "69035": 0,
                           "69034": 0,
                           "69037": 0,
                           "69053": 0,
                           "69052": 0,
                           "69036": 0,
                           "69039": 0,
                           "69038": 0,
                    };

        $(".referee-response-container,.js-referee-report").each(function(index, el) {
            var reportId = $(el).attr("data-reportid"),
                reportCount = reportIds[reportId] || 0;
            $(el).find(".comments-count-container,.js-referee-report-views").html(reportCount);
        });

        var uuidInput = $("#article_uuid"),
            oldUUId = uuidInput.val(),
            newUUId = "73a45994-a511-4f67-ba14-a6a85e065010";
        uuidInput.val(newUUId);

        $("a[href*='article_uuid=']").each(function(index, el) {
            var newHref = $(el).attr("href").replace(oldUUId, newUUId);
            $(el).attr("href", newHref);
        });

    });
</script>              </div>
        </div>

        
            
            <div class="o-page__footer sticky-email-wrapper">
                
                

                


<footer class="c-footer t-inverted">

    <div class="o-wrapper">
        <div class="o-layout">


                        
            <div class="o-layout__item u-mb--3">
                <div class="c-branding c-branding--research">
                    <img src="/img/research/F1000Research_white.svg" alt="F1000Research">
                </div>
            </div>


                        
            <div class="o-layout__item u-1/3@md u-mb--3">

                <span class="c-hr c-hr--thick c-hr--low u-mb--2"></span>

                <p class="t-h3 u-mt--0 u-mb--0">An innovative open access publishing platform offering rapid publication and open peer review, whilst supporting data deposition and sharing.</p>

            </div>


                        
            <div class="o-layout__item u-2/3@md">

                <span class="c-hr c-hr--thick c-hr--low u-mb--2"></span>

                <div class="o-layout">
                    <nav class="c-footer__nav">

                            <div class="o-layout__item u-3/5@sm u-mb--3">


                                <div class="o-columns o-columns--2">

                                                                            <a href="/browse/articles" class="t-body c-footer__nav-item "      >Browse</a>
                                                                            <a href="/gateways" class="t-body c-footer__nav-item "      >Gateways</a>
                                                                            <a href="/collections" class="t-body c-footer__nav-item "      >Collections</a>
                                                                            <a href="/about" class="t-body c-footer__nav-item "      >How it Works</a>
                                                                            <a href="https://blog.f1000.com/blogs/f1000research/" class="t-body c-footer__nav-item "      >Blog</a>
                                                                            <a href="/contact" class="t-body c-footer__nav-item "      >Contact</a>
                                                                            <a href="/developers" class="t-body c-footer__nav-item u-hide u-show@navbar"      >For Developers</a>
                                                                            <a href="/published/rss" class="t-body c-footer__nav-item "   title="RSS feed of published articles"     >RSS</a>
                                    
                                </div>

                            </div>

                            <div class="o-layout__item u-2/5@sm u-center u-right@sm u-mb--3">

                                <div class="u-hide u-show@lg">
                                    <div class="_mdl-layout">
                                        <a class="mdl-button mdl-js-button mdl-button--inverted mdl-button--no-shadow mdl-js-ripple-effect mdl-button--outline" href="/for-authors/publish-your-research"   data-test-id="footer_submit_research"  >Submit Your Research</a>
                                    </div>
                                </div>

                            </div>

                    </nav>
                </div>

            </div>

            <div class="o-layout__item u-mb--2">
                <div class="c-footer__share">
                        <div class="c-footer__share">
        <span class="c-footer__share-icon" title="Open Access">
            <span class="f1r-icon icon-100_open_access license-icon"></span>
        </span>

        <a class="c-footer__share-icon" href="//creativecommons.org/licenses" target="_blank" title="Creative Commons License CC-BY">
            <span class="f1r-icon icon-116_cc license-icon license-icon-cc"></span>
            <span class="f1r-icon icon-117_ccby license-icon license-icon-cc"></span>
        </a>

        <a class="c-footer__share-icon" href="//creativecommons.org/about/cc0" target="_blank" title="Creative Commons License CC0">
            <span class="f1r-icon icon-118_cco license-icon"></span>
        </a>

    </div>
                </div>
            </div>


                        
            <div class="o-layout__item u-1/3@md u-mb--3">

                <span class="c-hr c-hr--low u-mb--3"></span>

                <p class="c-footer__social u-mt--0 u-mb--0 u-white--low-med">Follow us
                    <a href="https://www.facebook.com/F1000" target="_blank" class="c-footer__social-icon f1r-icon icon-55_footer_facebook"></a>
                    <a href="https://twitter.com/#!/F1000Research" target="_blank" class="c-footer__social-icon f1r-icon icon-56_footer_twitter"></a>
                    <a href="http://www.youtube.com/user/F1000research" target="_blank" class="c-footer__social-icon f1r-icon icon-57_footer_youtube"></a></p>

            </div>


                        
            <div class="o-layout__item u-2/3@md u-right@md">

                <span class="c-hr c-hr--low u-mb--3"></span>

                <p class="t-caption u-white--low-med">&copy; 2012-2020 F1000 Research Ltd. ISSN 2046-1402 | <a href="/about/legal" class="copyrightLegal">Legal</a> | Partner of <a target="_blank" href="http://www.who.int/hinari/en/">HINARI</a>  &bull; <a target="_blank" href="http://crossref.org/">CrossRef</a> &bull; <a target="_blank" href="http://about.orcid.org/">ORCID</a> &bull; <a target="_blank" href="http://www.fairsharing.org">FAIRSharing</a></p>

            </div>
        </div>
    </div>

</footer>            </div>
        
    </div>

            <div class="js-cookie-spacer"></div>
        <div class="cookie-warning">
            <div class="instruction">The F1000Research website uses cookies. By continuing to browse the site, you are agreeing to our use of cookies. <a class="js-scroll-to" href="/about/legal/privacypolicy#use-of-cookies" data-scroll-target="#use-of-cookies">Find out more &raquo;</a></div>
            <div class="close-button"></div>
        </div>
    
    <script>
                    R.templateTests.simpleTemplate = R.template('<p class="$variable.one">$text</p><p class="${variable.two}">$text</p><p class="$!variable.three">$text</p><p class="$!{variable.four}">$text</p><p class="${selector}.five">$text</p>');
            R.templateTests.runTests();
        
        var F1000platform = new F1000.Platform({
            name: "f1000research",
            displayName: "F1000Research",
            hostName: "f1000research.com",
            id: "1",
            editorialEmail: "research@f1000.com",
            infoEmail: "info@f1000.com",
            usePmcStats: true
        });

                    $(function(){R.ui.dropdowns('.dropdown-for-authors, .dropdown-for-about, .dropdown-for-myresearch');});
            // $(function(){R.ui.dropdowns('.dropdown-for-referees');});

            $(document).ready(function () {
                if ($(".cookie-warning").is(":visible")) {
                    $(".sticky").css("margin-bottom", "35px");
                    $(".devices").addClass("devices-and-cookie-warning");
                }
                $(".cookie-warning .close-button").click(function (e) {
                    $(".devices").removeClass("devices-and-cookie-warning");
                    $(".sticky").css("margin-bottom", "0");
                });

                $("#tweeter-feed .tweet-message").each(function (i, message) {
                    var self = $(message);
                    self.html(linkify(self.html()));
                });

                $(".partner").on("mouseenter mouseleave", function() {
                    $(this).find(".gray-scale, .colour").toggleClass("is-hidden");
                });
            });
        
    </script>

            
<div class="sign-in-popup">
	<!-- <a href="#" class="sign-in shadow">Sign in <span class="sign-in-image-active"></span></a> -->
	<a href="#" class="sign-in ${locale}">Sign In <span class="arrow-closed sign-in-arrow-padding arrow-opened"></span></a>
	<div class="sign-in-form">

            <form action="https://f1000research.com/j_spring_oauth_security_check" id="googleOAuth" method="post"  target="_top" >
                                    <input class="target-field" type="hidden" name="target" value="/articles/9-941.html"/>
                            <input id="google-remember-me" name="_spring_security_oauth_remember_me" type="hidden" value="true"/>
        <input id="system-google" name="system" type="hidden" value="GOOGLE"/>
    </form>
            <form action="https://f1000research.com/j_spring_oauth_security_check" id="facebookOAuth" method="post"  target="_top" >
                                    <input class="target-field" type="hidden" name="target" value="/articles/9-941.html"/>
                            <input id="facebook-remember-me" name="_spring_security_oauth_remember_me" type="hidden" value="true"/>
        <input id="system-fb" name="system" type="hidden" value="FACEBOOK"/>
    </form>
            <form action="https://f1000research.com/j_spring_oauth_security_check" id="orcidOAuth" method="post"  target="_top" >
                                    <input class="target-field" type="hidden" name="target" value="/articles/9-941.html"/>
                            <input id="orcid-remember-me" name="_spring_security_oauth_remember_me" type="hidden" value="true"/>
        <input id="system-orcid" name="system" type="hidden" value="ORCID"/>
    </form>
		<form id="sign-in-form" class="login-container" action="https://f1000research.com/login" method="post" name="f">
           <div id="sign-in-form-gfb-popup"></div>

                                                            <input class="target-field" type="hidden" name="target" value="/articles/9-941.html"/>
                            			<input type="text" name="username" id="signin-email-box" class="sign-in-input" placeholder="Email address" autocomplete="email">
			<input type="password" name="password" id="signin-password-box" class="sign-in-input" placeholder="Password" autocomplete="current-password">
			<div class="sign-in-remember">
                <div class="checkbox-wrapper">
    				<input type="checkbox" id="remember-me" name="remember_me" class="checkbox is-hidden">
                </div>
                <span class="checkbox-label">Remember me</span>
			</div>
			<a href="#" class="sign-in-link" id="forgot-password-link">Forgotten your password?</a>
			<div class="sign-in-button-container margin-top margin-left-20 margin-bottom">
				<button type="submit" id="sign-in-button" class="sign-in-buttons general-white-orange-button">Sign In</button>
				<button type="button" id="sign-in-cancel" class="sign-in-buttons sign-in-cancel-button margin-left">Cancel</button>
				<div class="clearfix"></div>
			</div>
			<div class="sign-in-error">Email or password not correct. Please try again</div>
			<div class="sign-in-loading">Please wait...</div>
		</form>
		<div class="forgot-password-container">
			
<script type="text/javascript">
	$(function(){
		// Note: All the setup needs to run against a name attribute and *not* the id due the clonish
		// nature of facebox...
		$("a[id=googleSignInButton]").click(function(event){
            event.preventDefault();
            $("input[id=oAuthSystem]").val("GOOGLE");
            $("form[id=oAuthForm]").submit();
        });
        $("a[id=facebookSignInButton]").click(function(event){
            event.preventDefault();
            $("input[id=oAuthSystem]").val("FACEBOOK");
            $("form[id=oAuthForm]").submit();
        });
        $("a[id=orcidSignInButton]").click(function(event){
            event.preventDefault();
            $("input[id=oAuthSystem]").val("ORCID");
            $("form[id=oAuthForm]").submit();
        });
	});
</script>

<span class="text first">
	If you've forgotten your password, please enter your email address below and we'll send you instructions on how to reset your password.
    <p>The email address should be the one you originally registered with F1000.</p>
</span>
<input name="email" class="sign-in-input" id="email-forgot-password" type="text" placeholder="Email address">
<div class="forgot-password-email-error">
	Email address not valid, please try again
</div>
<div class="forgot-password-google-email-error">
    <p>You registered with F1000 via Google, so we cannot reset your password.</p>
	<p>To sign in, please click <a href="#" id="googleSignInButton">here</a>.</p>
    <p>If you still need help with your Google account password, please click <a href="https://www.google.com/accounts/recovery">here</a>.</p>
</div>
<div class="forgot-password-facebook-email-error">
    <p>You registered with F1000 via Facebook, so we cannot reset your password.</p>
    <p>To sign in, please click <a href="#" id="facebookSignInButton">here</a>.</p>
	<p>If you still need help with your Facebook account password, please click <a href="https://www.facebook.com/recover/initiate">here</a>.</p>
</div>
<div class="clearfix"></div>
<div class="forgot-password-captcha-error">
	Code not correct, please try again
</div>
<div class="clearfix"></div>
<div class="sign-in-button-container margin-left-20 margin-bottom">
	<button type="button" id="sign-in-reset-password" class="sign-in-buttons general-white-orange-button">Reset password</button>
	<button type="button" id="forgot-password-cancel" class="sign-in-buttons sign-in-cancel-button margin-left">Cancel</button>
	<div class="clearfix"></div>
</div>
<span class="text last">
	<a href="mailto:">Email us</a> for further assistance.
</span>
<form action="https://f1000research.com/j_spring_oauth_security_check" id="oAuthForm" method="post" target="_top">
                        <input class="target-field" type="hidden" name="target" value="/articles/9-941.html"/>
                <input id="oAuthSystem" name="system" type="hidden"/>
</form>
			<div class="forgot-password-server-error">Server error, please try again.</div>
			<div class="sign-in-success">
                <p>We have sent an email to <span id="email-value"></span>, please follow the instructions to reset your password.</p>
                <p>If you don't receive this email, please check your spam filters and/or contact .</p>
            </div>
			<div class="sign-in-loading">Please wait...</div>
		</div>

		<div class="sign-in-form-register-section">
			<div class="sign-in-button-container margin-left-20 margin-bottom">
				<a href="/register" title="Register"><button type="button" id="sign-in-register-button" class="sign-in-buttons general-white-orange-button">Register</button></a>
				<div class="clearfix"></div>
			</div>
		</div>

	</div>
</div>

<script type="text/javascript">
$(document).ready(function () {

    signIn.createSignInAsRow($("#sign-in-form-gfb-popup"));

    $(".target-field").each(function () {
        var uris = $(this).val().split("/");
        if (uris.pop() === "login") {
        	$(this).val(uris.toString().replace(",","/"));
        }
    });
});
</script>
        <div id="templateOverlay" class="is-hidden" hidden="hidden">
  <div class="o-overlay js-overlay is-hidden" hidden="hidden"></div>
</div>

<div id="templateExternalMessages" class="is-hidden" hidden="hidden">
  <div class="o-modal o-modal--auto@md js-external-messages is-hidden" hidden="hidden">
    <div class="o-modal__body">
      <section class="c-console">
        <div class="_mdl-layout c-console__bdy js-external-messages-body"></div>
        <footer class="_mdl-layout c-console__ftr o-flex o-flex--reverse js-external-messages-footer">
          <button type="button" class="mdl-button mdl-js-button mdl-button--raised mdl-button--colored c-console__btn js-external-messages-close" data-action="maintenance-close">I Understand</button>
        </footer>
      </section>
    </div>
  </div>
</div>

<script src="https://cdnjs.cloudflare.com/ajax/libs/moment.js/2.22.1/moment.min.js"></script>

<script src="/js/namespace.js"></script>
<script src="/js/constants.js"></script>
<script src="/js/utilities.js"></script>

<script>
                  F1000.ExtenalMaintenanceItems = [
    {
      start: '2018-12-10T14:21:00Z',
      end: '2018-12-13T16:00:00Z',
      msg: 'This site will be down for a short time on XX December. It is advisable not to start any submissions on that day or you may lose your work unless you save regularly.',
      cookieName: 'outage23122018',
      editor: false,
    }
  ];
</script>

<script src="/js/shared_scripts/cookie-helper.js"></script>
<script src="/js/shared_scripts/mdl-helper.js"></script>

<script src="/js/app/external-maintenance.js"></script>

                <script type="text/javascript">
            (function(i,s,o,g,r,a,m){i['GoogleAnalyticsObject']=r;i[r]=i[r]||function(){
            (i[r].q=i[r].q||[]).push(arguments)},i[r].l=1*new Date();a=s.createElement(o),
            m=s.getElementsByTagName(o)[0];a.async=1;a.src=g;m.parentNode.insertBefore(a,m)
            })(window,document,'script','//www.google-analytics.com/analytics.js','ga');

            ga('create', 'UA-5646075-11', 'auto');
            ga('require', 'displayfeatures');
            ga('send', 'pageview');
        </script>
        
                <script type="text/javascript" src="/js/app/research.analytics.js"></script>

        <!-- Start of HubSpot Embed Code -->
        <script type="text/javascript" id="hs-script-loader" async defer src="//js.hs-scripts.com/4475190.js"></script>
        <!-- End of HubSpot Embed Code -->
    
            <script src="https://my.hellobar.com/4e0495c6f18cbd68731a1dc1978195a144e767ba.js" type="text/javascript" charset="utf-8" async="async"></script>
    </body>

</html>